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CHAPTER 1: INTRODUCTION 
1.1 Methamphetamine abuse 
1.1.1 Prevalence of methamphetamine abuse 
 Methamphetamine (METH) is a commonly abused illicit psychostimulant. 
Originally synthesized from ephedrine in 1893 by chemist Nagai Nagayoshi [1], METH 
gained widespread popularity as an illicit recreational drug in the 1960’s [2]. Interestingly, 
METH was famously used by Adolph Hitler during World War II possibly to alleviate 
symptoms of idiopathic Parkinson’s disease [3]. Today METH remains a drug of 
widespread abuse in the United States and around the world [4-9]. METH use, particularly 
in the USA, is fueled by the ease of its manufacture, widespread availability [10], and 
addictive properties [11]. Approximately 1-2% of Americans have used METH in their 
lifetime [12], which pales in comparison to more popular illicit drugs (e.g. cocaine, heroin, 
marijuana), but still remains worrisome because of the health risks associated with METH 
use. The majority of METH in the United States is imported by criminal organizations 
based in Mexico [13, 14].  METH is also produced by clandestine synthesis which often 
results in severe injury to the person performing the synthesis [13]. The illicit manufacture, 
continued use, and abuse of METH remains a public health problem in the USA.  
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Figure 1: Prevalence of methamphetamine use. The map depicts the percentage of the 
population of individual countries that use amphetamine type stimulants.  (Source = United 
Nations Office on Drugs and Crime, World Drug Report, 2016) 
 
1.2 Methamphetamine toxicity 
 METH abuse predominantly produces two main toxic effects: cardiovascular 
toxicity and neurotoxicity. Cardiovascular toxicity, which accounts for most METH related 
deaths and emergency room visits, manifests as cardiac dysrhythmias, myocardial 
infarction, and aortic dissection [15-19]. Approximately 1.5% of METH users eventually 
perish as a result of their drug use [20]. However, many, but not all, METH users recover 
from their addiction and these users may face cognitive impairments, impaired motor 
function, increased risk of stroke, risk of developing parkinson’s disease, and possibly 
lasting psychosis due to METH-induced neurotoxicity [21-24].   
 
 
 
FIGURE 1 PREVALENCE OF METHAMPHETAMINE USE 
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Figure 2.  Dopamine pathways of the central nervous system. Mesolimbic DA projections 
originate in the ventral tegmental area and project to the nucleus accumbens. The 
nigrostriatal pathway includes DA neurons that project from the substantia nigra to the 
dorsal striatum. Meso cortical dopamine projections originate in the midbrain and project 
throughout the neocortex. 
 
1.2.1 Methamphetamine Neurotoxicity 
 METH neurotoxicity is primarily characterized by damage to the neurons of the 
nigrostriatal dopamine (DA) pathway [25].  DA neurons in the nigrostriatal pathway 
originate in the substantia nigra pars compacta (SNpc) and project to the dorsal striatum 
[26]. Heavy METH users have reduced dopamine transporter (DAT), a transporter protein 
specific for DA neurons, binding in the striatum following abstinence [27]. METH abusers 
also have reduced DA levels in the striatum [28]. Because both DA and DAT are specific 
to dopaminergic (DAergic) neurons it is assumed that DAergic nerve terminals of the 
striatum are destroyed following heavy METH use [29]. Despite massive damage to 
FIGURE 2 DOPAMINE PATHWAYS OF THE CENTRAL NERVOUS SYSTEM 
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DAegic nerve terminals of the striatum in rodent models of METH neurotoxicity, the 
DAergic neuron cell bodies in the SNpc remain relatively intact [30]. METH users also 
show significant activation of microglia in the striatum [31]. Microglia are activated in 
response to CNS injury [32, 33], and therefore the activation of microglial in the striatum 
of METH users suggest damage to striatal DAergic axons. However, microglia activation 
is not restricted to the striatum and was also observed in the midbrain, thalamus, and 
throughout the cortex [31]. 
Several studies suggest that DAergic nerve terminals recover following abstinence 
from METH [34, 35] (Figure 3). Because large scale synaptogenesis is not thought to occur 
in the adult brain, the apparent recovery of DAergic nerve terminals in the striatum may be 
due to neuroadaptations in response to METH, as opposed to the gross axotomy of DAergic 
axons. METH neurotoxicty likely involves a combination of both damage to striatal 
DAergic axons and neuroadaptation of nigral striatal DAergic neurons. 
 
 
FIGURE 3 RECOVERY OF STRIATAL DOPAMINE IN HUMAN METHAMPHETAMINE ABUSERS 
FOLLOWING PROLONGED ABSTINENCE FROM METHAMPHETAMINE. 
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Figure 3. Recovery of striatal dopamine in human methamphetamine abusers following 
prolonged abstinence from methamphetamine (Volkow, 2001, Neuroscience). Depicted 
are positron emission topography images of the human METH users that were administered 
radiolabled, methylphenidate, a dopamine transporter (DAT) ligand. Red, yellow, and blue 
depicts decreasing DAT density, respectively.  Shown here are the PET images from a drug 
naïve control, METH abuser following detox, and METH user following 24 months of 
abstinence. (Figure used with written permission from publisher) 
 
1.2.2 The role of hyperthermia 
 METH can induce life threatening hyperthermia in both humans and animal models 
of METH neurotoxicity [36-38]. In animal models of METH neurotoxicity METH-induced 
hyperthermia is directly proportional to the neurotoxic outcomes of METH [39]. 
Prevention of hyperthermia by lowering environmental temperature inhibits METH-
induced neurotoxicity [40, 41] while enhancing hyperthermia increases METH-induced 
neurotoxicity [42]. It remains unclear why hyperthermia plays such an important role in 
METH neurotoxicity. Likely explanations for the hyperthermia effect include the increased 
production of reactive oxidative species generation (ROS), toxic effects outside the CNS 
(e.g. liver toxicity), impaired the blood brain barrier (BBB), and enhance misfolding of 
cellular proteins [43]. 
1.2.3 Behavioral consequences of methamphetamine exposure 
 The primary behavioral effect of METH is the potent activation of motor behaviors. 
Motor behaviors includes the activation of locomotor activity (e.g. walking or running) and 
stereotypy (e.g. repetitive movements). Amphetamines activate nigral striatal DAergic 
pathway by increasing extracellular dopamine in the striatum [44]. Amphetamines increase 
extracellular DA in the striatum primarily through the interactions with DAT (Salahpour 
et al., 2008).  METH, like all amphetamines, produces differential effects on locomotor 
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activity with low doses increasing locomotor activity and high doses decreasing locomotor 
activity [45-47]. Although high-dose METH decreases locomotor activity, it subsequently 
increases stereotypy [47]. The motor effects of METH are primarily due to DA activation 
in the nigrostriatal DAergic pathway [48, 49]. Locomotor effects of amphetamines can be 
blocked or increased by the knockout [50] or overexpression of DAT [51], respectively. 
Exposure to neurotoxic doses of METH can result in long-term motor abnormalities and 
insensitivity to METH-induced locomotor activation [45]. 
1.2.4 Rodent models of methamphetamine neurotoxicity 
The rodent METH binge model is a convenient method to study the neurotoxic 
effects of METH. The METH binge model involves 4 administrations of relatively high 
doses of METH (10 mg METH / kg body weight) administered every 2 h. This binge model 
has several key advantages. The first advantage of binge model is robust depletion of 
monoamines in the striatum [52], that to some extent, recapitulates monoamine depletions 
seen in human users [28]. The second advantage is the severe hyperthermia produced 
during binge METH [53]. The third advantage of the binge METH model is the high level 
of experimental control afforded by an acute exposure to METH. Other paradigms, such 
as drug self-administration, produce heterogenous exposure to METH, which ultimately 
results in a high level of variability in the data obtained that can obscure the accurate 
analysis of METH’s action [54].  
 Binge METH results in the permanent, at least in part, loss of striatal DA axons and 
terminals [55, 56] which requires METH-induced hyperthermia [40]. Externally cooling 
animals during binge METH can attenuate many of the neurotoxic effects [53]. When 
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rodents are treated with high doses of METH in a cold room (i.e. 4°C) METH neurotoxicity 
is essentially prevented (Ali et al., 1994, Bowyer et al., 1994).  Binge METH models 
require that animals achieve body temperatures of 41-42°C to observe robust neurotoxicity 
in the striatum (Bowyer et al., 1994, Yuan et al., 2006). Because 41-42°C body temperature 
can be fatal, the animals can be cooled during binge METH by placing them on ice (Halpin 
et al., 2013). Despite external cooling of rats during binge METH the mortality rate in high-
dose METH experiments can still be 40-50% [57]. This mortality rate is not reflected in 
human users [20] (~1.5% mortality after 30 years of METH abuse), bringing into question 
the utility of a binge METH treatment regime. Furthermore, METH induced hyperthermia 
of 42°C is sufficient to denature many proteins [58] and multiple organ failure.  These 
consequences of hyperthermia make the specificity of the drug effect in METH binge 
models difficult to discern from the more global/gross toxicity due to a cellular heat shock 
response or organ failure. 
 Binge METH may not completely approximate human METH use. In humans the 
METH-induced reductions of striatal DAergic neuron markers recover given sufficient 
abstinence from METH [35]. The transient nature of METH-induced loss of striatal 
DAergic markers suggests neuroadaptations of DA neurons, and not gross axotomy of DA 
neurons, is a key components of METH neurotoxic effect in humans. Several alternative 
METH neurotoxicity animal models have been developed to better approximate human 
METH use. Chronic METH model, which is similar to METH binge model, involves 
exposure to high doses of METH over long periods of time (often several weeks). The 
chronic METH model has the advantage of lower mortality rates and less hyperthermia 
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when compared to binge METH models. However, this model suffers from a key 
drawback, in that METH is still administered by the experimenter, termed non-contingent 
administration, and not actively administered by the animal, termed contingent 
administration. Humans actively administer METH (i.e. contingent administration) and 
therefore non-contingent administration does not mimic human METH use. Drug self-
administration models have been used since 1962 to study drug addiction [59, 60] but used 
only recently to study METH neurotoxicity. METH self-administration does not produce 
neurotoxicity seen in binge METH models [61-63]. Only when animals are allowed to self-
administer METH for ~18 hours a day for weeks at a time meaningful reductions (~40-
50%) in striatal DAergic markers are observed [64, 65].  Interestingly, the reduction in 
striatal DAergic markers appears transient similar to what is seen in human METH users. 
Therefore, METH self-administration may be a more accurate model of human METH 
neurotoxicity than classical non-contingent models.  
1.2.5 Molecular mechanisms of methamphetamine neurotoxicity 
1.2.5.1 Dopamine 
 METH-induced DAergic neurotoxicity is due to several drug effects at the DAergic 
nerve terminal. The primary effect of METH is releasing of DA from pre-synaptic vesicles 
and pre-synaptic nerve terminals via interaction with vesicular monoamine transporter 2 
(VMAT2) [66-70] and DAT [71, 72], respectively. Free DA in the presynaptic terminal 
readily auto-oxidizes into a reactive dopamine quinone, which subsequently forms adducts 
with and damages cellular components [73-75]. DA released into the cytosol following 
METH produces excess oxidative stress damaging the nerve terminal [14, 74, 76]. METH 
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also binds to and reverses the function of DAT. Because DAT is the primary clearance 
mechanism of DA in the synapse, METH ultimately increases an efflux of DA out of the 
nerve terminal. Treatments that increase or decrease the available DA (i.e. vesicular, 
cytosolic, and extracellular DA stores) prior to METH treatment, appear to increase or 
decrease the neurotoxicity observed, respectively [68, 77].  
1.2.5.2 Neuroinflammation 
 Neuroinflammation plays an important role in several neurodegenerative diseases 
[78]. Neuroinflammation occurs with infection or toxic insult in the CNS. The neurotoxic 
insult of METH activates several neuroinflamatory responses that can activate microglia 
in the striatum [31, 79]. Microglia release proinflammatory cytokines which can induce 
cell death [80]. METH also increases the immunoreactivity of the reactive gliosis protein, 
glial fibrillary acidic protein (GFAP), in the striatum [81]. Induction of GFAP, termed 
reactive gliosis, in the CNS is a general response to injury or toxic insult [82]. Astrocytes, 
unlike microglia, can play a neuroprotective role [83]. 
1.2.5.2 Oxidative Stress 
 Oxidative stress is an important mechanism of METH neurotoxicity. METH can 
induce toxic hydroxyl radicals and superoxide [74, 84]. METH increases cytosolic DA 
concentrations through interactions with VMAT2 increasing auto-oxidation of DA [85].  
In humans, the increase in cytosolic DA can be metabolized by MAO-B, producing 
hydrogen peroxide and the metabolite DOPAC [86, 87]. Hydrogen peroxide can then 
produce hydroxyl radicals via the Fenton reaction [88]. Hydroxyl radicals are highly 
reactive and can damage a wide variety of cellular components [89].  
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1.2.6 Role of parkin in methamphetamine neurotoxicity 
1.2.6.1  Cellular functions of parkin  
 Parkin is an E3 ubiquitin ligase [90] expressed in neural bodies and neurites, but 
not glia, throughout the brain [91]. Parkin ubiquitinates damaged/dysfunctional proteins so 
they can be degraded by the proteasome. The ubiquitination of proteins and subsequent 
degradation of ubiquitinated proteins via the proteasome is referred to, collectively, as the 
ubiquitin proteasome system (UPS). Parkin has numerous proposed substrates including 
DAT [92, 93]. 
1.2.6.2  Methamphetamine impairs parkin function 
 METH impairs parkin function [94, 95].  Binge METH results in the transient 
reduction in parkin levels of striatal synaptosomes. The loss of parkin occurs within the 
first 24 h and returns to basal levels at 48 h following binge METH [94]. The METH-
induced loss parkin coincides with increased 4-hydroxynonanal modified proteins and 
decreased proteasomal activity in the striatum [94]. Treatment with the antioxidant 
compound, vitamin E, prevented these effects, and prevented the loss of striatal DA [94]. 
1.2.6.3 Neuroprotective effects of parkin 
 The overexpression of parkin protects against METH-induced neurotoxicity [96]. 
However, parkin knockout mice are not hypersensitive to the neurotoxic effects of METH 
[97]. The lack of hypersensitivity could be due to phenotype adaptations to compensate for 
the loss of parkin. Mutations in PARK2, the gene encoding parkin, have been found in 
patients with the neurodegenerative disease Parkinson’s disease (PD). The overexpression 
of parkin in the SNpc has shown some neuroprotective efficacy in PD models [98-102]. 
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PD and METH neurotoxicity are similar in that both involve damage to the nigrostriatal 
DAergic pathway. METH neurotoxicity models have been used to mimic the 
neurodegeneration of PD [103]. 
1.2.6.4 Parkin modulates dopamine release in the nigrostriatal DA pathway 
 As an E3 ubiquitin ligase, parkin is thought to exert neuroprotective effects by 
enhancing the removal of damaged/misfolded proteins. However, numerous studies now 
demonstrate that parkin plays a “non-classical” role in DA neurons of the nigrostriatal 
pathway [98, 104-106]. Studies manipulating parkin expression in nigrostriatal DA 
neurons suggest parkin modulates DA activity of these neurons, independently of parkin 
mediated neuroprotection via enhanced degradation of damaged substrates [97, 98, 104]. 
In general, loss of parkin appears to impair DA utilization while overexpression of parkin 
enhances DA utilization. DA utilization is a general term that refers to the normative the 
process of DA synthesis, packaging, release, and reuptake [105].Therefore, parkin’s effects 
on DA utilization may be through enhanced DA synthesis [98], packaging into vesicles 
[105], or release [106-108]. 
1.2.7 Role of α-synuclein in methamphetamine neurotoxicity 
 α-Synuclein is a small intrinsically disordered protein of unknown function. Several 
proposed functions of α-synuclein include SNARE mediated vesicle exocytosis, lysosomal 
function, and possibly intracellular vesicle transport [109]. α-Synuclein is expressed 
ubiquitously throughout the body and is abundantly expressed in the brain [110]. α-
Synuclein aggregation is important for the progression of PD, and correspondingly, has 
been the subject of intense study. Large cytoplasmic inclusions rich in α-synuclein are a 
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hallmark of PD. Similar aggregates have been observed in METH neurotoxicity models 
[111]. α-Synuclein is a possible substrate for parkin [112], however, parkin mediated 
ubiquitination does not appear to directly control α-synuclein turnover [113]. Furthermore, 
any direct interactions between α-synuclein and parkin are likely transient and weak [113]. 
 Increasing the expression of α-synuclein is toxic to dopamine neurons [114-117]. 
Preliminary studies have suggested the METH can increase expression of α-synuclein in 
the striatum [118, 119]. The METH-induced increase in striatal α-synuclein and oxidative 
stress may lead to toxic aggregation and neurotoxicity [120]. Knockdown of α-synuclein 
in rats can protect against METH induced loss of TH and DA [121, 122]. α-Synuclein 
modulates DA release via interactions with calcium channels [123] which could result in 
increased METH-induced DA release in the striatum.  
 DA, which is structurally similar to METH, is known to bind to α-synuclein [124] 
and subsequently promote its aggregation [124, 125].  Therefore, METH may also bind to 
α-synuclein, inducing a conformation change similar to that seen with DA, and increasing 
α-synuclein aggregation [126]. However, METH binding to α-synuclein was determined 
using a nanopore assay and another technique is needed to confirm the interaction between 
METH and α-synuclein. 
 α-Synuclein forms a stable tetramer in vivo [127]. Destabilization of this tetramer 
is a hypothesized initiating mechanism for the aberrant aggregation and neurodegeneration 
in PD [128]. It is unknown if METH can affect α-synuclein tetramer stability. Interactions 
between α-synuclein and cellular lipids stabilizes the n-terminus α-helix conformation of 
α-synuclein and drive the formation of higher-order α-synuclein oligomers. Disruption of 
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interactions between α-synuclein and cellular lipids can impair tetramer/oligomer 
formation. DA forms adducts with α-synuclein stabilizing the aggregation prone protofibril 
α-synuclein species [129], and impairing α-synuclein lipid binding [130]. Presumably, 
METH-induced increase in free cytoplasmic DA would promote α-synuclein adduct 
formation, and subsequently impair tetramer formation, possibly resulting in the toxic 
aggregation of α-synuclein. The aggregation of α-synuclein may be directly involved in 
METH-induced neurotoxicity and may help explain the apparent increased incidence of 
PD in METH users [24]. However, any direct relationship between METH neurotoxicity 
and α-synuclein remains untested and unclear. 
1.2.8 Role of axonal transport in methamphetamine neurotoxicity 
1.2.8.1  Axonal transport defined 
Neurons are highly polarized cells that transmit and receive 
electrical/neurochemical signals. Neurons consist of three distinct parts including the cell 
body, the axon, and the axon terminal.  Axons are appendages that project from the cell 
body to a distal location. The point at which the axon ends is termed the nerve terminal or 
button.  Nerve terminals are the “business end” of the neuron in that they are heavily 
enriched in cellular machinery involved in neurotransmission (e.g. receptors, 
neurotransmitter filled vesicles, membrane transport proteins etc.). Neurotransmitters can 
have rapid turnover at the nerve terminal, and therefore, synthesis of neurotransmitters 
occurs locally at the nerve terminal to ensure constant availability of these important 
signaling molecules. However, other important nerve terminal components such as proteins 
and organelles are not normally generated at the nerve terminal because nerve terminals 
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lack the genetic information and protein synthesizing machinery. Axonal transport is the 
process by which neurons supply nerve terminals with proteins and organelles to meet the 
requirements of the nerve terminal. Axonal transport is also important in the trafficking of 
cellular components back to the cell body. Axonal transport becomes especially crucial for 
the healthy function of neurons, whose subcellular compartments, are vastly separated from 
each other by space and time. For example, human peripheral neurons can have axons that 
project a distance 106 greater than the radius of the cell body. 
 Axonal transport is responsible for the trafficking of cellular cargo to the distal 
nerve terminal. Known cargos that are actively transported via axonal transport include 
mitochondria [131], lipid vesicles [132, 133], soluble proteins [134], and membrane 
proteins (embedded in lipid vesicles)[135].  
1.2.8.2 The machinery of axonal transport 
 Axonal transport of cargo can either be toward the nerve terminal (i.e. anterograde) 
or towards the cell body (retrograde). Motor proteins, such as kinesin and dyenin, are a 
main driving force of axonal transport. Motor proteins utilize ATP to generate motive force 
carry their cargo along the axon.  Cargo can move in the axon by either slow or fast axonal 
transport [136] and the directionality of transport switches rapidly, often with long pauses 
between periods of rapid movement. Numerous adapter proteins and motor proteins are 
thought to regulate the axonal transport of specific cargo in a complex signaling network. 
(See figure 4 for summary) 
 Microtubules (MT) are required for axonal transport.  MT are long polymers 
consisting of α- and β-tubulin heterodimers. MT are highly dynamic structures that cycle 
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between elongation (rescue) and rapid depolymerization (sometimes referred to as 
catastrophe) [137]. Axonal transport requires stable and long-lived MT.  Compounds that 
depolymerize MT inhibit axonal transport and compounds that stabilize MT enhance 
axonal transport [138, 139]. 
1.2.8.3 The role of tubulin post-translational modifications in axonal transport 
 There are several known post translational modifications (PTM) of α-tubulin 
including detyrosination (DetyTUB) and acetylation (AcetTUB). Following α-tubulin 
synthesis the c-terminal tyrosine residue is proteolytically removed by an unidentified 
carboxypeptidase, generating DetyTUB. DetyTUB can be re-tyrosinated by tubulin 
tyrosine ligase [140, 141]; however, the removal of the remaining glutamate residue makes 
the detyrosination irreversible.  DetyTUB is associated with long lived stable MT [142] 
required for axonal transport, although the PTM does not itself confer stability. AcetTUB 
is generated by two acetyltransferases, MEC-17 (also known at αTAT1 or α-tubulin N-
acetyltransferase 1) and ARD1-NAT1, that acetylate lysine 40 of α-tubulin [143]. α-
Tubulin can only be acetylated when following its incorporation into a MT polymer. 
AcetTUB can be deacetylated by histone deacetylase 6 (HDAC6) and sirtuin-2 [144, 145]. 
Although AcetTUB is not thought to directly impart stability to MT per se, AcetTUB is 
highly enriched on stable long-lived MT polymers. 
1.2.8.4 Role of axonal transport in neurodegeneration 
 Axonal transport dysfunction has been implicated in several neurodegenerative 
diseases including Parkinson's disease and Alzheimer's disease [146-148].  Many studies 
suggest that deficits in axonal transport impair the removal of damaged/dysfunctional 
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cellular components (e.g. proteins) and organelles (e.g. mitochondria), ultimately resulting 
in neurodegeneration [149]. It remains unclear whether axonal transport deficits are a cause 
of neurodegeneration or a symptom of neurodegenerative processes.  
1.2.8.5 Possible role of axonal transport in METH neurotoxicity 
 It is unknown whether METH can impair axonal transport. There are several 
preliminary studies that suggest METH can impair MT stability. Endothelial cells treated 
with METH show reduced levels of AcetTUB, suggesting a loss of MT stability [150]. As 
previously mentioned, the reduction in striatal DAergic nerve terminal markers following 
METH are partially reversible given sufficient abstinence from METH. Therefore, it is 
possible that axonal transport is impaired/downregulated following METH exposure and 
subsequently recovers following abstinence from METH. 
1.2.8.6 The use of MT stabilizing compounds as axonal transport enhancing drugs 
 Several recent investigations have found that new class of MT stabilizing drugs, 
called epothilones, can be used to enhance axonal transport in neurons of the CNS [139, 
151, 152]. Epothilone D is a particularly promising compound for the enhancement of 
axonal transport. Systemic treatment with Epothilone D results in increased the number of 
stable MT in CNS neurons [152]. Several treatments with Epothilone D can delay 
neurodegeneration in several animal models of PD and AD [152, 153]. Epothilone D 
potently stabilizes MT polymers [154], and readily accumulates in the brain [155], making 
it a good candidate for treatment of axonal transport deficits in the CNS. Epothilone D was 
in clinical trial for Alzeihmers disease but these trials have since been discontinued, 
possibly due to issues with efficacy and safety. 
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Figure 4. Axonal transport. (Maday S, Twelvetrees AE, Moughamian AJ, Holzbaur EL 
(2014) Axonal transport: cargo-specific mechanisms of motility and regulation. Neuron 
84:292-309.) Axonal transport occurs over the entire length of the axon. The processes can 
either transport cargo to or from the cell nerve terminal (anterograde and retrograde 
transport, respectively). Axonal transport is involved with the trafficking of numerous 
cellular cargoes including vesicles, mitochondria, mRNA, neurofiliments, tubulin, and 
cytosolic proteins. Motor proteins kinesin and dynein are the main driving force for 
anterograde and retrograde transport, respectively. Both motor proteins require intact 
microtubule polymers. (Figure used with written permission from publisher). 
 
FIGURE 4 AXONAL TRANSPORT 
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1.3 Project Overview 
1.3.1 Project Rationale 
There are currently no therapeutic interventions to inhibit or reverse the neurotoxic 
effects of METH on the central nervous system (CNS). The process of axonal transport as 
well as the proteins parkin and α-synculein have proposed roles in METH neurotoxicity.  
Investigation into these factors, and how they relate to METH neurotoxicity, could provide 
insight into possible therapeutic targets to treat METH neurotoxicity. 
1.4 Specific Aims and Hypothesis 
1.4.1 Aim 1  
Establish the presence of axonal transport deficit in the nigrostriatal DA pathway 
following neurotoxic administration of METH. Hypothesis: Neurotoxic regimen of METH 
will result in axonal transport impairment. 
1.4.2 Aim 2  
Restore DAergic terminal function via enhancing axonal transport in the 
nigrostriatal DA pathway. Hypothesis: Stabilization of microtubules will restore METH-
induced decreases in striatal DAergic markers. 
1.4.3 Aim 3 
  Determine whether deficit in E3 ligase parkin mediates the METH-induced 
impairment in axonal transport. Hypothesis: Loss of parkin will potentiate METH-induced 
impairment of axonal transport. 
1.4.4 Aim 4 
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Investigate whether altered assembly of α-synuclein species mediates the METH-
induced impairment in axonal transport. Hypothesis: METH will alter α-synuclein 
multimerization leading to impaired axonal transport. 
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CHAPTER 2: VALIDATION OF DRUG SELF-
ADMINISTRATION AS A METH TOXICITY MODEL 
 
2 Background 
 Methamphetamine (METH) abuse results in long-term depletion of striatal 
DAergic nerve terminal components [35]. This depletion may be partially due to damage 
to striatal DAergic axons [31, 55].  Therefore, a good model to study METH abuse should 
produce long-lived DA depletion in the striatum similar to what is observed in human 
METH users [27, 35, 156-158].  
 Rodent drug self-administration is an old technique commonly used to study the 
addictive properties of drugs [159]. Only recently, drug self-administration procedures 
have been employed to specifically study the neurotoxic properties of METH [62, 63, 160]. 
The use of self-administration for the study of METH neurotoxicity remains speculative 
because rodent METH self-administration models fail to produce robust neurotoxicity in 
the striatum, unless the self-administration sessions are significantly prolonged [160]. 
Furthermore, rodent drug self-administration does not engender the same pattern of drug 
taking in humans. Rodents will self-administer METH at regular intervals [161] while 
human users generally administer several large doses over the period of several days. This 
can be explained because the half-life of METH is significantly shorter in rats, making 
frequent administration necessary to maintain a steady blood levels [162]. 
 METH self-administration models have some advantages over models that use non-
contingent administration. First, METH self-administration may better approximate human 
abuse. Human abusers are not passively administered METH, but instead, undergo many 
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complex behaviors to seek out and take METH. These complex behaviors and the 
environmental stimuli associated with them, make the administration of METH 
“contingent.” Contingent administration requires that operant conditioning is controlling 
the drug taking/seeking behavior. Like with all operant behaviors, a discrimitive stimulus 
signals the availability of reinforcing stimulus. The reinforcing stimulus “drives” behavior 
by increasing its probability in the future. METH is a potent reinforcer that can easily shape 
the operant behavior of lever pressing in rodents. Numerous studies have demonstrated that 
self-administered (i.e. contingent) drugs produce distinct neurochemical responses in the 
brain [65, 163], which are likely to influence the development of neurotoxicity. As eluded 
to, this phenomenon is likely a result of the complicated learning and drug seeking 
behaviors during self-administration.  As most profoundly demonstrated by hollerman, J.R. 
and Schultz, W. (1998), where the simple light stimulus signaling drug administration 
drastically altered the subsequent activity of DA neurons [164]. 
 Here we explored the use of a short-access self-administration protocol to study 
METH neurotoxicity in the striatum.  
2.1 Materials and methods 
2.1.1 Chemicals and materials 
 D-methamphetamine HCl (METH) (Sigma-Aldrich, St. Louis, MO) was dissolved 
in sterile saline to a concentration of 0.5 mg METH / mL saline. METH solutions were 
sterile filtered through a 0.22 µm membrane. Ketamine (100 mg / mL), xylazine (20 mg / 
mL), surgical drapes, wound clips, silk sutures, and surgical gauze was purchased from 
Henry Shein Animal Health (Dublin, OH). Precision grain based food pellets were 
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purchased from Bioserve (Flemington, NJ). Catheter plugs, catheter extenders, and 22 ga 
Renathane catheter tubing was purchased from Braintree Scientific (Braintree, MA). 
Heparin/dextrose catheter lock solution and 22 ga blunt needles were purchased from SAI 
infusion. Infusion harnesses and tethers were purchased from Instech Laboratories 
(Plymouth Meeting, PA). Operant chambers and MED-PC software were purchased from 
Med Associates (Fairfield, VT). 
2.1.2 Subjects 
 Adult male Long-Evans rats (Envigo, Indianapolis, IN) between the weights of 200-
250g were used. All animals were fasted overnight before lever training. For the remainder 
of the study animals were allowed ad libitum access to food and water. For the duration of 
the study all animals were singly housed in clear bottom polycarbonate cages with Sani-
Chip bedding.  Animals were inspected upon arrival for signs of abnormalities such as 
disease and/or distress. Following an acclimation period of 7 days each animal was 
weighed and assigned a study number. For the duration of the study animals were be 
weighed on a weekly basis and on days of drug self-administration.  
 All animals were implanted with a chronic indwelling jugular catheter. The catheter 
was flushed daily with 1 mL sterile saline and filled with 0.5 mL heparine/dextrose catheter 
lock solution. Between flushing the catheter was plugged using a 22 ga stainless steel 
catheter plug. Animals whose catheter lost patency prior to the end of study was removed 
from the study.  All catheter solutions were sterile filter through a 0.22 µm filter and drawn 
up in the biohood.   
2.1.3 Jugular Catheter Surgery 
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 Animals were anesthetized with a mixture of ketamine (100 mg ketamine / kg body 
weight) xylazine (6 mg xylazine / kg body weight). To maintain surgical plane anesthesia 
booster shots of ketamine (20 mg ketamine /kg body weight) were administered.  All 
anesthetic agents were administered via intraperitonal (i.p.) injection. 
 Once the animal has reached a deep state of anesthesia (does not respond to tail 
pinch) the animal’s hair was removed from both incision sites. (See Figure 5) 
 
Figure 5. Jugular catheter surgery incision sites. The drawing depicts the site of surgical 
incisions for the implantation of the chronic intradwelling catheter in rats. The jugular 
catheter is implanted into the jugular vein (arrow) and inserted just proximal to the right 
atrium.   
 
 Petroleum based ointment was placed in each of the animal’s eyes prior to surgery. 
Both incision sites were then cleaned thoroughly with both betadine and isopropyl alcohol 
(scrubbing the site 3 times with each solution; in an outward circular motion). The animal 
was then placed in dorsal recumbancy and small 0.25’’ incision was made on the right side 
of the animal’s neck. Using blunt dissection methods, the animal’s jugular vein was 
FIGURE 5 JUGULAR CATHETER SURGERY INCISION SITES 
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exposed just anterior to the pectoral muscle.  The jugular vein was isolated from 
surrounding tissue and tied with a sterile silk suture to stop blood flow to the heart.  A small 
incision was made in the jugular vein, the catheter inserted, and then was tied into place 
using another sterile silk suture just posterior to the catheter insertion site. The catheter was 
flushed with sterile saline and blood was briefly drawn into the catheter line to ensure 
correct placement. The catheter was then cleared with sterile solution. The animal was then 
flipped over and an incision made between in the scapular region. Forceps were used to 
separate the skin from the underlying tissue and muscle.  Once an area was cleared under 
the skin, connecting both incisions, the catheter line was then closed using a 22-gauge steel 
plug and pulled through the dorsal incision site. At this time the catheter line was secured 
to muscle in the neck and back using silk sutures. Once secure the catheter was flushed 
with locking solution consisting of 0.5 mL heparin/dextrose. The incision sites are closed 
using sutures or wound clips. Animal was then placed on warming pad to recover. During 
recovery, the catheter line could be cut to the desired length (approximately 1 inch from 
incision site).  
2.1.4 Methamphetamine self-administration behavioral procedures 
 Initial lever training was conducted prior to the catheter surgery. During the training 
phase animals are placed on limited food access (food removed approximately 5pm night 
prior to training and returned following training the next day). Animals then are allowed to 
respond for three 30 min sessions of fixed ratio (FR) 1. Animals are limited to 30 rewards 
per session. Once animal has reached the maximum session rewards at FR1 schedule of 
reinforcement they can then undergo catheter surgery. Following recovery from catheter 
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surgery (7-10 days) the wound clips and/or sutures are removed from incision sites. The 
animal was then allowed to administer METH (0.1 mg METH / kg bodyweight / per 
infusion) on an FR1 schedule for 7 consecutive days. Each drug infusion results in a 20s 
timeout to prevent accidental overdose. Following 7 consecutive days of responding on 
FR1 schedule, animals were placed on FR5 schedule on day 8. Animals were then allowed 
to respond for 7 days on FR5 schedule. Behavioral output was continuously recorded with 
MEDPC software. (See table 1) 
2.1.5 High-Performance Liquid Chromatography 
 Procedures were conducted as previously described [165]. All procedures were 
conducted on ice or under refrigeration. Briefly, tissues were sonicated in 0.5 mL of 0.3 N 
perchloric acid for 30 s, and the resulting homogenate was centrifuged for 30 min at 12,000 
x g. The pellet was dissolved in 1M NaOH overnight at 4°C, and protein concentration was 
determined using the bicinchoninic acid (BCA) protein assay (ThermoScientific). To 
measure DA content, 20 µl of the supernatant was injected into mobile phase containing 
90 mM sodium dihydrogen phosphate monohydrate, 50 mM citric acid, 1.7 mM 1-octane 
sulfonic acid, 50 µM EDTA, and 10% acetonitrile (ThermoScientific), at a flow rate of 0.5 
mL/min. Samples were separated using a C-18 reverse-phase column (150 X 3.2, 3 µM 
particle size; ThermoScientific). DA and its metabolites were then detected 
electrochemically (electrode 1: -150 V, electrode 2: +220 V). Final values are reported as 
picograms of analyte per microgram of protein. 
2.1.6 Immunohistochemistry 
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 Rats were euthanized via live decapitation, the brain removed, and cut to separate 
the right and left hemispheres. The left hemisphere was placed into 50 mL of 4% 
paraformaldehyde in PBS. The brain was kept in the paraformaldehyde solution for 3 days 
at 4°C, and then transferred to 10% glycerol (1 day) and 20% glycerol (1 day). Fixed brains 
were then flash frozen in isopentane cooled with slurry of ethanol and dry ice. 30 µM 
sagittal sections were then cut using cryostat (Thermoscientific) and the sections 
rehydrated in PBS for 1 h. Sections were then incubated in blocking buffer (PBS, 0.1% 
Triton X-100, 1% m/v bovine serum albumin) for 1 h at room temperature.  Sections were 
incubated overnight at 4°C with anti-TH antibody (EMDMillipore) in blocking buffer. 
Sections were then incubated with blocking buffer containing Alexa Fluor® 488 goat anti-
mouse (Invitrogen, Carlsbad, CA) diluted 1:400 for 2.5 h at room temperature. DRAQ5 
(Invitrogen) was used according to the vendor protocol to stain nuclei. Sections were then 
mounted using Fluoromount (SouthernBiotech, Birmingham, AL). Slides were imaged 
using a Leica SP3 laser scanning confocal microscope (Leica, Wetzlar, Germany). The 
non-compressed raw single z-plane images were exported from the Leica Image Analysis 
Suite (Leica). These images were then analyzed using Imaris co-localization analysis 
software (Bitplane South Windsor, CT). For each image automatic thresholding and 
masking functions were used to prevent interference from signal noise and variations in 
signal intensity. The resulting percent co-occurrence in the TH channel was normalized to 
non-treated control for ease of graphical comparison. The final value represents the 
percentage of signal overlap within the TH signal. 
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Table 1. Self-Administration parameters.  
 Lever Training Acquisition Day 1-7 Maintenance Day 8-21 
Schedule 1 1 5 
Session length (min) 30 180  180  
Max Rewards 30  999  999  
Timeout (s) 0 20 20 
Reward Food Pellet 0.1mg/kg METH 0.1mg/kg METH 
 
2.2 Results 
2.2.1 Lever Training 
 Food deprived rats quickly acquired the lever press behavior on a FR1 schedule of 
reinforcement. All animals met the criteria of 30 rewards (food pellets) by the third day of 
lever training. The lever press behavior for several animals was “hand shaped” by manually 
delivering the pellet as the rat’s behavior more closely approximated a lever press.  
2.2.2 Methamphetamine intake during self-administration 
 Following the implantation of jugular catheters animals were allowed to respond 
for METH. Responding on day 1 was relatively robust with animals administering 
approximately 1.5 mg METH / kg bodyweight (Figure 6). The robust responding on day 1 
was likely due to prior lever training. Animal responding slightly decreased within the first 
few days to 1 mg METH / kg bodyweight.  By day 7 responding had stabilized to about 
1.75 mg METH / kg BW.  
 On day 8 the FR1 was increased to an FR5. Correspondingly, responding increased 
5-fold of that seen using the FR1 schedule.  For the remainder of the study animals self-
administered approximately 1.75 mg METH / kg bodyweight.  
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 Animals that were allowed to respond for infusions of saline showed extinction of 
lever press behavior within the first three days. Responding remained very low for the 
remainder of the study.  
Figure 6. Responding during self-administrations session. The mean number of responses 
(left) and drug intake (right) during 14 days of self-administration. Each daily session was 
4 h in length. Animals trained under an FR1 for first seven days and a FR5 for the remaining 
7 seven days.  Each response consists of a single lever press. Each injection consisted of 
0.1 mg METH / kg bodyweight or saline. n =4. 
2.2.3 Gross dopamine axon pathology of the striatum following methamphetamine 
self-administration 
 Binge METH results in large scale axotomy of the striatal dopaminergic axons in 
rats [55]. TH staining of the striatum shows dense DAergic axon enervation in animals that 
self-administered both saline and METH (Figure 7). The overall intensity of TH staining 
and the morphology of TH axons were indistinguishable from saline and METH exposed 
animals. (Figure 7) 
  
FIGURE 6 RESPONDING DURING SELF-ADMINISTRATION SESSIONS 
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FIGURE STRIATAL DAERGIC AXONS 21 DAYS FOLLOWING METHAMPHETAMINE SELF-ADMINISTRATION 
Figure 7. Striatal DAergic axons 21 days following methamphetamine self-administration. 
Fixed brain slices were stained with an antibody specific for tyrosine hydroxylase (TH) 
and a dye specific for nuclei (DRAQ5). Tissue was then imaged using confocal 
microscopy. High contrast images of both channels are displayed in the first two columns. 
Pseudo colored images of overlaid channels are shown in the last two columns. Low 
magnification images of the entire striatum depicted on the right. The top panel include 
images from a rat that was only exposed to saline during selfadministration session and the 
bottom panels depict a rat that self-administered methamphetamine for 14 consecutive 
days. Images depict a lack of damage/destruction to striatal dopaminergic axons following 
methamphetamine self-administration.  
 
2.2.4 Striatal dopamine content following methamphetamine self-administration 
FIGURE 7 STRIATAL DAERGIC AXONS 21 DAYS FOLLOWING METHAMPHETAMINE SELF-ADMINISTRATION 
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 Binge METH results in large dopamine loss in the rat striatum [166]. Following 
METH self-administration, we measured dopamine and dopamine metabolite content in 
the striatum. We observed little difference in the striatal dopamine content of rats exposed 
to saline or METH (Figure 8). Dopamine metabolites were also similar between saline and 
METH treated animals (Data not shown).  
Figure 8.  Striatal dopamine content 21 days following methamphetamine self-
administration. Dopamine was separated by HPLC and measured by electrochemical 
detection. Striatal dopamine content was normalized to saline treated animals. Student t-
test was conducted to compare treatment groups (NS). n = 3-4. 
 
2.3 Discussion 
 Here we determined that rats would readily respond for an intravenous injection of 
0.1 mg METH / kg bodyweight. The level of responding observed here is slightly less than 
other METH self-administration studies [65, 160]. However, those studies use Sprague 
Dawley rats and here we used Long-evans rats. Genetic differences between rat strains can 
affect the robustness of drug self-administration acquisition and maintenance [167, 168]. 
FIGURE 8 STRIATAL DOPAMINE CONTENT 21 DAYS FOLLOWING 
METHAMPHETAMINE SELF-ADMINISTRATION 
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Our findings suggest that Long-Evans rats are less robust responders for METH than 
Sprague Dawley rats.  
 The main objective here was to determine if METH self-administration would 
result in detectable DAergic neurotoxicity in the striatum. We did not observe signs of 
neurotoxicity following 14-day exposure to METH self-administration. Striatal dopamine 
levels and TH axon abundance/morphology were similar between saline and METH 
exposed animals. This finding is in agreement with numerous studies that show only 
extended access can produce symptoms of neurotoxicity [160, 169].  The lack of toxicity 
is likely due to the short access to METH. Longer exposures (>12 h) seem to be required 
for detectable neurotoxicity in the striatum. The lack of toxicity may also be due to the 
relatively modest METH intake observed here with Long Evans rats. During the 4 h session 
most animals self-administered approximately 1.5-2.0 mg METH / kg bodyweight. This 
level of exposure may be sufficient to engender robust addictive behaviors (e.g. cue 
induced reinstatement) but likely insufficient for neurotoxicity.  
2.4 Conclusions 
 Daily short access METH self-administration does not produce neurotoxicity in the 
striatum. The short access daily exposure, commonly used for addiction studies, is likely 
not a good model to study the neurotoxic effects of METH. Future studies utilizing self-
administration to model METH neurotoxicity should focus on extended access paradigms, 
as described elsewhere [65]. Otherwise, METH neurotoxicity studies in rodents should 
focus on non-contingent administration. 
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CHAPTER 3 -- THE ROLE OF AXONAL TRANSPORT IN 
METHAMPHETAMINE NEUROTOXICITY 
 
Results in chapeter three are transcribed from the peer-reviewed manuscript: 
“Killinger BA, Moszczynska A (2016) Epothilone D prevents binge methamphetamine-
mediated loss of striatal dopaminergic markers. Journal of Neurochemistry 136:510-525”. 
Killinger B. was responsible for designing, conducting, writing, and reporting results 
transcribed in chapter 3. Moszczynska A. was responsible for writing, editing, and 
reviewing the manuscript prior to acceptance by the Journal of Neurochemistry. The 
following work was conducted to begin to address the possibility that axonal transport may 
play in role in METH neurotoxicity. Furthemore, it was conducted to determine if the 
neuroprotective compound, epothilone d, could prevent/reverse the neurotoxic effects of 
METH. 
3 Background 
 Methamphetamine (METH) is a widely abused neurotoxic psychostimulant. When 
administered in high doses, METH induces long-term deficits in striatal dopaminergic 
(DAergic) markers, including the dopamine transporter (DAT), tyrosine hydroxylase (TH), 
dopamine (DA), and DA metabolites [170-173]. To some extent, the loss of DAT, TH, DA, 
and its metabolites is due to physical loss of axonal terminals [55]. Extended abstinence 
from METH results in partial recovery of these DAergic markers in experimental animals 
and humans [35, 52, 55, 173-175], suggesting compensatory changes within the 
nigrostriatal DA pathway. There is little evidence that DAT and TH are locally synthesized 
in the axons in the adult brain; therefore, axonal transport might be required to restore DAT 
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and TH to DAergic terminals. Axonal transport impairment is an early marker of several 
neurodegenerative diseases [146] and may also precede development of METH 
neurotoxicity or play a role in predisposing METH users to development of Parkinson's 
disease [176]. It is not known whether METH alters axonal transport in the nigrostriatal 
DA pathway. 
 Axonal transport requires cytosolic polymers called microtubules (MTs) that 
consist of heterodimers of the cytoskeletal proteins α-tubulin and β-tubulin. Several post-
translational modifications (PTMs) of α-tubulin, including detyrosination, tyrosination, 
and acetylation, are thought to play a role in regulating MT structure and function [177]. 
Specifically, acetylated (AcetTUB) and detyrosinated (DetyTUB) α-tubulin are highly 
enriched in stable long-lived MTs [178], are present in axons [179], and preferentially 
recruit the anterograde motor protein kinesin [180, 181]. Conversely, β-III-tubulin 
(βIIITUB) imparts dynamicity to MTs [182], is highly expressed in somatic neurons [183], 
and confers resistance to taxane-mediated MT stabilization [184, 185]. In axons, 
tyrosinated α-tubulin (TyrTUB) is enriched in newly formed MTs and in a highly dynamic 
MT population that is sensitive to nocodazole-mediated depolymerization [186]. Overall, 
MTs enriched with DetyTUB and/or AcetTUB are more rigid and support axonal transport, 
whereas MTs enriched with TyrTUB and/or βIIITUB are more dynamic and impede axonal 
transport. Although early alterations in MT structure and function have been reported in 
several models of DA neuron neurodegeneration [153], it is not known whether neurotoxic 
METH treatment alters MTs in the nigrostriatal DA pathway. 
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 Epothilone D (EpoD) is a neuroprotective taxane-like compound that stabilizes 
MTs, promotes MT assembly, and ultimately enhances axonal transport in neurons [151]. 
Treatment with EpoD increases the number of stable MTs that are highly enriched with 
AcetTUB [187, 188]. Recently, it was shown that systemic injection of EpoD could 
attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced loss of DAergic 
neurons in the nigrostriatal DA pathway of mice through stabilization of MTs and 
subsequent promotion of axonal transport [153]. It is currently unknown whether EpoD 
treatment can prevent METH-induced deficits in striatal DAergic markers. 
 The primary objective of this study was to investigate whether axonal transport 
plays a role in the development of deficits in DAergic markers in nigrostriatal axons in 
response to binge METH. We hypothesized that METH treatment would destabilize MTs 
in striatal DAergic axons, which would subsequently impair axonal transport from the 
substantia nigra pars compacta (SNpc) to the dorsal striatum. To investigate this 
hypothesis, we employed a moderately toxic METH regimen to avoid extensive damage to 
DAergic axons and examined striatal MTs at a time point when they are expected to be 
maximally destabilized [153]. To assess MT stability, we utilized antibodies against 
specific PTMs of α-tubulin and antibody against βIIITUB. Using immunofluorescent 
staining we identified a significant decrease in AcetTUB, a marker of stable MTs, in TH-
positive striatal axons in rats treated with binge METH. Our second objective was to 
investigate the effects of the MT-stabilizing compound EpoD on the development of 
METH-induced DAergic deficits and MT dynamics within the striatum. We hypothesized 
that EpoD treatment would prevent the METH-induced loss of striatal DAergic markers. 
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To test this hypothesis, we administered two treatment regimens of EpoD alone or in 
combination with binge METH to adult Sprague-Dawley rats. Low doses of EpoD 
prevented decreases in the levels of DA, TH, and DAT and in the levels of AcetTUB in the 
striatum. High doses of EpoD potentiated METH-induced deficits in DA, DA metabolites 
and DAT and METH-induced acetylation of striatal MTs. In conclusion, our data suggest 
that binge METH has destabilizing effect on axonal transport in the nigrostriatal DA axons, 
which can be prevented by low doses of MT-stabilizing drug EpoD. 
3.1.1 Materials and Methods 
3.1.2 Subjects 
 A total of 71 adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 
350-400 g (on postnatal day 80) were used for experiments. All animal procedures were 
conducted in strict adherence to the Wayne State University Institutional Animal Care and 
Use Committee approved protocol # A-05-07-13.  
3.1.3 Drug Treatments 
 D-Methamphetamine HCl (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
sterile saline (0.9% NaCl) to a final concentration of 10 mg/mL. Binge METH treatment 
consisted of four successive intraperitoneal (i.p.) injections of METH (10 mg/kg METH-
HCl, 8 mg/kg freebase METH) administered at 2-h intervals at ambient temperature of 21–
22°C. In our hands, this METH regimen leads to moderate deficits in DA (20–25%) when 
measured at 7 days after the administration of the drug. 
 EpoD (Abcam, Cambridge, UK) was dissolved in dimethylsulfoxide (DMSO) to a 
final concentration of 0.5 mg/mL (working solution for low doses) and 5 mg/mL (working 
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solution for high doses). Rats in the EpoD groups were treated with either low doses of 
EpoD (EpoDL) or high doses of EpoD (EpoDH). Specifically, the EpoDL group received 
a single injection of 0.3 mg/kg EpoD 30 min prior to METH or saline, 0.1 mg/kg during 
METH or saline binge (1 h after the 3rd injection), and 0.1 mg/kg 24 h after the last 
injection of METH or saline. The EpoDH group received a single injection of 3 mg/kg 
EpoD prior to METH or saline, 1 mg/kg during METH or saline treatment, and 1 mg/kg 
after the last injection of METH or saline. All the rats received < 0.4 mL/kg DMSO. 
Exposure to DMSO was minimized to avoid the potentially confounding side effects of 
DMSO [171, 189-192]. Rectal temperatures were measured using a Thermotemp rectal 
probe (Physitemp, Clifton, NJ, USA). All the rats were killed via live decapitation 3 days 
after the last METH or saline injection. The details of the overall study design are 
summarized in Fig. 9. The 3rd-day time point was chosen for brain analysis because a 
previous study on axonal transport impairment showed that MPTP-induced changes to 
MTs occurred early (i.e., within 3 days) after the neurotoxic insult and prior to DAergic 
axon loss [153]. In rats, binge METH toxicity, manifested by deficits in DAergic markers, 
develops over approximately 3 days [40, 174, 193]. 
3.1.4 Tissue collection 
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 All tissues were collected on ice, and the brains were rinsed with ice-cold 
phosphate-buffered saline. To measure total protein and neurotransmitter levels, both the 
striatum and SNpc were dissected from the right hemisphere using blunt dissection 
methods. The resulting tissue pieces were then immediately placed on dry ice and stored 
at −80°C until assayed. The left hemisphere was post-fixed in paraformaldehyde for 72 h 
at 4°C. The post-fixed brains were processed as previously described [96]. 
Figure 9. Study design to investigate methamphetamines effects on axonal transport. Study 
Design. Adult male Sprague–Dawley rats weighing 350–400 g were used for all 
experiments. Methamphetamine chloride (METH HCl) (4 × 10 mg/kg, i.p.) or saline (1 
mL/kg) was administered to rats at 2-h intervals (solid red arrows). The animals were killed 
3 days after the last METH or saline injection (solid black arrow) and assessed for the 
levels of tubulins and dopaminergic (DAergic) markers in the striatum and substantia nigra 
pars compacta (SNpc). A separate group of rats was treated with a microtubule-stabilizing 
drug epothilone D (EpoD) or vehicle 24 h before, during (after the 3rd injection) and 24 h 
after binge METH or saline treatment (purple arrows). Three 30-min open-field motor 
activity measurements were performed for both groups at times indicated by dotted black 
arrows. The second group of animals was also killed at 3 days after the last METH or saline 
injection and assessed for striatal tubulins and DAergic markers. 
 
3.1.5 Western blot 
 Western blot analysis was conducted as previously described [96]. Polyvinylidene 
difluoride membranes were probed with one of the following primary antibodies: anti-DAT 
(1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-β-actin (1 : 5000; Cell 
FIGURE 9 STUDY DESIGN TO INVESTIGATE METHAMPHETAMINES EFFECTS ON AXONAL TRANSPORT 
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Signaling Technology, Danvers, MA, USA), anti-DetyTUB (1 : 1000; Millipore 
Corporation, Billerica, MA, USA), anti-TyrTUB (1 : 1000; Millipore), anti-AcetTUB (1 : 
1000; Cell Signaling), anti-βIIITUB (1 : 1000; Abcam), anti-α-tubulin (1 : 1000; Santa 
Cruz Biotechnology), anti-dynein (1 : 1000; Santa Cruz Biotechnology), anti-kinesin heavy 
chain (1 : 1000; Santa Cruz, Biotechnology), anti-GFAP (1 : 1000; abcam), anti-caspase-3 
(1 : 1000; Cell Signaling), or anti-4-hydroxynonenal (4-HNE (1 : 500, R&D Systems, 
Minneapolis, MN, USA) and appropriate secondary antibodies. The blots were developed 
using a LAS4000 Bioimager (GE Healthcare, Piscataway, NJ, USA). All the blots 
contained at least two samples representative of each experimental condition. 
Immunoreactivity was quantified using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). 
3.1.6 Immunohistochemistry 
 Fixed brain tissues were processed as previously described [96]. Citrate buffer 
antigen retrieval (ThermoFisher, Waltham, MA, USA) was applied to all tissue sections. 
The sections were incubated overnight at 4°C with an anti-TH antibody and antibodies 
specific for one of the following: AcetTUB, TyrTUB, DetyTUB, βIIITUB, or α-tubulin – 
all of which were diluted 1 : 500 in the blocking buffer. The sections were then incubated 
for 2.5 h at 21°C with the blocking buffer containing diluted (1 : 400) Alexa Fluor® 488 
goat anti-mouse (Invitrogen, Carlsbad, CA, USA) and Alexa Fluor 598 goat anti-rabbit 
(Invitrogen) antibody. DRAQ5 (Invitrogen) was used to stain nuclei. The sections were 
then mounted using Fluoromount mounting medium (Southern Biotech, Birmingham, AL, 
USA). The immunostaining was imaged using the Leica TCS SPE-II laser scanning 
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confocal microscope (Leica, Wetzlar, Germany). Non-compressed raw single z-plane 
images were exported from the Leica Image Analysis Suite (Leica). These images were 
then analyzed using Imaris co-localization analysis software (Bitplane South Windsor, CT, 
USA). For each, image automatic thresholding and masking functions were used to prevent 
interference from signal noise and variations in signal intensity. The resulting percent co-
occurrence in the TH channel was normalized to that in the non-treated control for ease of 
graphical comparison. The final value represents the percentage of signal overlap within 
the TH signal. 
3.1.7 High-performance liquid chromatography 
 The procedures were conducted as previously described [165]. All the procedures 
were conducted on ice or under refrigeration. Briefly, the tissues were sonicated in 0.5 mL 
of 0.3 N perchloric acid for 30 s, and the resulting homogenate was centrifuged for 30 min 
at 12 000 × g. The pellet was dissolved in 1 M NaOH overnight at 4°C, and protein 
concentrations were determined using the bicinchoninic acid protein assay 
(ThermoScientific). To measure DA content, 20 μL of the supernatant was injected into 
the mobile phase containing 90 mM sodium dihydrogen phosphate monohydrate, 50 mM 
citric acid, 1.7 mM 1-octane sulfonic acid, 50 μM EDTA, and 10% acetonitrile 
(ThermoScientific), at a flow rate of 0.5 mL/min. The samples were separated using a C-
18 reverse-phase column (150 × 3.2, 3 μM particle size; ThermoScientific). DA and its 
metabolites were then detected electrochemically (electrode 1: −150 V, electrode 2: +220 
V). The final values are reported as nanograms of analyte per microgram of protein. 
3.1.8 Open-field motor activity 
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  The gross motor activity of all the animals was assessed using the Opto-Varimex 
4 Auto Track open-field Plexiglass chamber (Columbus Instruments, Columbus, OH, 
USA). At the beginning of each session, the animals were placed in the middle of the 
Plexiglass chamber, and their subsequent movement and position were recorded 
continuously. For each animal, gross motor activity was assessed for three 30-min sessions. 
The sessions were conducted the day before METH treatment, immediately after the third 
METH injection (before the 2nd EpoD dose), and 24 h after the last METH injection 
(before the 3rd EpoD dose). Locomotor activity was calculated automatically from the raw 
beam-break data by the Opto-Varimex software. 
3.1.9 Functional observational battery 
 FOB assessments are useful to catalog neurotoxic effects when little is known about 
the potential neurotoxicity of a drug. Therefore, we conducted a shortened FOB based 
on[194] 24 h after binge METH. Briefly, technicians were blinded to all treatment 
conditions and only provided with animal identification numbers. Prior to the FOB, each 
technician was given instructions on how to document each of the scaled (1=least response, 
5=most response) and quantal (i.e., was the clinical sign present or absent?) scores. Each 
animal was assessed by three different technicians.  A specific measure was reported only 
if there was >90% interobserver agreement.   
3.1.10 Statistical analysis 
 Datasets containing two experimental groups were analyzed using unpaired two-
tailed Student's t-test with and without Bonferroni correction for multiple comparisons. To 
analyze datasets with three or more groups, one-way analysis of variance (anova) followed 
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by Tukey's post hoc test was performed. Two-way anova was performed on selected 
datasets to determine whether there was an interaction between METH and EpoD effects. 
Two-way repeated measures anova with Student–Newman–Keuls post hoc test was used 
to analyze the core body temperature data. Acclimation behavior was analyzed using 
simple linear regression analysis. All graphs were generated using GraphPad Prism 5 
(GraphPad Software Inc., La Jolla, CA, USA), and all statistical operations were performed 
using SPSS (IBM). Statistical significance was set at p < 0.05. 
3.2 Results 
3.2.1 The effects of binge METH on DAergic markers in the striatum 
 Prior to the treatments, an average core body temperature of the animals was 
36.6°C, which is the normal temperature for adult rats (Fig. 10a). Saline treatment did not 
significantly affect core body temperature at any time point. One hour after the first 
injection of METH, the rats had an average temperature of 38.9°C. Core body temperatures 
of the METH-treated animals significantly increased at 1, 3, 5, and 7 h after the first METH 
injection compared to saline controls. Core body temperatures were the highest at 5 and 7 
h after the first METH injection, with mean values of 39.8°C and 40.5°C, respectively. 
 Compared to striatal whole-tissue lysates from saline-treated rats, there was a 
significant reduction in both DAT (−68%) and TH (−33%) immunoreactivity in striatal 
whole-tissue lysates from METH-treated animals at 3 days after the last injection of the 
drug (Fig. 10b and d). There was no significant difference in DAT or TH immunoreactivity 
between saline and METH rats in the SNpc tissue lysates (Fig. 10c). The loss of striatal 
DAT and TH was verified in fluorescently labeled brain slices, which showed a visible and 
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proportional reduction in DAT and TH signal within the striatum of the METH-treated rats 
compared with the striatum of the saline controls (Fig. 10e). High-contrast single-plane 
images of TH-labeled striatal axons in the striatum showed swollen axons and fragmented 
TH immunoreactivity 3 days after METH (Fig. 10f). 
 
Figure 10. Levels of dopaminergic (DAergic) markers in the rat striatum and substantia 
nigra pars compacta (SNpc) 3 days after binge methamphetamine (METH). Rats were 
treated with four successive intraperitoneal (i.p.) injections of either saline (SAL) 
(1 mL/kg) or METH-HCl (10 mg/kg) at 2-h intervals. Three days later, the animals were 
killed and brain tissue was harvested. (A) Core body temperature of animals during binge 
METH or SAL treatment measured 1 h after each injection. METH induced significant 
hyperthermia over time ***p < 0.001 SAL vs. METH, two-way anova with repeated 
measures followed by Student–Newman–Keuls post hoc test, n = 5). (B and C) Quantified 
dopamine transporter (DAT) and tyrosine hydroxylase (TH) immunoreactivities in the 
striatum (B) and SNpc (C). METH significantly reduced DAT (−68%) and TH (−33%) 
immunoreactivity in the striatum (*p < 0.025, **p < 0.01, Student's two-tailed t-test with 
Bonferroni correction, n = 5) and not in the SNpc. (D) Representative western blot images 
of DAT (72 kDa), TH (64 kDa), and β-actin (45 kDa) from rats administered saline (S) or 
METH (M). β-Actin immunoreactivity was used as a loading control. All band density 
values were normalized to the saline controls. (E) Fluorescently labeled DAT (red) and TH 
(green) in brain tissue slices of the striatum and SNpc. The images depicting the striatum 
are magnified 40× to show individual axons; the SNpc images are magnified 4× to show 
FIGURE 10 LEVELS OF DAERGIC MARKERS IN THE RAT STRIATUM AND SUBSTANTIA NIGRA PARS 
COMPACTA (SNPC) 3 DAYS AFTER BINGE METHAMPHETAMINE 
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the total surface of this area. Channel overlay shows co-localization of green and red signal 
in yellow. (F) High-contrast images of TH immunoreactivity in striatal brain slices show 
the morphology of TH-labeled striatal axons. All data are expressed as mean ± SEM. 
 
3.2.2 The effects of binge METH on microtubules in the nigrostriatal dopamine 
pathway 
 AcetTUB, DetyTUB, TyrTUB, and βIIITUB immunoreactivities were detectable 
in both the SNpc and the striatum (Fig. 11a). There were no detectable differences in the 
immunoreactivity of any of the tubulins in the SNpc tissue lysates between the saline- and 
METH-treated rats (Fig. 11b). The immunoreactivity of both βIIITUB and DetyTUB was 
significantly lower (−10% and −14%, respectively) in the striatal lysates of the METH-
treated animals compared to the lysates of the saline-treated controls (Fig. 11c). AcetTUB 
and TyrTUB immunoreactivity in striatal lysates did not differ between saline- and METH-
treated animals. The ratio of TyrTUB to DetyTUB was significantly higher (+26%) in 
striatal lysates of animals treated with METH than in saline controls (Fig. 11d).  
 Because MT PTMs that are assessed in total tissue lysates are not specific for 
DAergic axons, we probed striatal tissue sections with anti-TH antibody and antibodies 
against different tubulins to assess METH effect on MTs in DAergic axons. The results 
showed high basal levels of DetyTUB, AcetTUB, and βIIITUB in the striatum (Fig. 11f, 
g, and h). In agreement with previous reports, these MT populations were differentially 
expressed in axons and cell bodies; more specifically, DetyTUB and AcetTUB were more 
enriched in axons as opposed to the cell bodies. DetyTUB, AcetTUB, and βIIITUB were 
highly expressed in DAergic axons as well as in the surrounding TH-negative axons and 
cell bodies (Fig. 11f, g, and h). In the rats treated with METH, DAergic axons were 
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enriched with βIIITUB (Fig. 11h) and deficient in both AcetTUB (Fig. 11f) and DetyTUB 
(Fig. 11g). The immunofluorescence co-occurrence analysis revealed a significant loss of 
AcetTUB in the TH-positive axons (−52%) 3 days after binge METH as compared to saline 
controls (Fig. 11e). There was also a loss of DetyTUB (−33%) in these axons as well; 
however, it did not reach statistical significance. TyrTUB was not readily detectable in the 
TH-positive axons and, therefore, not quantified (data not shown). 
 
Figure 11. Tubulins in the striatum and substantia nigra pars compacta (SNpc) 3 days after 
methamphetamine (METH) treatment. Rats were treated with four successive 
intraperitoneal (i.p.) injections of either saline (SAL) (1 mL/kg) or METH-HCl (10 mg/kg) 
at 2-h intervals and killed 3 days later. (A–C) Western blot analysis of lysates from the 
striatum (B) and SNpc (C) labeled with antibodies specific for detyrosinated α-tubulin 
FIGURE 11 TUBULINS IN THE STRIATUM AND SUBSTANTIA NIGRA PARS COMPACTA (SNPC) 3 DAYS AFTER 
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(DetyTUB, 50 kDa), tyrosinated α-tubulin (TyrTUB, 50 kDa), βIII tubulin (βIIITUB, 52 
kDa), acetylated α-tubulin (AcetTUB, 50 kDa), α-tubulin (αTUB, 50 kDa), and β-actin (45 
kDa) (loading control). (A) Representative western blot images for (B) and (C). METH 
significantly decreased the immunoreactivity of DetyTUB (−14%) and βIIITUB (−10%) 
in striatal but not nigral tissue lysates (*p < 0.05 Student's two-tailed t-test without 
Bonferroni correction for multiple comparisons, n = 5). (D) Compared to saline, METH 
increased the ratio of TyrTUB to DetyTUB in striatal lysates (+26%, *p < 0.05 Student's 
two-tailed t-test, n = 5). (F–H) Images of fixed striatal brain slices fluorescently labeled for 
(F) AcetTUB, (G) DetyTUB, and (H) βIIITUB (all depicted in red) as well as for tyrosine 
hydroxylase (TH) (green) and nuclei (blue). (E) Quantification of co-occurrence of tubulins 
and TH in striatal tissue slices. Co-occurrence is defined as the percentage of TH signal 
that contains the tubulin signal above a threshold. METH significantly decreased the 
immunoreactivity of AcetTUB (−52%) and DetyTUB (−33%) in TH-positive striatal axons 
(*p < 0.017, Student's two-tailed t-test with Bonferroni correction n = 5). All band density 
values and co-occurrence values were normalized to the respective saline controls. The 
data are expressed as mean ± SEM. 
 
3.2.3 The effects of EpoD on METH-induced alterations to microtubules in the 
striatum 
 Treatment with EpoDL slightly increased DetyTUB immunoreactivity in the 
striatum following saline (+36%) and markedly following METH (+78%) when compared 
with DMSO/saline treatment (Fig. 12a). When compared with EpoDL/saline treatment, 
DetyTUB increased in EpoDL/METH group by 31%. Treatment with EpoDH had little 
effect on the tubulins when administered alone, but when EpoDH was administered with 
METH, it resulted in a substantial loss of DetyTUB signal compared to DMSO/saline 
(−60%) and EpoDH/saline (−62%) group. All treatments minimally affected total striatal 
TyrTUB immunoreactivity. Compared to DMSO/saline controls, AcetTUB levels were 
reduced in the animals treated with both DMSO/METH and EpoDH/METH (−36% and 
−70%, respectively). Compared to EpoDH/saline, EpoDH/METH decreased AcetTUB 
levels by 67%. In contrast, the animals treated with EpoDL/METH had AcetTUB levels 
similar to those treated with DMSO/saline and those treated with EpoDL/saline. The 
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animals treated with DMSO/METH and EpoDH/METH had markedly lower levels of 
striatal βIIITUB compared with the DMSO/saline-treated animals (−46% and −55%, 
respectively) (Fig. 12b). α-Tubulin levels were similar across all the treatment groups. The 
animals treated with METH exhibited a small loss of the motor protein dynein (−28%) 
(Fig. 12c). In contrast, the animals treated with EpoDL and EpoDH together with METH 
did not show the loss of dynein in the striatum. Striatal kinesin signal was significantly 
greater in the striatal lysates of animals treated with EpoDH/METH (162%), but unchanged 
in all other treatment groups. EpoDL decreased the ratio of TyrTUB to DetyTUB in the 
striatum when administered with METH treatment (−70%) (Fig. 12d). The animals treated 
with EpoDH/METH showed a 2.8-fold increase in the ratio of TyTUB to DetyTUB 
compared to animals treated with DMSO/SAL. 
 The core body temperature profiles for the rats used in this experiment (Figs 12-
14) are shown in Fig. 14a. The average core body temperature (36.8°C) remained 
unchanged at all time points after treatment with DMSO/saline, EpoDL/saline, or 
EpoDH/saline (Fig. 14a). The animals treated with METH displayed significant 
hyperthermia at 1, 3, 5, and 7 h after the first injection of METH as compared to saline 
controls. A maximum mean body temperature of 39.8°C was observed in the 
DMSO/METH and EpoDH/METH group at 3 h after the first METH injection. The 
EpoDL/METH group reached 40.0°C 7 h after METH. There were no significant 
differences in hyperthermia between DMSO/METH-, EpoDL/METH-, and 
EpoDH/METH-treated rats with the exception of EpoDL/METH versus EpoDH/METH 
group comparison at 7 h after the first METH injection. Even though the maximum core 
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body temperatures in DMSO/METH group were lower in the second than in the first 
experiment (39.8°C vs. 40.5° C), the deficits in DAT and TH between the experiments 
were not very different (−68% and −33% vs. −50% and −27%). The loss of AcetyTUB was 
higher, whereas the loss of DetyTUB was comparable in the second experiment (−36% vs. 
−12% and −16% vs. 14%, respectively), suggesting that the METH-induced changes in 
MT PMTs do not depend on temperature. In support, there was no correlation between 
AcetyTUB or DetyTUB immunoreactivity and METH-induced hyperthermia (not shown). 
 
 
FIGURE 12 STRIATAL TUBULINS IN RATS TREATED WITH EPOTHILONE D (EPOD) AND METHAMPHETAMINE (METH) 
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Figure 12. Striatal tubulins in rats treated with epothilone D (EpoD) and methamphetamine 
(METH). Rats was divided into six subgroups. Two subgroups were treated with four 
successive intraperitoneal (i.p.) injections of either saline (SAL) (1 mL/kg) or METH-HCl 
(10 mg/kg). The remaining subgroups were treated with SAL or METH and with a low 
dose of epothilone (EpoD) (EpoDL; 0.5 mg/kg), high dose of EpoD (EpoDH; 5 mg/kg) or 
dimethylsulfoxide (DMSO) administered in 3 i.p. injections before, during, and after binge 
METH or saline. All animals were killed 3 days later and the striatal lysates were analyzed 
for (A) post-translational modifications of α-tubulin (α-TUB): detyrosinated α-tubulin 
(DetyTUB, 50 kDa), tyrosinated α-tubulin (TyrTUB, 50 kDa), and acetylated α-tubulin 
(AcetTUB 50 kDa), (B) tubulin isoforms: α-TUB (50 kDa) and βIII tubulin (βIIITUB, 52 
kDa), and (C) motor proteins: kinesin (heavy chain, 120 kDa) and dynein (95 kDa). α-TUB 
was used as a loading control for DetyTUB AcetTUB and TyrTUB while β-actin (45 kDa) 
was used as a loading control for other proteins. The immunoreactivities were normalized 
to saline/DMSO-treated controls. (A) Compared to METH alone, EpoDL/METH treatment 
increased, whereas EpoDH/METH treatment decreased the immunoreactivity of DetyTUB 
(+112% and −52%, respectively) and AcetyTUB (+66% and −52%, respectively). The 
DetyTUB and AcetyTUB in EpoDH/METH rats were also significantly decreased when 
compared with EpoDH/SAL controls (−62% and 67%, respectively). (B–D) In the 
EpoDH/METH-treated rats, βIIITUB immunoreactivity was decreased (−55% vs. 
DMSO/SAL) kinesin immunoreactivity was increased (+95% vs. EpoDH/SAL) and the 
ratio of TyrTUB to DetyTUB was increased (2.8-fold and 3.1-fold vs. DMSO/SAL and 
EpoDH/SAL, respectively). (E) Representative western blot images. All data are expressed 
as mean ± SEM. *p < 0.05, **p < 0.01 treatment vs. DMSO/SAL, #p < 0.05, ##p < 0.01, 
EpoD/SAL vs. EpoD/METH, ∏ (bracket) p < 0.05 differences within SAL and METH 
subgroups, one-way anova followed by Tukey's post hoc test, n = 4–13. Analysis of 
DetyTUB and AcetTUB data by two-way anova with Tukey post hoc test revealed co-
treatment (DMSO, EpoD) x treatment (SAL, METH) interaction for DetyTUB and 
TyrTUB/DetyTUB ratio (F(2.42) = 2.82, p < 0.05 and F(2,43) = 6.29, p < 0.01, 
respectively). 
 
3.2.4 The effects of EpoD on METH-induced decreases in the levels of DAergic 
markers in the striatum  
 Treatment with EpoDL alone increased striatal DA content by 40% without 
significantly affecting the levels of DA metabolites 3,4-dihydroxyphenylacetic acid 
(DOPAC) or homovanillic acid (HVA) (Fig. 13a–c). Conversely, the animals treated with 
EpoDH exhibited reduced striatal DA content (−50%) without significant reduction in 
striatal DOPAC or HVA content. The animals treated with METH alone had lower striatal 
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DA and DOPAC tissue concentrations (−63% and −48%, respectively) compared to the 
saline-treated animals. EpoDL reduced the METH-induced deficit in DA (to −43%) 
whereas EpoDH increased it (to −92%). Similar reductions in striatal DOPAC content were 
found in the EpoDL/METH-treated rats and in the rats treated with METH alone (−48%), 
while EpoDH/METH-treated rats showed 77% deficit in DOPAC. The ratio of the DOPAC 
to DA was similar in the animals treated with DMSO/saline, EpoDL/saline, and 
EpoDH/saline. Following METH, rats treated with DMSO or EpoDH showed a significant 
increase in the ratio of DOPAC to DA compared to the control rats (~ 2-fold and ~ 3.8-
fold, respectively); EpoDL restored DOPAC/DA ratio to the control value, that is, the 
animals treated with EpoDL/METH had a similar ratio of DOPAC to DA as the 
DMSO/saline-treated controls (Fig. 13d). 
 Both EpoDL and EpoDH significantly increased DAT (2.3-fold and 1.6-fold, 
respectively) (Fig. 13e), but not TH (Fig. 13f), immunoreactivity in the striatal lysates. The 
animals treated with DMSO/METH had significant reductions in both DAT (−50%) and 
TH (−27%). Although there was a significant reduction in striatal DAT when comparing 
EpoDL/saline- to EpoDL/METH-treated rats (−57%), the EpoDL/METH-treated animals 
had DAT levels that were similar to those of the DMSO/saline-treated animals, indicating 
a ‘rescue’ of DAT levels by EpoDL. The animals treated with EpoDH/METH showed 
drastic reductions in striatal DAT immunoreactivity (> 80%). The loss of TH in the 
EpoDH/METH-treated animals was similar to that in the DMSO/METH-treated animals. 
Reductions in TH were not observed in the EpoDL/METH-treated animals compared to 
DMSO/saline controls. Compared to EpoDL/saline controls, EpoDL/METH treatment 
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decreased DA, DOPAC, DAT, and TH levels to similar extents as METH treatment 
compared to saline treatment (by 59%, 36%, 57%, and 18%, respectively). EpoDH/METH-
induced decreases in relation to EpoDH/saline controls (−86%, −69%, −94%, −36%) 
where larger than those induced by DMSO/METH compared to DMSO/saline controls. 
 To assess inflammatory response in the experimental groups, GFAP 
immunoreactivity was measured in striatal lysates by western blotting analysis. Compared 
to DMSO/saline controls, GFAP immunoreactivity was significantly increased in the 
striatum 3 days after DMSO/METH (+57%) and EpoDH/METH (+69%) treatment (Fig. 
13g). In contrast, GFAP expression was not significantly increased in the animals treated 
with EpoDL/METH. Although full-length pro-caspase-3 (~ 35 kDa) was detected in all the 
lysates, the activated cleaved caspase-3 (~ 15 kDa) was not detected in striatal lysates under 
any treatment condition. Striatal levels of 4-HNE were slightly increased (~ 10%) after 
binge METH alone (data not shown). 
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Figure 13. Striatal dopaminergic (DAergic) markers in rats treated with epothilone D 
(EpoD) and methamphetamine (METH). A group of rats was divided into six subgroups. 
Two subgroups were treated with four successive intraperitoneal (i.p.) injections of either 
saline (SAL) (1 mL/kg) or METH-HCl (10 mg/kg). The remaining subgroups were treated 
with SAL or METH and with a low dose of epothilone (EpoD) (EpoDL; 0.5 mg/kg), high 
dose of EpoD (EpoDH; 5 mg/kg) or dimethylsulfoxide (DMSO) administered in 3 i.p. 
injections before, during, and after binge METH or saline. All animals were killed 3 days 
later and the striatal lysates were analyzed for (A–F) DAergic markers, (G) glial fibrillary 
acidic protein (GFAP, 50 kDa), and (H) caspase-3 (35 and 17 kDa). β-Actin was used as a 
loading control. EpoDL and EpoDH alone both increased dopamine transporter (DAT) 
immunoreactivity (2.3-fold and 1.6-fold, respectively) while they have the opposite effects 
on DA (+40% and −50%, respectively). EpoD administration potentiated the METH-
induced deficits in striatal (A) DA (−63% vs. 92%), (B) 3,4-dihydroxyphenylacetic acid 
(DOPAC) (−48% vs. −77%), and (F) dopamine transporter (DAT, 60–80 kDA) (−50% vs. 
FIGURE 13 STRIATAL DAERGIC MARKERS IN RATS TREATED WITH EPOTHILONE D (EPOD) AND METHAMPHETAMINE (METH) 
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−90%) as well as in (D) the METH-induced increase in DOPAC/DA ratio (2-fold vs. 3.8-
fold). Compared to DMSO/SAL group, DA and DAT content in EpoDL/METH group was 
decreased by 43% and 50%, respectively, while compared to EpoDL/SAL group these 
markers were decreased by 59% and 57%, respectively. (F) Tyrosine hydroxylase (TH, 60 
kDa) content in EpoDH/METH group significantly decreased in relation to EpoDH/SAL 
group (−36%). (G) DMSO/METH and EpoDH/METH treatment increased GFAP 
immunoreactivity (+57% and +69%, respectively). (H) Neither treatment activated 
caspase-3. (H) Representative western blot images. Band density values were normalized 
to DMSO/SAL values. All data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p 
< 0.001, treatment vs. DMSO/SAL; #p < 0.05, ##p < 0.01, ###p < 0.001, EpoD/SAL vs. 
EpoD/METH; ∏ (bracket) p < 0.05 differences within SAL and METH subgroups; one-
way anova followed by Tukey's post hoc test, n = 4–13. Analysis of DA, DAT, and 
DOPAC/DA data by two-way anova with Tukey post hoc test revealed co-treatment 
(DMSO, EpoD) × treatment (SAL, METH) interaction for DAT and DOPAC/DA ratio 
(F(2.43) = 7.17, p < 0.01 and F(2,44) = 5.79, p < 0.01, respectively). 
 
3.2.5 Behavioral response of rats to EpoD and METH  
 Figure 14b–d depicts the analysis of motor activity counts 24 h before, during (after 
the 3rd METH injection), and 24 h after binge METH. Prior to METH administrations, the 
animals in all treatment groups displayed similar locomotor activity profiles (Fig. 14b). A 
similar pattern of locomotor activity was maintained across all the sessions by the animals 
treated with DMSO/saline and EpoDH/saline. The animals treated with EpoDL/saline or 
EpoDL/METH displayed increased stereotypy (seen as dense green nodules) during the 
treatment phase. The animals treated with DMSO/METH also displayed more stereotypy 
than DMSO/saline controls, but less than EpoDL/METH-treated rats (Fig. 14c). The 
animals treated with EpoDH/METH displayed less stereotypy than the other two METH 
groups; instead, they maintained hyperlocomotion during METH administration (Fig. 14b). 
The treatment with EpoDL/METH produced the highest levels of stereotypy and the 
greatest suppression of distance traveled. During the post-treatment phase (24 h post-
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METH), the animals treated with METH showed significant reduction in the overall motor 
activity when compared with saline controls regardless of EpoD dose. 
 During the pre-treatment session, the animals from all groups displayed normal 
acclimation behavior that was characterized by a marked negative correlation between the 
distance travelled and the duration of the session (Fig. 14d). The animals treated with either 
DMSO/saline, EpoDL/saline, or EpoDH/saline exhibited similar acclimation behavior 
throughout all behavioral sessions. In the animals treated with DMSO/METH, 
EpoDL/METH, or EpoDH/METH, the slope between the distance traveled and time was 
lost during the treatment session because of emergence of stereotypy, with animals from 
the EpoDH group simultaneously maintained locomotor activity and stereotypy. During 
the post-treatment session, the slope for DMSO/METH and EpoDL/METH groups 
recovered slightly (to 23% and 10%, respectively, of their pre-treatment values) (Fig. 14d). 
 Table 2 shows the results of the FOB conducted 24 h after the final dose of METH.  
Animals treated with DMSO/saline and EpoD/saline had similar FOB scores and a 0% 
mortality rate. Although DMSO/METH-treated animals showed slightly less arousal than 
DMSO/saline-treated controls, and the mortality rate was much higher (42%). 
EpoD/METH was associated with an even higher mortality rate (50%). Nearly 70% of the 
animals in the EpoD/METH group displayed overt clinical abnormalities associated with 
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gross toxicity, whereas only 16% of the DMSO/METH group displayed overt clinical 
abnormalities. 
  
Figure 14. Locomotor activity of rats treated with epothilone D (EpoD) and 
methamphetamine (METH). Rats was divided into six subgroups. Two subgroups were 
treated with four successive intraperitoneal (i.p.) injections of either saline (SAL) (1 
mL/kg) or METH-HCl (10 mg/kg). The remaining subgroups were treated with SAL or 
METH and with a low dose of epothilone (EpoD) (EpoDL; 0.5 mg/kg), high dose of EpoD 
(EpoDH; 5 mg/kg) or dimethylsulfoxide (DMSO) administered in 3 i.p. injections before, 
during, and after binge METH or saline. (A) Core body temperatures were recorded before 
METH (0.5 h) and 1 h after each METH or SAL injection. METH induced significant 
hyperthermia over time (***p < 0.001 SAL vs. METH, two-way anova with repeated 
measures followed by Student–Newman–Keuls post hoc test, n = 3–11). (B) 
Representative activity maps. Continuous green line traces animal's movement during each 
FIGURE 14 LOCOMOTOR ACTIVITY OF RATS TREATED WITH EPOTHILONE D (EPOD) AND METHAMPHETAMINE 
(METH) 
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30-min session. The animals treated with EpoDH/METH displayed less stereotypy (seen 
as dense green nodules) than other METH groups; instead, they maintained 
hyperlocomotion during METH administration. (C) Quantification of total motor activity 
counts during the 30-min open-field tests performed 24 h before METH (pre-treatment), 
after the third METH injection (treatment), and 24 h after the last METH injection (post-
treatment). The rats treated with EpoDL/SAL or EpoDL/METH displayed increased 
stereotypy during the treatment phase. The animals treated with DMSO/METH also 
displayed more stereotypy than DMSO/saline controls but less than EpoDL/METH-treated 
rats. (D) Acclimation behavior during each of the 30-min locomotor activity sessions. 
Linear regression analysis was performed between the distance traveled and time. All data 
are expressed as mean ± SEM. *p < 0.05, treatment vs. DMSO/SAL; #p < 0.05, EpoD/SAL 
vs. EpoD/METH; ∏ (bracket) p < 0.05, differences within SAL and METH subgroups; 
one-way anova followed by Tukey's post hoc test, n = 4–13. Analysis of stereotypy data 
by two-way anova with Tukey post hoc test revealed a trend for co-treatment (DMSO, 
EpoD) × treatment (SAL, METH) interaction for total time spent in stereotypy (ST) 
(F(2,36) = 7.17, p = 0.073). Abbreviations: DT, total distance traveled; RT, total time at 
rest; ST, total time spent in stereotypy; AT, total ambulatory time; BSM, bursts of 
stereotypy; HC, horizontal counts; AC, ambulatory counts; EpoDL, low-dose EpoD; 
EpoDH, high-dose EpoD. 
 
Table 2. Functional Observation Battery 
Parameter 
DMSO/Saline
C (n=3) 
EpoDH/SalineC 
(n=3) 
DMSO/METHC 
(n=6) 
EPODH/METHC 
(n=7) 
Click 
ResponseA  
5.4 ± 0.29 4.4 ± 0.96 3.2 ± 0.83 2.7 ± 0.92 
ArousalA  6.4 ± 0.29 5.7 ± 1.06 4.3 ± 0.98 3.5 ± 0.65 
Home Cage 
PostureB  
0/3 1/3 1/6 5/7 
PorforinB  0/3 0/3 1/6 5/7 
PiloerectionB  0/3 0/3 1/6 4/7 
Mortality Rate 0/9 (0%) 0/9 (0%) 6/14 (42%) 7/14 (50%) 
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3.3 Discussion 
 Our first important finding was the loss of stable MTs in striatal DAerigic axons 
following binge METH. Although we report the loss of a few tubulins in the striatum, only 
the loss of AcetTUB appeared to be specific for striatal DAergic axons. Our second 
significant finding was that the treatment with the MT-stabilizing drug EpoD could prevent 
the METH-mediated loss of AcetTUB and the loss of striatal DAergic markers when 
administered at a low dose while potentiating METH-mediated losses of DAergic markers 
and markers of stable MTs when administered at a high dose. Finally, we demonstrated 
that EpoD treatment produced acute effects on METH-induced hyperlocomotion and 
stereotypy, raising the possibility that MT stabilization has an effect on DA signaling. 
 Binge METH administration results in both reversible and irreversible loss of 
striatal DAergic markers with the latter being considered a manifestation of ‘classic’ 
METH neurotoxicity. These ‘classic’ neurotoxic effects of METH are mediated, in part, 
by oxidative stress [195] and can induce reactive gliosis and pro-apoptotic caspase-3 
cleavage throughout the striatum [40, 196, 197]. We observed only a mild increase in the 
immunoreactivity of the reactive gliosis marker GFAP and no signal for cleaved caspase-
3 in the striatum of METH-treated animals (Fig. 13i). Striatal levels of 4-hydroxynonenal 
were also only slightly increased (~ 10%) after binge METH (data not shown). These 
results suggest that the METH-induced oxidative stress and loss of DAergic terminals was 
modest and that the marked deficits in DA, DAT and DOPAC were, in most part, reversible 
and caused by other than neurodegeneration mechanisms. Consequently, the MT 
alterations we are describing predominantly reflect combination of transient METH effects 
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on MTs and neuroadaptive responses in DAergic neurons, and not ‘classic’ neurotoxicity 
per se (i.e., a physical loss of DAergic axons). This interpretation is further supported by a 
relatively modest reduction in striatal DA content (~ 22%) observed 7 days following the 
same regimen of binge METH (data not shown). DA deficits are normally much greater (> 
60%) in ‘classic’ METH neurotoxicity models at this time point [40, 198]. We did observe 
swollen axons with discontinuous TH signal in the striatum following METH; these axons 
were similar to the ‘empty’ axons lacking vesicles, mitochondria, and other components 
detected in the nigrostriatal DA pathway in 1-methyl-4-phenylpyridinium (MPTP)-treated 
mice [153]. Some of these TH-positive axons are likely irreversibly damaged [55], but the 
GFAP and TH data suggest that most axons are not. The lack of gross neurotoxicity is 
likely explained by the lack of severe hyperthermia (≥ 41°C), which is a crucial determinant 
of METH-induced neurotoxicity [40, 193]. In our hands, the METH-treated animals 
displayed acute hyperthermia; however, the effect was modest (average core body 
temperature of approximately 40°C). Some of the effects of METH on DAergic markers at 
regimens that do not increase core body temperatures above 40.5°C are short-lasting [52, 
173, 174, 193], a finding that agrees with higher DA loss at 3 days than at 7 days after 
METH in our drug regimen. Although small, the increase in GFAP immunoreactivity was 
present in DMSO/METH and EpoDH/METH groups, but not in EpoDL/METH group, 
suggesting that administration of EpoDL with METH prevented METH-triggered reactive 
gliosis. Lack of caspase-3 activation in the striatum indicates that EpoDH did not augment 
METH-mediated toxic events such as mitochondrial dysfunction or oxidative stress in 
striatal neuronal cell bodies [199]. 
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 The heterogeneity of α-tubulin PTMs in polymerized MTs is thought to impart their 
different functions [200-202]. MTs that are enriched in AcetTUB and DetyTUB 
preferentially recruit the anterograde motor protein kinesin and promote axonal transport 
[180, 203], whereas TyrTUB is highly enriched in newly formed and dynamic MTs [186]. 
In agreement with recent findings in endothelial cells [150], we found that METH exposure 
led to the loss of AcetTUB, which is highly enriched in stable MTs. The loss of AcetTUB 
was more pronounced in TH-positive striatal axons than in striatal tissue lysates (Fig. 11), 
suggesting some level of specificity of this effect for striatal DAergic axons. METH also 
resulted in a significant increase in the ratio of TyrTUB to DetyTUB, further suggesting 
the loss of stable MTs within the striatum. The increased ratio of TyrTUB to DetyTUB 
may also be indicative of the increased recruitment of CAP-glycine proteins [204, 205], 
which are required for initiation of dynein-mediated retrograde axonal transport [206], 
possibly to remove cellular components oxidatively damaged by METH [207, 208]. 
 The βIIITUB deficit observed in METH-treated rats could reflect decreased levels 
of MTs in DAergic axon [209]. This scenario is unlikely because the co-occurrence of 
βIIITUB with TH immunostaining was not decreased. Alternatively, given the known MT-
destabilizing effects of βIIITUB over-expression [184], the loss of striatal βIIITUB might 
reflect increased MT stability in non-DAergic striatal components, such as neurons, in 
response to METH. βIIITUB has numerous functions, including a role in mitochondrial 
respiration, neurogenesis, axonal guidance and intracellular trafficking as well as axonal 
maintenance, including association of MTs with kinesin [182, 210-212]. METH-mediated 
alterations in any of these functions or adaptive responses to METH effects could be 
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reflected in the βIIITUB deficit [199, 213, 214]. In summary, our results suggest that 
METH exposure resulted in the loss of stable MTs in striatal DAergic axons, an effect that 
would impede axonal transport and could account for the transient (i.e., reversible) loss of 
striatal DA, DOPAC, DAT, and TH observed 3 days after METH. 
 The loss of AcetTUB can impair axonal transport [215]. Since EpoD increases 
AcetTUB levels [153, 188], we hypothesized that EpoD would attenuate the METH-
induced deficits in AcetTUB and, ultimately, the loss of striatal DAergic markers. Only the 
low dose of EpoD (EpoDL) produced the desired effects. EpoDL prevented the METH-
mediated loss of AcetTUB (Fig. 4), DA, DAT, and TH (Fig. 13). As the deficits in striatal 
DAergic markers were similar in DMSO/METH and EpoDL/METH rats when compared 
to their respective controls, the EpoDL protection likely involved keeping DAergic 
markers at the physiological levels via axonal transport and not via attenuation of 
neurodegeneration. In agreement, EpoDL increased striatal DetyTUB levels and, 
consequently, the ratio of DetyTUB to TyrTUB while administered alone and in 
combination with METH, supporting also the data on a robust effect of epothilones on MT 
stability [216-218]. In contrast, co-administration of EpoDH with METH resulted in a 
potentiation of the METH-induced loss of AcetyTUB and in a drastic loss of DetyTUB and 
DAergic markers. Lack of an effect of EpoD and METH, alone or in combination, on 
TyrTUB levels suggests the lack of their effect on the formation of new MTs [217]. 
Collectively, our data indicate that the low-dose EpoD stabilized MTs and restored the 
levels several striatal DAergic markers decreased by METH, whereas high-dose EpoD 
impaired MT function and potentiated the depletion of striatal DA and DAT induced by 
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METH. It was not surprising given the known neurotoxic potential of taxols [219]. 
Consequently, treatments with EpoD at doses outside the ‘therapeutic window’ may 
produce unintended neuropathy in humans, particularly those with already compromised 
CNS such as METH users. Neuroprotective EpoD doses are likely different for different 
species. The high dose of EpoD was chosen based on the results from a previous study in 
which this dose was found to be neuroprotective against MPTP in mice [153]. Mice differ 
from rats and humans in responses to DAergic toxins. In humans, recent phase 1 clinical 
trials testing EpoD effects against Alzheimer disease employed much smaller dose of EpoD 
than the dose in the investigation of Cartelli and colleagues. 
 The animals treated with EpoDH/METH exhibited a drastic increase in kinesin 
levels. Motor protein kinesin is guided from the cell body to the axon by tyrosination of α-
tubulin [181]. Therefore, the METH-induced increases in kinesin might reflect an 
adaptational response in moderately destabilized striatal MTs in the axons or cell bodies 
surrounding the striatal DAergic axons. Previous findings have suggested a role of kinesin 
in the initial neural plasticity and development of drug addiction [220, 221]. METH 
exposure induces dendritic spines plasticity in the dorsal striatum [222]. Therefore, the 
increase in kinesin observed in the EpoDH/METH group could be explained by an increase 
in dendritic plasticity in this brain area. Future studies are needed to determine the 
specificity and function of METH-induced kinesin up-regulation. 
 In the striatum, DAergic innervation constitutes a few % of total pool of striatal 
components. EpoD- and METH-induced alterations in tubulin PTMs and in MT-associated 
proteins observed in the striatal whole-tissue lysates were 10% or greater; therefore, it is 
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likely that the METH-induced alterations of MTs are not exclusive to DAergic axons. 
Nevertheless, the METH-induced changes in particular MT PMTs within DAergic axons 
might be different from the changes induced by the drug within other striatal components. 
 EpoDL alone increased striatal DA, suggesting that EpoD increased the DA vesicle 
pool, possibly by promoting anterograde axonal transport of DA-containing vesicles [223, 
224]. EpoDH had the opposite effect on the striatal DA content, causing a marked reduction 
in the neurotransmitter. It remains unclear why the two EpoD doses produced the opposite 
responses. Administration of high EpoD doses can result in overstabilization of MTs [225], 
with a consequent impairment of axonal transport [226]. We did not observe an increase in 
AcetyTUB after EpoDH alone in the striatal lysates; however, such increase might have 
occurred in DAergic axons. Alternatively, EpoD may have had an effect on DA synthesis 
and/or metabolism [227, 228]. As expected [229], METH treatment increased the ratio of 
DOPAC to DA. EpoDH treatment exacerbated the METH-induced increase in the ratio of 
DOPAC to DA, whereas EpoDL produced the opposite result than EpoDH, seemingly 
suppressing METH-induced increase in the DOPAC/DA ratio. EpoDL treatment alone had 
similar effect on the DAT as it had on DA levels, whereas striatal TH levels remained 
relatively unchanged (Fig. 13), suggesting that EpoDL treatment preferentially enhances 
anterograde transport of the DAT and DA storage vesicles in relation to TH. This 
differential effect may be explained by differences in cargo transport rates. In general, 
membrane proteins are transported by fast axonal transport, whereas cytosolic proteins 
primarily by slow axonal transport [230]. Consequently, the DAT could have been 
transported at a higher rate than TH, causing EpoD enhancement of axonal transport at the 
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3rd-day time point more obvious for the DAT than for TH. On the other hand, TH, DA, 
and DAT all can be transported by fast axonal transport [135, 231] and, therefore, the 
observed differences might not be simply because of different axonal transport velocities. 
EpoD may have differentially affected retrograde axonal transport or terminal turnover 
(degradation) of these DAergic markers (they are degraded by different cellular processes: 
the proteasome, enzymatic metabolism, and lysosome, respectively). In the absence of 
METH, EpoDL and EpoDH both increased the levels of striatal DAT but had different 
effects on MT stability. Literature data indicate that both stabilization and destabilization 
of MTs can induce increased trafficking of the DAT to the plasma membrane [232, 233], 
thus indicating the importance of proper balance in MT dynamics. In the presence of 
METH, EpoDH decreased the immunoreactivity of DAT. This could have resulted from 
METH-mediated inhibition of DAT axonal transport overcoming the effect of EpoDH. 
 It can be speculated that enhancing anterograde transport of DA storage vesicles 
and DAT would increase cytosolic DA levels within DA terminals and would exacerbate 
METH neurotoxicity [199]. In our study, EpoDL increased striatal DAT and DA levels and 
decreased the METH-induced loss of DAergic markers. The increase in DAT was higher 
than the increase in DA; this might have resulted in increased release of DA via the DAT 
and, consequently, prevented DA-mediated oxidative stress. Our behavioral data (Fig. 14) 
support this scenario. EpoDH alone also increased the striatal DAT levels, but resulted in 
drastic depletions of DAT and DA contents following METH. The additive DA and DAT 
depleting effects of EpoDH and METH was likely a consequence of destabilization of MTs 
by both drugs via their depolarization [218, 234] and/or changes to DAergic markers 
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metabolism or turnover. Finally, since binge METH impairs mitochondrial function and 
decreases ATP [199], a deficit in ATP may have contributed to decreased transport of 
DAergic markers, and mitochondria, to the terminals. 
 METH-induced DA release induces locomotor activation and binge METH can 
result in long-lasting alterations in locomotor behavior [45, 235]. As expected, METH 
alone increased stereotypy during its administration as well as disrupted normal 
acclimation behavior and suppressed locomotor activity 24 h after METH exposure (Fig. 
6). EpoDL alone increased stereotypy during the treatment session, but had little effect on 
locomotor activity 24 h following treatments. This suggests there may be some acute 
effects of EpoD on signaling in the nigrostriatal DA pathway. The influence of MT stability 
on DA signaling and local DA synthesis may account for this effect [227, 228]. These 
studies showed decreased DAergic neurotransmission in mice with decreased MT stability, 
manifested by decreased levels of DA and its metabolites, decreased DA synthesis and 
release, decreased levels of DA D2 receptor, and decreased locomotor activity during the 
day. The EpoDL-induced increase in MT stabilization evoked opposite effects with up-
regulation of DAT levels possibly reflecting an adaptive response to the increase in DA 
release. Administration of EpoDL with METH appeared to exacerbate the METH-induced 
effects on stereotypy, likely because of combined effect on DA release. Animals in the 
EpoDL/METH group displayed a nearly 2-fold increase in this measure compared to 
DMSO/METH-treated animals, whereas EpoDH suppressed METH-induced stereotypy. 
The dose-dependent biphasic effect of EpoD on METH-induced stereotypy during the 
treatment paralleled EpoDL effects on DAergic markers observed on the 3rd day. METH-
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induced stereotypy is mediated mainly by post-synaptic D1 receptors in the striatum [236]. 
Hence, the data suggest that the EpoDL-mediated changes in MTs and DAergic markers 
occurred during METH administration and increased DA efflux. It is plausible that the 
‘protective’ effect of EpoDL involved decreasing the levels of free intracellular DA and, 
consequently, preventing DA-mediated oxidative stress, a notion supported by lack of 
increased GFAP expression. The EpoDL protection could have also involved keeping up 
proper axonal transport not only of DAergic markers but also of mitochondria and removal 
of damaged components from DAergic terminals [237]. In contrast, the EpoDH-induced 
potentiation of METH-induced losses in DAergic markers could have been mediated by 
impaired anterograde transport of these markers and mitochondria, as well as by impaired 
removal of damaged neuronal components because of inhibition of their retrograde 
transport or autophagy [238-240]. The emergence of hyperlocomotion instead of 
stereotypy in EpoDH/METH rats suggests a decrease in DAergic neurotransmission and 
supports the notion of an impaired transport of DA-containing vesicles. An alternative 
explanation for the decreased DAergic neurotransmission in these rats is EpoDH-mediated 
suppression of DAT activity with a resultant decrease in the reverse transport of DA and 
an increase in free cytosolic DA and its metabolism. This is supported by the increased 
DOPAC/DA ratio in EpoDH/METH rats. An increase in free DA accompanied by a deficit 
in ATP (because of an impaired transport of mitochondria) could have increased an 
oxidative stress within DAergic terminals. All the animals displayed a significant 
suppression of behavior following METH regardless of EpoD dose, suggesting the changes 
in DAergic markers persisting at 3 days post-METH did not affect motor activities. 
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Together, the locomotor activity data support the hypothesis that EpoD may have acute 
effects on striatal DAergic signaling. Future studies should focus on measuring DA release 
in the striatum following EpoD treatment to clarify molecular mechanisms underlying 
these findings. 
 The FOB performed 24 h after binge METH revealed that animals treated with 
EpoD/METH exhibited significantly less activity and alertness than METH-treated 
animals. The observed abnormal gait, posture, and responsiveness were parkinson-like and 
are consistent with striatal DA depletion greater than 80%. Indeed, animals in the 
EpoD/METH group had, on average, 85% reduction in striatal DA 72 h after METH. 
Therefore, the combination of EpoD and METH seemed to produce a parkinson-like motor 
deficit. FOB results suggested that EpoD increases the likelihood of poor clinical outcome 
after METH. Overall, the data support the idea that MT stability has a significant influence 
on DAergic nerve terminal function and that MT stabilization can have toxic consequences 
in DAergic neurons in METH-exposed animals.   
 In summary, we found a deficit in stable MTs, accompanying deficits in DAergic 
markers, within striatal DAergic axons 3 days following binge METH exposure. 
Furthermore, treatment with a low dose of MT-stabilizing drug EpoD prevented the 
METH-mediated loss of stable MTs and loss of striatal DAergic markers. The deficits in 
MT stability have been implicated in DA signaling-related disorders including 
schizophrenia, depression, and Parkinson's disease [146, 227, 228, 241, 242]. EpoD has 
been tested, with some success, to treat these disorders [146, 242, 243]. Our data suggest 
that EpoD may be effective in restoring striatal axonal transport and DAergic function in 
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animal models of METH abuse [244-246]and also in human users of the drug, potentially 
attenuating the risk for development of Parkinson's disease [176]. Further studies are 
needed to determine the ‘therapeutic window’ for the treatment of METH neurotoxicity. 
Figure 15. Summary of findings for axonal transport studies. Dopaminergic cell bodys 
(Left) in the substantia nigra projects to the axon nerve teminals in the striatum (right). 
Between the cell body and the axon terminals, the process of axonal transport takes place 
in the axon. Axonal transport is required for the health and maintenance of striatal 
dopaminergic nerve terminals. Axonal transport requires stable long lived microtubles that 
are rich in acetylated and detyrosinated α-tubulin. We assessed post-translational 
modifications of microtubles within the dopaminergic axons. We found a reduction in 
deytrosinated and acetylated α-tubulin in the striatal axons following binge 
methamphetamine. We also found a reduction in neuron specific tubulin, β-III tubulin. 
FIGURE 15 SUMMARY OF FINDINGS FOR AXONAL TRANSPORT STUDIES 
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Treatment with a microtuble stabilizing drug, epothilone D, was able to inhibit the 
reduction of these microtubles following methamphetamine. Together, our data here 
suggests that methamphetamine can impair axonal transport in nigral striatal dopamine 
neurons. Furthermore, microtuble stabilizing drugs can be used to reverse/prevent this 
effect of methamphetamine.  
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CHAPTER 4 PARKIN’S ROLE IN METHAMPHETAMINE 
NEUROTOXICITY 
 
4 Background 
 Parkinson’s disease (PD) is a progressive neurodegenerative disease affecting 
dopamine (DA) neurons of the nigrostriatal motor pathway [247, 248]. PD patients develop 
motor symptoms including rigidity, impaired posture, and abnormal gait.[249] Loss-of-
function mutations of PARK2, which encodes the E3 ubiquitin ligase PARKIN, are found 
in patients with familial PD. [250] Several Park2-/- rodent models (PKO) have been 
generated but they lack the phenotype or pathology consistent with a PD.[24, 97, 248, 251] 
It remains unclear why PKO animals lack a robust phenotype considering the proposed 
vitale role of parkin for DA neuron health and function. 
Methamphetamine (METH) exposure may increase the risk of developing PD.[24] 
METH is a neurotoxic psychostimulant that increases oxidative stress, inactivates parkin, 
and results in the gross axotomy of striatal DA axons.[25, 27, 55, 252] Following high-
dose METH exposure rats display lasting PD-like behaviors [45]. Recently, we determined 
that METH may impair microtubule stability within DAergic axons of the striatum 
contribute to its neurontoxicity. Parkin has been shown to be a possible MT stabilizing 
factor.  The neurotoxic effects of METH in PKO rats are unknown.  
 PKO rodents have abnormal DA signaling and metabolism. PKO mice are 
insensitive to evoked synaptic potentials [34] and evoked DA release in the striatum.[106, 
253, 254] METH potently evokes DA release in the striatum. When challenged with low 
doses of METH and d-amphetamine PKO rodents display blunted DA release.  
69 
 
 
 
 Here, we investigated the hypothesis that PKO rats would be hypersensitive to the 
neurotoxic effects of METH.  
4.1 Materials and methods 
4.1.1 Parkin knockout animals 
 Thirty-two age matched (PND 65-75) wildtype (Harlan, Indianapolis, IN) and 
PARK2 -/- (PKO, SageLabs, St. Louis, MO) male Long-Evans rats were used for all studies. 
Rats were allowed unrestricted access to food and water. Animals were group housed (four 
rats per cage) until 24 h prior to testing, when they were separated and singly housed until 
the end of the study. All procedures were conducted in adherence with the Wayne State 
University institutional animal care and use committee-approved protocol no. A3310-01.  
4.1.2 Drug treatments 
 Methamphetamine (METH) HCl (Sigma-Aldrich, St. Louis, MO) was diluted in 
saline (0.9% NaCl) to a final concentration of 6 mg METH / mL. Daily bodyweights were 
recorded and used to calculate the amount of drug administered.  During binge METH 
treatment animals were administered four successive injections of 6 mg METH / kg 
bodyweight or 1 mL saline / kg bodyweight each 2 h apart.  For the subsequent METH 
challenge animals received a bolus dose of 2 mg METH / kg BW 24 h following the last 
injection of binge METH.  
4.1.3 Open-field motor behavior measurement 
 Locomotor measurements were made using Opto-verimax open-field locomotor 
chamber (Columbus Instruments, Columbus, OH). Two small fans were constantly running 
to produce sufficient white-noise during behavioral testing. Prior to treatments animals 
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were placed in the open-field chamber for 1 h and allowed to acclimate.  Following 
acclimation animals were administered binge METH.  Animals remained in their open-
field chambers except for METH injections and body temperature measurement 1 h 
following each METH injection. Animals were removed from the chambers 5 h following 
the last METH injection. Therefore, locomotor behavior was continuously monitored for a 
total of 12 h. 24 h hollowing binge METH, a brief locomotor behavior session was 
conducted. During this session animal were placed in the open-field chambers and allowed 
to acclimate for 10 min. Animals then received a single bolus dose of METH (2 mg METH 
/ kg BW) and their locomotor behavior continuously monitored for 2 h. 
 
Figure 16. Study design summary for parkin studies.  Adult male Sprague Dawley rats 
were treated with binge methamphetamine (Red line). Following binge methamphetamine 
animals were administered a challenge dose of methamphetamine (blue line). Following 
treatements animals were allowed to recover for 3 days (black line) and the tissue was 
harvested (arrow). During each of the three phases of the study open-field behavior was 
monitored. Following recovery, a functional observation battery was conducted (FOB). 
Together this study design allowed for the assessment of motor behavior of rats during and 
following exposure to methamphetamine.  
 
4.1.4 Tissue collection 
FIGURE 16 STUDY DESIGN SUMMARY FOR PARKIN STUDIES 
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 72 h following the last METH injection animals were euthanized via live 
decapitation. The brain was removed and immediately placed on ice. Brain regions of 
interest were collected using blunt dissection methods, placed on dry ice, and stored at -
80°C. The left hemisphere of the brain was fixed for 3 days in PBS (10 mM Na2HPO4, 1.8 
mM KH2PO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4) containing 4% paraformaldehyde at 
4°C. The fixed brain was then processed as previously described.[57] 
4.1.5 High-performance liquid chromatography 
 HPLC procedures are as previously described.[96] Briefly, ~ 10 mg of tissue was 
sonicated in 0.5 mL 0.3 N perchloric acid (SigmaAldrich). Samples were then centrifuged 
at 17,000 x g for 30 min at 4°C. 10-80 µl of the supernatant was injected onto a C-18 
reverse phase column (ThermoScientific).  Analytes were detected using an 
electrochemical detector (Dionex Coulochem III, E1 = -150 mV, E2 = +220 mV) and 
compared to known standards of dopamine (DA, Sigma-Aldrich), 3-Methoxytyramine (3-
MT, Sigma-Aldrich), 3,4-Dihydroxyphenylacetic acid (DOPAC, Sigma-Aldrich), and 
Homovanillic acid (HVA, Sigma-Aldrich) diluted in 0.3 N perchloric acid. The resulting 
peaks were integrated and quantified using chromeleon software (ThermoScientific, 
Waltham, MA). The remaining pellet was dissolved in 1 M NaOH, overnight, at 4°C. The 
crude protein content of the dissolved pellet was determined using bicinchoninic acid assay 
(ThermoScientific). Final values are presented as pg analyte / ng protein. 
4.1.6 Tissue fractionation 
 Tissue was homogenized in 1 mL of ice cold homogenization buffer (0.32M 
sucrose, PMSF) using 12 strokes in a douce homogenizer. The resulting slurry is then 
72 
 
 
 
centrifuged at 800 x g for 17 min at 4°C and the supernatant (S1) retained. The S1 is then 
centrifuged at 18,000 x g for 24 min at 4°C and the resulting supernatant (S2) fraction 
retained. The S2 (cytosolic fraction) and P2 (synaptosomal) fractions were then solubilized 
with the addition of 20 mM tris-HCl pH 8.0 and 2% sodium dodecyl sulphate (SDS). 
Protein concentration of each sample was determined using the BCA assay (Thermo Fisher 
Scientific). 
4.1.7 Western blot 
 Western blot procedures are as previously described [57]. Briefly, 15 µg of protein 
from each fraction was separated on a 12% SDS-PAGE. The proteins were then transferred 
to a methanol activated PVDF membrane by applying a voltage of 25V for 16 h at 4°C. 
PVDF membranes were then rinsed with ultrapure water, dried, and reactivated with 
methanol. The PVDF membranes were then blocked in TBST (50 mM Tris-HCl, 150 mM 
NaCl, 0.05% Tween-80) containing 5% milk m/vol (blocking buffer) for 1 h at room 
temperature. PVDF membranes were then incubated in blocking buffer containing primary 
antibodies (DAT, Santacruz; AcetTUB, Cell Signalling; TH, EMDMillipore; β-actin, 
EMDMillipore) diluted 1:1000 overnight at 4°C. PVDF membranes are then washed three 
times in TBST and incubated in horse radish peroxidase conjugated secondary antibodies 
(Santa Cruz) diluted in blocking buffer for 1 h at room temperature. PVDF membranes 
were then washed three times in TBST, incubated in ECL substrate (Thermofisher) for 5 
min, and imaged using Imagequant (GE). Densiotometry analysis on the resulting images 
was conducted using ImageJ software (National Institute of Health). Uncut representative 
images are provided for each experiment. 
73 
 
 
 
4.1.8 Immunohistochemistry 
 Fixed brain tissues were processed as previously described [57]. Citrate buffer 
antigen retrieval (ThermoFisher) was used for all tissue sections. Coronal tissue sections, 
30 µm in thickness, were collected from each animal’s striatum. Six sections were 
harvested from 2.16 mm to -0.2 from bregma according to Paxinos & Watson’s rat brain 
atlas. Sections were incubated overnight at 4°C with TH, AcetTUB, or GFAP antibody all 
diluted 1:500 in blocking buffer. Sections were then incubated with blocking buffer 
containing diluted Alexa Fluor® 488 goat anti-mouse (Invitrogen, Carlsbad, CA) and 
Alexa Fluor 598 goat anti-rabbit (Invitrogen) both diluted 1:400 for 2.5 h at room 
temperature. DRAQ5 (Invitrogen) was used to stain nuclei. Sections were then mounted 
using Fluoromount (SouthernBiotech, Birmingham, AL). Slides were imaged using a Leica 
SP3 laser scanning confocal microscope (Leica, Wetzlar, Germany). Three stacks 
(consisting of 30+ optical slices per stack) were imaged at high magnification (630X) in 
the dorsal striatum of each slice. The non-colapsed raw single z-plane images were 
exported from the Leica Image Analysis Suite (Leica). These images were then analyzed 
using Imaris co-localization analysis software (Bitplane South Windsor, CT). For each 
image automatic thresholding and masking functions were used to prevent interference 
from signal noise and variations in signal intensity. The resulting percent co-occurrence in 
the TH channel was normalized to non-treated control for ease of graphical comparison. 
The final value represents the percentage of signal overlap within the TH signal. 
4.1.9 Data analysis 
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 All data was graphed and analyzed using graphpad prism software (La Jolla, CA). 
Clustering analysis was conducted using the heatmap2 package for R statistically 
programming software.  ANOVA with a post hoc test was used on the data. Statistical 
significance was set at p < 0.05. 
4.2 Results 
4.2.1 PKO rats display atypical locomotor response to binge METH 
 WT and PKO rats treated with saline displayed normal rodent acclimation behavior 
characterized by the progressive decrease in locomotor activity from the beginning to the 
end of the open field session (Figure 17A). WT rats displayed a brief (~20 min) increase 
in distance traveled after the first METH dose, followed by a prolonged period of decreased 
locomotion (~8.3 h), and eventual recovery of locomotor activity towards the end of the 12 
h binge METH session. In contrast, PKO rats treated with METH displayed an atypical 
activity pattern across the 12 h binge METH session. Following the fist injection of METH, 
PKO rats displayed a robust increase in distance traveled, followed by a prolonged period 
of sporadic locomotor activity (from 140-640 min.), and eventually a loss of locomotor 
activity at the end of the binge session. Approximately half of the PKO rats were 
completely immobile (i.e. in a position of lateral recumbency) by the end of the METH-
binge session. 
 PKO rats displayed an apparent abnormal locomotor response to METH. When we 
conducted an unsupervised clustering analysis of the locomotor activity patterns (i.e. 
distance traveled), we found three unique clusters (Figure 17B). Most notably, PKO rats 
treated with METH formed a unique cluster with the exception of 1 animal. Comparing the 
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heat map between all animals it is apparent the sustained distance traveled throughout the 
binge session defined the abnormal behavioral phenotype of PKO rats. The cluster analysis 
highlights the apparent unique locomotor activity pattern displayed by PKO rats following 
METH. Saline treated WT and PKO were apart of the same cluster, and therefore, the 
overall behavioral activity between drug naïve WT and PKO were essentially the same. 
This finding is important because there are conflicting reports in the literature as to the 
development of behavioral abnormalities in parkin deficient mice [106, 251].  Data here 
supports previous studies that determined the inactivation of parkin does not result in a 
behavioral phenotype [251]. Only when PKO rats were exposed to neurotoxic doses of 
METH was a behavioral phenotypic divergence between WT and PKO rats evident.  
 PKO rats developed abnormal motor behavior approximately 3 h into the binge 
METH treatment (Figure 17C). Following the first, second and third dose of METH, PKO 
rats’ movements became highly uncoordinated and PKO animals appeared to have 
difficulty righting themselves, falling backwards or on the side. They did not move 
forward, they circled backwards.  Following the fourth injection of METH several PKO 
rats displayed a complete loss of locomotor activity, often lying in a lateral recumbent 
position. The motor abnormalities lasted for at least 24 h following METH, but in several 
animals, the motor abnormalities were observable as long as 72 h following METH. At 24 
h following METH, PKO rats treated with binge METH had decreased activity, rigid 
movement, abnormal gait, and moved primarily by walking backwards while their WT 
counterparts recovered and were moving around. 
76 
 
 
 
 All METH treated animals displayed hyperthermia 1 h following each METH 
injection when compared to saline (Figure 17E). The magnitude of hyperthermia during 
binge METH was indistinguishable between WT and PKO rat. However, some PKO rats 
(50%) were externally cooled by placing on ice to prevent death. WT animals treated with 
METH did not require external cooling. Because external cooling lowers body temperature, 
it is possible that PKO rats in fact had higher temperatures that WT rats in response to 
METH, but was not observed because of external cooling. Other reports have shown that 
parkin inactivation results in hypersensitivity to drug induced hyperthermia [255].    
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Figure 17. Locomotor activity of parkin knockout (PKO) rats during binge 
methamphetamine (METH) treatment. Age matched (PND 65-75) wildtype (WT) Long-
Evans rats and Park2 -/- (PKO) Long-Evans rats were administered binge (4 injections of 
6 mg METH / kg bodyweight, i.p., each 2 hours apart) methamphetamine (METH) while 
open-field locomotor behavior was continuously monitored. (A) Distance traveled before 
(≤60 min), during (60-480 min), and after (480-720 min) binge METH treatment. Red lines 
represent the mean distance traveled (cm/min). Black arrows indicate the time of METH 
injections. (B) Cluster analysis of the distance traveled for the entire 12 h session. Red 
shade depicts high behavioral count for the interval and green shade depicts a low 
behavioral count. The lines to the left of the plot depict the relatedness of each animal’s 
behavioral session. The shorter the line connecting adjacent animals the more similar the 
behavioral pattern. Treatment conditions are listed to the right of the heatmap; PKO = 
parkin knockout rat treated with binge saline, PKOM = parkin knockout rat treated with 
binge METH, WT= WT rat treated with binge saline, WTM= WT rat treated with binge 
METH. (C) Still-frame images from video recorded during binge METH session. WT and 
PKO animals. Images from METH treated animals depicted. Red dotted box outlines 
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images from time-points when impaired motor behavior phenotype is observable in PKO 
rats. (D) Core-body temperature before, after, and during binge METH treatment. Core-
body temperatures were recorded via rectal probe 1 h following each METH injection. ! 
Acclimation vs. time-point, One-way repeated measures ANOVA, p<0.05. *Saline vs. 
METH, One-way ANOVA, p<0.05, Tukey post hoc, p<0.05. n=6. Distance = total 
movement of the animal in the x, y directions. BL= Baseline.  
 
4.2.2 PKO rats have blunted locomotor response to methamphetamine 
4.2.2.1 PKO rats’ locomotor response to acute high dose METH 
 Following the first METH injection of the binge treatment (6 mg METH / kg) PKO 
rats’ response displayed a greater in magnitude (+22%) and duration (+48%) in locomotor 
activity when compared to METH treated WT rats (Figure 18). METH-induced locomotor 
activity was slightly delayed in PKO rats with peak responses occurring approximately 10 
min following WT animals. Increased locomotor activity was not observed in WT and PKO 
rats treated with saline. 
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FIGURE 18 LOCOMOTOR RESPONSE OF PARKIN KNOCKOUT (PKO) RATS TO HIGH DOSE METHAMPHETAMINE (METH) 
Figure 18. Locomotor response of parkin knockout (PKO) rats to high dose 
methamphetamine (METH). The line graph depicts locomotor activity (i.e. distance 
traveled) prior to and following the first METH injection (6 mg METH / kg bodyweight) 
of the binge METH session. The arrow denotes the time of the METH injection. All 
measurments were recorded during open-field sessions. Data plotted as the mean (±SEM) 
distance traveled each minute of the open-field session. WT = Wild-type, PKO = Parkin 
knockout. n=3-6. 
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4.2.2.2 PKO rat’s locomotor response to low dose METH 
 All rats received a non-toxic challenge dose of METH (2 mg METH / kg 
bodyweight) 24 h following binge METH, and open-field activity was measured for 2.1 h. 
WT rats previously treated with binge saline displayed a significant increase in distance 
traveled (Figure 19A, top panel) and horizontal counts (19B, bottom panel). In WT drug 
naive animals, the challenge METH dose resulted in a 10.48-fold greater response than the 
initial METH dose of the binge session (i.e. 6 mg METH / kg bodyweight). In contrast, 
drug naïve PKO rats displayed significantly blunted locomotor response to METH 
challenge. METH exposed WT rats displayed a locomotor response similar to the drug 
naïve PKO rats. METH exposed PKO rats nearly lacked a discernible response to the 
METH challenge. 
 Cluster analysis of the distance traveled during the METH challenge shows three 
distinct clusters. PKO rats exposed to METH were mostly (83%) clustered together in a 
low responding group. The second cluster was comprised of animals from all four 
treatment groups. The third cluster was mostly WT drug naïve animals (86%), which 
displayed the most robust response to the METH challenge. The lack of response to low-
dose METH of the binge METH treated PKO rats can be easily visualized at the top of the 
heatmap (i.e. dark green color). 
 Statistical comparison of the total challenge session activity between treatment 
groups verified the effect seen in figure 19A and 19B (Figure 19C). WT animals treated 
with binge saline showed the most robust response to the challenge dose with the least time 
resting and most distance traveled. WT animals treated with binge METH showed slightly 
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decreased activity during the challenge dose, but this effect was non-significant. The most 
significant effect can be seen in the PKO rats treated with binge METH. These rats spent a 
significant amount of time resting and increased distance traveled when compared to 
WT/Saline and WT/METH.  Lack of locomotor response to the METH challenge in the 
PKO/METH group was not significantly different from the PKO/Saline group. 
  
 
Figure 19. Locomotor response of parkin knockout (PKO) rats to methamphetamine 
(METH) challenge. WT and PKO animals were first treated with either binge saline or 
binge METH. 24 hours following the binge session animals were challenged with a single 
intraperitoneal injection of 2 mg / kg METH. Gross locomotor behavior was recorded for 
a total of 2 h. (A) Distance traveled and horizontal movements were plotted for each binge 
treatment group. The means behavior counts were plotted for each minute of the challenge 
session. (B) Unsupervised cluster analysis was performed on the distance traveled during 
the challenge session. Red shift depicts high locomotor activity and green depicts lower 
locomotor activity. Treatment conditions are listed to the right of the heatmap; PKO = 
parkin knockout rat treated with binge saline, PKOM = parkin knockout rat treated with 
binge METH, WT= WT rat treated with binge saline, WTM= WT rat treated with binge 
FIGURE 19 LOCOMOTOR RESPONSE OF PARKIN KNOCKOUT (PKO) RATS TO METHAMPHETAMINE (METH) 
CHALLENGE 
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METH. (C) Total mean values of distance traveled and resting time for animals during the 
challenge session.  One-way AVOVA, *Dunnets post-hoc test, **Tukey post-hoc test, p < 
0.05. The data are expressed as mean ± SEM, n = 4-6 
 
4.2.3 Striatal dopamine depletion in PKO rats following binge METH 
 Binge METH results in long-term depletion of striatal DAergic markers. Here we 
assessed several DAergic markers in PKO and WT rats treated with binge METH at 3 d 
after the last injection of the drug. Results show modest reduction in striatal DA of WT rats 
treated with binge METH (Figure 20A). WT and PKO rats treated with saline show similar 
striatal DA content. However, PKO rats treated with binge METH had drastically reduced 
striatal DA contents (-80%) when compared to the saline treated PKO animals. DA 
metabolites were unchanged in all treatment groups. In addition, binge METH-treated PKO 
rats displayed augmented 5-HT los as compared to binge METH-treated WT rats (-52% 
vs. 22%) (not shown). 
 Dopamine transporter (DAT) levels were significantly reduced in striatal 
synaptosomes from WT rats following binge METH (Figure 20B). DAT levels were 
similar to WT saline treated animals for both saline treated and METH treated PKO rats. 
TH levels were only significantly decreased in METH treated PKO rats, when compared 
to saline treated WT rats.  
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Figure 20. Striatal DAergic markers in parkin knockout (PKO) rats 3 days following binge-
methamphetamine (METH). (A) Dopamine and metabolites measured in striatal tissue by 
HPLC. (B) Dopamine transporter (DAT) and tyrosine hydroxylase (TH) levels in striatal 
synaptosomes. Protein levels were measured by western blot. β-actin was used as a loading 
control. Representative western blot images for DAT (C) and TH (D). *, ***One-way 
ANOVA, Tukey’s post hoc test, p<0.05, n = 5-8. S= saline, M = METH. The data are 
expressed as mean ± SEM. 
 
4.2.4 Reactive gliosis in the striatum following binge METH 
 Damage to the axons of the striatum following binge METH coincides with reactive 
gliosis. Here we measured the reactive gliosis marker, glial fibrillary acidic protein 
(GFAP), in fixed striatal brain slices of PKO rats treated with METH. Results show 
widespread GFAP staining throughout the striatum following binge METH in both WT 
and PKO rats (Figure 21B). Reactive glia could be seen infiltrating DAergic axons of the 
striatum (Figure 21C). The induction of GFAP seemed more robust in WT animals treated 
FIGURE 20 STRIATAL DAERGIC MARKERS IN PARKIN KNOCKOUT (PKO) RATS 3 DAYS FOLLOWING BINGE-
METHAMPHETAMINE (METH) 
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with METH (Figure 21D). Both PKO rats treated with saline and METH showed evidence 
of reactive gliosis. However, when we assessed tissue expression of GFAP in the striata of 
these animals using WB we did not observe any change between animals (blots not shown). 
It is unclear as to why the tissue expression of GFAP did not change while reactive glia 
could be seen in the tissue slices. One possible explanation is the high heterogeneity of the 
distribution of astrocytes in the brain [256] that can make it difficult to make meaningful 
quantifications of reactive gliosis by WB or IHC.  Therefore, although infiltration of 
reactive astrocytes into the striatum following METH appears self evident (21B) it is not 
clear if the quantification (21D) is accurately estimating differences in reactive gliosis 
between experimental groups. Further complicating the interpretation is the numerous 
other biological functions of reactive astrocytes, both neuroprotective and neurotoxic 
[257]. Because we only observed modest reductions in striatal DAergic markers in WT and 
PKO rats following binge METH (Figure 20) the observed reactive gliosis may not be 
related to gross DAergic axotomy of the striatum. Studies reporting reactive gliosis 
following METH utilized much higher doses of METH, and subsequently, observed greater 
hyperthermia and DAergic marker reduction than reported here [40, 56, 258, 259]. 
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FIGURE 21 REACTIVE GLIOSIS IN THE STRIATUM OF PARKIN KNOCKOUT (PKO) RATS TREATED WITH BINGE 
METHAMPHETAMINE (METH) 
Figure 21. Reactive gliosis in the striatum of parkin knockout (PKO) rats treated with binge 
methamphetamine (METH). Fixed brain sections from WT and PKO rats treated with 
binge METH were probed for tyrosine hydroxylase (TH) and Glial Fibilary Glial fibrillary 
acidic protein (GFAP).  (A) Location of the sagital sections taken for staining. (B) Low 
magnification images of the striatum. EC = external capsule and DS = dorsal striatum. 
Scale bar = 1 mm (C) High magnification confocal images of the striatum displaying dense 
clusters of activated glia. (D) Quantification of mean fluorescent intensity of GFAP 
staining in the dorsal striatum. 3 brain slices per animal. 3 confocal stacks of ~30-60 images 
each for each brain slice. *One-way ANOVA, Tukey’s post-hoc test, p<0.05. The data are 
expressed as mean ± SEM, n = 4. 
 
4.2.5 AcetTUB in the striatum following binge METH 
 Previously we determined that there are reduced levels of acetylated α-tubulin 
(AcetTUB) per α-tubulin in striatal DAergic axons following exposure to neurotoxic 
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METH [57]. Here we measured total levels of AcetTUB in striatal tissue and investigated 
the amount of AcetTUB in striatal DAergic axons. Results show that administration of 
binge METH resulted in decreased AcetTUB in the striatum of WT animals (Figure 22A). 
PKO rats had reduced levels of AcetTUB, regardless of METH treatment, when compared 
to saline treated WT animals.  
 Levels of AcetTUB were reduced within striatal DAergic axons of WT rats 
following binge METH (Figure 22B, C). PKO rats had apparent reductions in AcetTUB 
within striatal DAergic axons regardless of METH treatment. However, the reduction in 
AcetTUB was slight, and not statistically significant. Interestingly, in contrast to our 
previous findings the correlation coefficient measure between TH and AcetTUB was very 
low (>0.1), suggesting little to no overall correlation between TH and AcetTUB. This 
observation may hold particular significance because AcetTUB is usually found enriched 
in axons [260, 261] and overall TH positive axons of the striatum appeared to contain very 
little AcetTUB. Although this idea is not further explored here, it could potentially help 
explain why DAergic axons of the striatum are particularly sensitive to MT destabilizing 
compounds [223]. If DAergic axons are already deficient in stable MT rich in AcetTUB, 
then destabilization of MT may be particulary difficult for the neuron to recover from.  
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FIGURE 22 ACETYLATED ALPHA-TUBULIN IN PARKIN KNOCKOUT (PKO) RATS 3 DAYS FOLLOWING BINGE METH 
Figure 22. Acetylated α-tubulin in parkin knockout (PKO) rats 3 days following binge 
METH. Rats were treated with binge METH and a single challenge METH dose 24 
following binge METH. (A) Soluble proteins were extracted from striatal tissue and 
analyzed by western blot. Membranes were probed with antibodies specific for acetylated 
α-tubulin (AcetTUB) and α-tubulin (α-TUB). (B) Fixed brain tissue was sectioned and 
probed with antibodies specific for AcetTUB (red) and tyrosine hydroxylase (TH, green). 
Nuclei were stained with DRAQ5 (blue). Sections were imaged using confocal 
microscopy. (C) The degree of colocalization was determined using Leica colocalization 
software. Mean values are represented for each treatment group. Mean values derived from 
3 slices per animal. *p<0.05. The data are expressed as mean ± SEM. 
 
4.2.6 METH challenge does not result in loss of DAergic markers in the striatum 
 To indirectly assess DAergic function in the nigrostriatal pathway all animals were 
given a small challenge dose (2 mg METH / kg body weight) 24 hours following binge 
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METH. The challenge dose of METH did not likely result in long term (i.e. 7 days or more 
following METH exposure) DAergic neurotoxicity. Several studies, including our own, 
have demonstrated that exposure to up to 12-fold the challenge METH dose not robustly 
produced striatal DA depletion or overt signs of neurotoxicity [165, 262]. 3-times the 
challenge dose did not change striatal DA content 7 days following METH exposure 
(Figure 23).  
 
Figure 23. Striatal dopamine (DA) content 7 days following a single intravenous (IV) 
injection of methamphetamine (METH). Adult male SD rats were injected with 6 mg 
METH / kg body weight via lateral tail vein. 7 days following METH administration 
animals were sacrificed and striatal DA content measured by HPLC. All values were 
normalized to the average DA content of saline treated rats. The data are expressed as mean 
± SEM, n = 4-7. 
 
 DA content measured in WT and PKO treated with challenge METH was 
approximately 110 pg DA / µg protein (see figure 20A), in agreement with published 
striatal DA content of drug naïve rats [263-265]. Furthermore, LE rats and SD rats had 
similar striatal DA content, therefore strain differences in DA driven behaviors, suggested 
here and elsewhere [266], are likely not due to striatal DA content. 
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4.2.7 METH challenge does not alter colocalization of AcetTUB with TH labeled 
axons in the striatum 
 The challenge METH dose likely does not produce changes to AcetTUB levels in 
striatal DAergic axons. Significantly higher doses of METH (12-fold higher) result in 
relatively modest reduction in AcetTUB in DAergic axons of the striatum [264]. To test 
whether the challenge METH dose can alter AcetTUB levels in striatal DAergic axons we 
compared drug naïve WT and PKO rats with WT and PKO treated with challenge METH. 
Results show that the abundance of AcetTUB within DAergic axons were similar between 
drug naïve and challenge treated WT and PKO rats (Figure 22). Therefore, the challenge 
dose cannot account for the differences seen in AcetTUB levels within DAergic axons.  
4.3 Discussion 
 Here, PKO animals displayed a loss of motor control approximately 4 h into binge 
METH treatment (Figure 17C). The development of this behavioral-phenotype coincided 
with the peak in METH induced hyperthermia (Figure 17D). Counter-intuitively, the 
observable loss of motor control was associated with a subsequent increase in total 
locomotor activity (Figure 17A and 17B). However, the video record of the session 
revealed that the PKO rats’ locomotion was highly abnormal during the METH binge. 
Specifically, the PKO rats were walking backwards in a circular manner and were losing 
balance when they tried to stand up. Movements were both sporadic and uncoordinated. 
Backward walking and circling are mediated by simultaneous release of DA and 5-HT after 
administration of high doses of METH or other amphetamines [267, 268]. The PKO rats 
treated with METH had very low DA and 5-HT levels at 7 d after METH binge, confirming 
89 
 
 
 
that the release of both neurotransmitters was substantial in these rats.  Balance impairment 
and the associated backward falling in Parkinson’s disease do not respond to L-DOPA 
treatment and, therefore, was suggested to be a result of defective noradrenergic 
neurotransmission [269]. We did not measure noradrenaline levels in our rats; however, 
since it is well known that METH releases DA, 5-HT and noradrenaline, it can be 
speculated that balance impairment and fallings observed in the PKO rats were due to 
defective noradrenergic neurotransmission. As expected, WT rats remained in stereotypy 
through the METH binge after the initial increase in locomotor activity and did not display 
backward walking or circling despite increased release of DA and 5-HT.  Most likely, the 
extent of their release did not reach high enough levels (as in the PKO rats), particularly 
the extent of 5-HT release [267]. Somewhat smaller (but not statistically significant) 
stereotypy in the PKO rats than in the WT rats could have been due to decreased levels of 
striatal postsynaptic D2 receptor in these rats (unpublished results) [270]. 
Following binge METH, the WT rats’ horizontal locomotion recovered whereas 
PKO rats’ locomotion ceased and the uncoordinated movements remained. The behavioral 
and neurochemical data collectively suggest that binge METH almost entirely depleted 
striatal monoaminergic stores in the PKO rats and to a lesser extent in the WT rats.  The 
depletions in DA and 5-HT levels were not likely due to degeneration of DAergic and 5-
HTergic terminals because they were not accompanied by deficits in the other DAergic/5-
HTergic markers.  The loss of motor function in the PKO rats was accompanied with 77%-
deficit in DA, which is at the level generally required to see obvious motor abnormalities 
in PD [271].  In stark contrast to parkin PKO rats, WT rats displayed a similar magnitude 
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of METH induced hyperthermia but with no dramatic loss of motor function during or after 
binge METH. WT rats tolerate high METH doses without a loss of motor function [272] 
because the depletion of DA stores is less than 70-80% after 5-8 mg/kg freebase METH 
[165].  
Significantly higher than in the WT rats monoaminergic deficits in the PKO rats 
suggest higher METH-induced DA release via the DAT or slower uptake of DA back to 
the terminal in these rats. The first scenario would require increased availability of DAT at 
striatal presynaptic nerve terminals. Drug-naïve PKO rats, however, had slightly lower 
levels of the DAT compared to their WT counterparts. As our technique measured DAT in 
crude synaptosomal fractions, the assessment of distribution of the DAT between purified 
plasma membrane and endosomal fraction in both phenotypes is warranted.  Binge METH 
did not result in depleted striatal DAT and therefore METH in these animals may have 
supported greater DA release during the binge and subsequent depletion of DA from 
presynaptic nerve terminals.  Slower uptake of DA back to the terminal in drug-naïve 
animals or during METH binge could also be due to altered DAT trafficking (endosomes-
plasma membrane and axonal) or due to an altered kinetics of DA transport. Drug naïve 
PKO rats did not significantly differ from drug naïve WT rats in basal locomotor activity. 
Their exploratory behavior was somewhat decreased compared to the WT rats, which can 
be indicative of reduced extracellular DA in the striatum [250].  Only when PKO rats were 
challenged with the DAergic agonist METH the differences in the nigrostriatal DA 
pathway function were revealed. Thus, the initial locomotor response to 6 mg/kg METH 
was more robust in the PKO rats than in the WT rats. On the other hand, the initial response 
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of the PKO rats to the low METH dose (2 mg/kg) was lower than in the WT controls, in 
agreement with a previous report [106]. This locomotor response of the PKO rats was 
similar to the WT rats that were previously treated with binge METH. Most drastically, 
PKO rats previously exposed to binge METH did not display a locomotor response to low 
dose METH due to almost complete depletion of DA pools. Generally, low doses of METH 
potently increase horizontal locomotor activity while high doses of METH potently 
suppress it due to the emergence of stereotypy [273]. Low doses of METH release 
cytoplasmic pool of newly synthesized DA [274]; therefore, our finding suggests that 
cytoplasmic DA pool is lower in PKO rats than in WT rats. Alternatively, the pool is not 
different between the phenotypes but the release of DA via DAT is slower in PKO rats than 
in WT rats.  Interestingly, the increase in locomotor activity after the 6 mg/kg-dose of 
METH is delayed in the PKO rats compared to the WT controls so is the suppression of 
locomotor activity, suggesting malfunction of the DAT. Our findings support the growing 
body of evidence for parkin being an important regulator of DA neuron development, 
health, and function [275]. Together, this data suggests that drug naïve PKO rats display 
some hypodopaminergia in the nigrostriatal pathway, which can be highly exacerbated by 
treatment with binge METH.     
Post-synaptic signaling at the striatal DA nerve terminals is greatly influenced by 
dopamine recetor 2 (D2R) and dopamine receptor 1 (D1R). In the striatum, D1R has 
important roles in controlling spontaneous motor behavior and the locomotor response to 
psychostimulants [276, 277]. Interestingly, the AcetTUB pathway appears to excert some 
control over D2 function [278], and here we found that PKO rats may have reduced levels 
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of AcetTUB in the striatum. Other preliminary results from our lab (not depicted here) 
suggest a reduced level of postsynaptic D2 in the striatum of PKO rats, adding credence to 
the idea that parkin may excert some control of DAergic neuron function in the striatum 
via signaling pathways affecting the D2 receptor. Of note, mice lacking parkin do not 
display deficits in either the levels of dopamine receptors or their function [34]. 
 Hyperthermia is crucial in the development of METH induced DAergic toxicity 
[40, 279] and METH can activate the heatshock pathway [280]. Here hyperthermia was 
appeared to be necessary to produce PD-like phenotype in the PKO rats. The magnitude of 
hyperthermia was not statistically different between PKO rats and WT, with slightly higher 
response thermic response in the PKO rats. However, WT rats did not display any motor 
deficits. Therefore, we hypothesize that PKO rats are more sensitive to the cellular 
heatshock of hyperthermia. During heatshock, HDAC6 is recruited to damaged/misfolded 
proteins in ubiquitin dependent manner [281]. Recently, parkin mediated ubiquitination of 
damaged misfolded proteins was shown to recruit HDAC6 in response to cell stress [281]. 
Therefore, it is logical to assume that PKO rats may have a deficient heatshock response 
and because heatshock response is neuroprotective, this could explain observed 
neurotoxicity in PKO rats. In support of this interpretation the observed loss of motor 
function occurred near the time-point when METH induced hyperthermia was the greatest. 
METH induced hyperthermia did not significantly differ between WT and PKO rats. 
However, PKO rats would lack the ubiquitination of protein aggregates required for 
HDAC6 recruitment. This would likely result in the toxic accumulation of aggregated 
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proteins in the cytosol. The data presented here is insufficient to confirm or reject this 
hypothesis.  
 Total levels of AcetTUB were reduced in the striatum of PKO rats, regardless of 
METH exposure. AcetTUB is a marker for stable long-lived MT required for axonal 
transport. Therefore, PKO animals may have impaired axonal transport in the striatum, 
possibly making them sensitive to neurotoxic METH. In further support of this 
interpretation we observed a similar phenotype as the PKO rats when WT rats were treated 
with high dose of a MT stabilizing compound EpoD [264]. The high dose of EpoD reduced 
AcetTUB levels in the striatum and resulted in profound neurotoxicity.  
 Colocalization analysis revealed that METH decreased AcetTUB within DAergic 
axons, as we have shown previously [264]. However, PKO rats were insensitive to this 
effect of METH, as AcetTUB levels with DAergic axons were similar between saline and 
METH treated PKO rats. This pattern seems to verify the western blot quantification of 
total soluble AcetTUB. However, the measured decreased AcetTUB in PKO rats was less 
using colocalization analysis. This is likely due to the non-quantitative nature of IHC [282, 
283] when compared to the quantitative validity of western blotting [284]. Furthermore, 
the loss of AcetTUB measured by western blot, may mostly represent the pool of AcetTUB 
outside TH axons, and therefore be more indicative of tissue levels of AcetTUB. In this 
regard, it is possible that the MT of DAergic axons are insensitive to toxic METH insult in 
PKO rats. On the other hand, glia activation suggest some damage to DAergic axons of the 
striatum. Reactive gliosis in PKO rats following binge METH was less than that observed 
in WT rats.  Reactive glia can be neuroprotective following some neurotoxic insults via 
94 
 
 
 
release of glia cell derived neurotrophic factor, maintenance of blood brain barrier, 
sequestration of toxic oxidative species, and the release of anti-inflammatory molecules 
[285]. Therefore, it is possible that the observed sensitivity of PKO to METH neurotoxicity 
could be due to insufficient reactive gliosis. The data presented here are insufficient to 
affirm or reject this interpretation.   
 Fruitful future investigations may look at the role of parkin overexpression, 
knockout or knockdown on the substrates that are involved in neurotransmitter synthesis, 
packaging, and release. For example, cell division control related protein 1 (CDCREl-1) 
may be a likely downstream factor responsible for parkin’s influence on DA function [108].  
CDCREl-1 appears to have SNARE–like functions that inhibit exocytosis [286].  Parkin-
mediated ubiquitination of CDCREl-1 would enhance the turnover of CDCREl-1 in parkin 
overexpressing rats, possibly inhibiting exocytosis of DA. In the same vein, parkin may be 
exerting influence on DA function via interactions with K63 of α-synuclein [281].  α-
Synuclein overexpression and knockout curiously produce effects DA release similar to 
that of parkin [287, 288]. The similar effects of parkin and α-synuclein on DA 
neurotransmission are a tantalizing clue, suggesting convergence of the two pathways 
during neurodegeneration. However, the possible common pathway between the two 
proteins in METH neurotoxicity has yet to be elucidated.  
4.4 Conclusions 
 PKO rats are hypersensitive to the neurotoxic effects of METH. Correspondingly, 
PKO rats develop severe motor impairments during binge METH. Parkin appears have 
some functional control over DA signaling in the nigrostriatal motor pathway, as suggested 
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by relative hypolocomotion in PKO rats. Together, the results support the hypothesis that 
parkin plays a role in maintaining the healthy and proper functioning of nigrostriatal 
DAergic neurons. In PKO rats, AcetTUB levels in the striatum are not different from WT 
saline treated controls. Therefore, parkin likely does not influence axonal transport via 
post-translational modification of MT. If parkin does influence axonal transport in the 
nigrostriatal pathway it is likely by some other means that MT stabilization. Future studies 
should focus on unilateral overexpression of parkin and its influence on striatal DAT 
expression as well as DA synthesis packaging and release.  
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CHAPTER 5 – MEASURING Α-SYNUCLEIN TETRAMER 
ABUNDANCE IN BRAIN LYSATES 
 
Results in chapter five are transcribed from the peer-reviewed manuscript: Killinger 
BA, Moszczynska A (2016) Characterization of alpha-Synuclein Multimer Stoichiometry 
in Complex Biological Samples by Electrophoresis.  Killinger B. was responsible for 
designing, conducting, and reporting transcribed in chapter 3. Moszczynska A. was 
responsible for editing and reviewing the manuscript prior to acceptance by Analytical 
Chemistry. This project was initiated as an attempt to address the need for an easy 
reliable technique to measure protein complex formation in complex biological samples. 
Although the technique was developed and applied to α-synuclein multimerization, 
subsequent studies have shown the techniques applicability to other soluble complexes 
[289]. 
5 Background 
 Parkinson’s disease (PD) is a neurodegenerative disease characterized by the 
formation of proteinaceous inclusions, termed “Lewy bodies” that contain large amounts 
of α-synuclein, a small cytosolic protein for which the biological function is still unclear 
[109, 290].  In vivo α-synuclein occurs as a variety of multimers including a dimer, 
tetramer, and octomer which appear to be biologically important and possibly resistant to 
toxic aggregation [127, 291, 292]. New therapeutic strategies for treating PD may involve 
the use of drugs to stabilize soluble multimeric α-synuclein to prevent the formation of 
higher order soluble toxic multimers [293]. 
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 Soluble monomeric α-synuclein is an intrinsically disordered protein and behaves 
like a larger protein of ~50-60 kDa when assessed using a number of techniques including 
size-exclusion chromatography and blue native gel electrophoresis (BN-PAGE) [127]. The 
unusual behavior of α-synuclein makes the separation of native multimers from the 
monomer, according to mass, particularly challenging. Chemical crosslinking can be used 
to preserve α-synuclein multimers allowing their separation from the monomer by 
traditional sodium dodecylsulphate polyacrylamide electrophoresis (SDS-PAGE) [291, 
293, 294]. α-Synuclein multimerizes upon binding to phospholipid membranes, but it 
remains unclear whether free soluble α-synuclein can form stable soluble multimers. Upon 
binding to phospholipid membranes α-synuclein adopts defined secondary structure and 
subsequently multimerize [290, 295]. Although the interaction between α-synuclein with 
phospholipid membranes is intimately involved in the multimerization process and 
biological function of α-synuclein, the molecular details of this interaction remain unclear. 
 Here, we developed a new technique, termed “multimer-PAGE,” to quantify the 
multimerization of α-synuclein in complex biological samples. Using this technique, it is 
possible to compare the ratio of α-synuclein multimers between 14 brain tissue samples 
without the need for specialized equipment.  
5.1 Materials and Methods 
5.1.1 Animals 
 20 adult male Sprague Dawley (SD) rats (250-350g) were pair housed in 
polycarbonate cages at approximately 70°F. Rats were euthanized via live decapitation. 
Following euthanasia, the brain was removed and dissected on ice. All collected brain 
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tissue was placed on dry ice, and frozen at -80°C until assayed. All procedures were 
conducted in accordance with the Wayne State University institutional care and use 
committee approved protocol #A3310-01. 
5.1.2 Sample preparation 
 All procedures were conducted on ice and in a cold room. Frozen brain tissue 
samples weighing approximately 25-200 mg were homogenized in 1 mL 1 X BN-PAGE 
sample buffer (Invitrogen, Waltham, MA) for native separation or phosphate buffered 
saline pH 7.4 (PBS) for in-solution crosslinking experiments. All solutions contained 
EDTA free protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Tissue was 
disrupted using 30 strokes in a 7 mL dounce homogenizer. Following homogenization, 
samples were briefly vortexed and incubated on ice for 30 min. For some experiments, 
0.5% m/vol NP40 (Boston Bioproducts, St. Ashland, MA) or 1% m/vol digitonin (Sigma) 
was added to the lysate prior to the 30 min incubation on ice. The sample was then 
centrifuged at 18,000 x g for 30 min. Following centrifugation the supernatant (S1) was 
carefully transferred to a pre-chilled 1.5 mL eppendorf tube. To determine protein 
concentration of the sample, 8 µl of the S1 was transferred to a separate eppendorf tube 
containing 2 µl of 10% m/vol SDS, mixed well, and incubated at room temperature for 10 
min. This delipidated sample was then used to determine the protein content using 
bicinchoninic acid assay (BCA assay, Thermofisher, Waltham, MA). Samples were diluted 
to a final concentration of 0.1-4 mg protein / mL, depending on the experiment. The 
insoluble pellet (P1) was resuspended in 1.5 mL RIPA buffer (10mM Tris-HCl pH 8.0, 1% 
Triton X-100, 0.1%m/v sodium dodecyl sulphate, and 140 mM NaCl) mixed thoroughly, 
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and incubated on ice for 1h. The P1 sample was then centrifuged at 18,000 x g for 30 min 
at 4°C, and the supernatant retained (S2). The S2 was then processed for lipid and protein 
quantification. α-Synuclein was purified as previously described [296]. Relative purity of 
α-synuclein was determined by SDS-PAGE and subsequent Coomassie Blue G-250 
staining. The lyophilized purified α-synuclein was dissolved in 1 x BN-PAGE sample 
buffer for native separation or PBS for in-sample crosslinking experiments to a final 
concentration of 4 mg protein / mL. 
5.1.3 Lipid and protein isolation 
  Bulk lipid extraction was performed essentially as previously described [297]. 
Briefly, 20 mL of a chloroform and methanol mixture (2:1) was added to 1 g of rat brain 
tissue. The tissue was homogenized via sonication for 2 min. The homogenate was 
vortexed well, 4 mL of PBS added, and the sample vortexed again. The sample was then 
allowed to sit for 5 min to allow the solution to separate into two phases. The organic phase 
containing the purified lipids at the bottom of the tube was carefully removed and dried 
under vacuum using a Centrivap DNA Concentrator (Labconco, Kansas City, MO). The 
purified lipids were then resuspended in 200 µl 1 X BN-PAGE sample buffer containing 
10% m/vol NP40, bath sonicated for 30 min, and centrifuged at 18,000 x g to remove any 
insoluble lipids not incorporated into the NP40 micelles. Isolated lipids were used within 
24 h to avoid excessive lipid oxidation. Extracted brain lipids were used for generating a 
lipid standard for total lipid determination and to generate mixed micelles only (Figure 25A 
and D). 
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 To extract lipid and proteins from individual lysates we first diluted the samples to 
2 mg protein / mL using the appropriate buffer in a 1.5 mL eppendorf tube. The dilution 
was conducted to yield a final sample volume of 150 µl. Then 600 µl methanol and 150 µl 
chloroform were added to each sample. Samples were mixed well, 450 µl of dH20 added 
to each sample and mixed well again. Samples were then centrifuged at 14,000 x g for 5 
min. The upper aqueous phase was then carefully discarded, making sure not to disturb the 
precipitated proteins between the lower and upper phase. 450 µl of methanol was then 
added to each sample, vortexed, and centrifuged at 14,000 x g for 5 min. The methanol 
chloroform mixture contained the lipids and precipitated proteins are found in the pellet. 
The extracted lipids from individual samples were used to quantify the amount of soluble 
lipids (Figure 25D). The precipitated proteins from individual samples were used for mixed 
micelles experiments (Figure 25A).  
  The precipitated proteins (300 µg) were dissolved in 100 µl 1 X BN-PAGE sample 
buffer containing either 0.5% NP40 or 0.5% NP40 brain lipid mixture. Samples were 
mixed thoroughly, allowed to sit on ice for 30 min, and mixed thoroughly again. All 
samples were then centrifuged 18,000 x g for 30 min to remove any remaining insoluble 
lipids or proteins. Protein content of each mixture was then determined using BCA assay. 
5.1.4 Blue native polyacrylamide gel electrophoresis 
 Procedures were conducted as previously described[298].  Briefly, linear gradient 
2.8-13%T and non-gradient 6%T gels were used for all BN-PAGE separations. All gradient 
gels were poured by hand using a linear gradient former built as previously described [299]. 
A 2.8%T gel was used for the sample wells.  0-0.5% m/v Coomassie Blue G-250 (Sigma-
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Aldrich, St. Louis, MO) was added to all samples immediately prior to electrophoresis and 
4-50 µg of brain tissue lysate protein or 50-200 ng purified α-synuclein were loaded into 
each sample well of  the BN-PAGE gel. Either native page marker (Invitrogen) or 1 µg of 
bovine serum albumin (BSA, Santa Cruz Biotechnology, Dallas, TX) diluted in 1 X BN-
PAGE buffer was used as a protein standard. Electrophoresis was conducted using running 
buffer (100mM bis-tris, 100 mM tricine) containing either 0.001% (for non-detergent 
samples) or 0.01% (for detergent samples) G-250 at 100 V until the samples entered the 
gel, and then 180 V for approximately 3 h (until the dye front reached the end of the gel) 
at 4°C. When detergent samples were resolved, the running buffer containing 0.01% G-
250 was replaced by the running buffer containing 0.001% G-250, approximately half-way 
through the run. 6%T BN-PAGE gels were run under the same conditions but stopped once 
samples had migrated about 2 cm into the resolving gel. Once electrophoresis was complete 
the lanes of the gel were either excised for 2D electrophoresis or electroblotted onto 
methanol activated polyvinylidene fluoride (PVDF) membranes. Electroblotting of BN-
PAGE gels was performed at 20 V for 3 h at 4°C using the BN-PAGE running buffer. 
Following electroblotting, PVDF membranes were fixed for 20 min in 10% acetic acid, 
rinsed with ultrapure water, and then dried.  
5.1.5 In-gel crosslinking 
 Excised gel pieces were washed with PBS three times for 10 min at 4°C to remove 
excess bis-tris and 6-aminocaproic acid because could compete with crosslinking reactions. 
Gel lanes were then incubated for 5-30 min at 4°C in PBS containing either 1% 
paraformaldehyde (PFA), 1% glutaradehyde, 0.1-2 mM Dithiobis 
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(succinimidylpropionate) (DSP, ThermoFisher Scientific, Waltham, MA), 0.1-2 mM 3,3'-
dithiobis (sulfosuccinimidyl propionate) (DTSSP, Thermofisher Scientific), or 0.1-2mM 
disuccinimidyl glutarate (DSG, ThermoFisher Scientific). DSP, DTSSP, and DSG must 
first be dissolved in DMSO to a concentration of 25 mM before adding drop-wise to the 
PBS. Gels were then incubated in 375 mM Tris-HCl pH 8.8 buffer (when resolving by 
SDS-PAGE gradient gel) or 125 mM Tris-HCl pH 6.8 (when resolving by non gradient 
SDS-PAGE gel), both containing 2% SDS for 1 h at room temperature.  
5.1.6 2D-Sodium dodecyl sulfate gel electrophoresis 
 Excised gel strips were placed in-between Mini PROTEAN® system glass plates 
with a 1 mm spacer (Biorad, Hercules, CA). Each gel strip was positioned with the lowest 
percentage gel facing down (to ensure proteins leave the gel strip during electrophoresis). 
When 6%T BN-PAGE gel was used the orientation of the gel strip wasn’t crucial. 
Approximately 30 mm space is needed on the end of the gel strip for comb placement to 
form 2 wells. The glass plates containing the gel strip were then locked into the Bio-Rad 
gel stand and checked for leaks. Then a 3-16%T linear gradient or 12%T gel was poured 
between the glass plates leaving approximately 10 mm space under the excised gel piece 
for the sample gel. For 12%T gel, a 1 cm space was left for the stacking gel to ensure 
sufficient band focusing. Butanol was gently layered over the top of the gradient and the 
gel was allowed to polymerize at room temperature for ~1 h. Once the gel was polymerized, 
the butanol was removed and a sample gel of 3%T was poured around the gel strip. Tilting 
the gel stand slightly prevented bubbles from forming under the gel strip bubbles. The 2-
well comb was placed in between the glass plates and 30 min was allowed for 
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polymerization. Alternatively, 2D-SDS-PAGE gels can also be precast (without the 
excised gel strip). However this requires custom well comb, which can be fashioned out of 
polystyrene sheets purchased from most hobby stores. Reduction in band resolution, due 
to uneven migration of the sample out of excised gel, was observed when using precast 
gels and therefore the method should generally be avoided. Gels were then run at 125 V 
until the dye front reached the end and gels were then transferred to PVDF membrane in 
Towbin transfer buffer (25mM Tris-HCl, 192mM glycine, and 20% methanol) using the 
constant of 20 V for ~16 h at 4°C.  
5.1.7 Immunodection 
 Dried membranes were reactivated in 100% Methanol for 1 min and then rinsed 
with ultrapure water. To confirm even transfer, all membranes were stained using Ponceau 
S (Sigma-Aldrich). Membranes were incubated in blocking buffer which consisted of 5% 
m/vol milk diluted in TBST (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-80, pH 8.0) 
for 1 h at room temperature. Then membranes were incubated in blocking buffer containing 
either monoclonal (BD Biosciences) or polyclonal (Santa-Cruz) anti-α-synuclein 
antibodies diluted 1:1000, overnight at 4°C. Parkin monoclonal and polyclonal antibodies 
were diluted 1:1000 in blocking buffer and incubated with membranes over-night at 4°C.  
Membranes were then washed 2 X 10 min with TBST before incubating in the appropriate 
HRP conjugated anti-body diluted 1:5,000 in blocking buffer for 1 h at RT.  Membranes 
were then washed 2 X 10 min with TBST, incubated 5 min in ECL substrate, and imaged 
using GE Imagequant LAS 4000 (GE Health Care, Little Chalfont, United Kingdom).  
5.1.8 In-sample crosslinking 
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 Brain tissue lysates in PBS (see section 2.2) were diluted to concentrations ranging 
between 0.1-4 mg protein / mL.  DSP or DSG (1 mM) were added to each sample and 
incubated at 4°C for 10 min. The reaction was quenched with 50 mM Tris-HCl pH 8.0 for 
15 min. 1 X SDS-PAGE sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 
and 0.1% bromophenol blue) was then added to each sample, mixed well, and heated at 
90°C for 5 min. 10 µg protein from each sample was added to each well. DSP crosslinker 
arm was cleaved by adding 5 mM dithiothreitol (DTT) prior to heating the sample. Purified 
α-synuclein was dissolved in PBS to a concentration of 4 mg / mL and crosslinked with 2 
mM DSP for 10 min at 4°C. The reaction was quenched with 50 mM Tris-HCL pH 8.0 for 
15 min.  
5.1.9 Determination of total lipid content 
 Total sample lipid content was determined essentially as previously described 
[300]. Specifically, lipids isolated from the samples were dissolved in 100 µl chloroform. 
The chloroform solution was then placed into a disposable 12 X 75mm borosilicate glass 
tube (Corning Inc., Corning, NY) and allowed to dry completely. Standards were generated 
by dissolving a known mass of isolated rat brain lipids (see section 2.4) or canola oil (local 
grocery store) in chloroform. Standard solutions were then pipetted into 6 glass tubes to 
yield 5-400 µg total lipid, and dried completely. Then, 100 µl of concentrated sulfuric acid 
(Sigma-Aldrich) was placed in each tube and incubated at 90°C for 20 min. The tubes are 
then cooled immediately using an ice water bath, and solutions transferred to a clear 
polystyrene 96-well plate (Thermofisher). Light absorbance was measured at wavelength 
540 nm, then 50 µl of phosphor-vanillin solution (0.2 mg vanillin dissolved in 1 mL 17% 
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phosphoric acid) was added, and the plate incubated at room temperature for 10 min. The 
plate was then read at 540 nm again, and the background (i.e. first absorbance 
measurement) was subtracted from sulfo-phospho-vanillin absorbance (i.e. second 
absorbance measurement). Detection limit was determined to be approximately 5 µg lipid. 
5.1.10 Polyacrylamide gel-solutions 
 All gels were formed using two stock polyacrylamide solutions. The first 40%T 
acrylamide stock solution that can be purchased (Biorad) was used for all SDS-PAGE gels.  
The second 40%T acrylamide stock solution is made by mixing 48 g acrylamide (Fisher 
Scientific) and 1.5 g N,N-Methylenebisacrylamide (Fisher Scientific) in 100 mL ultrapure 
water (heating to 40°C required to dissolve completely). This second acrylamide solution 
was used only for BN-PAGE gels. BN-PAGE gel buffers were prepared as previously 
described[301]. Stacking gel buffer (125mM Tris-HCl pH 6.8, 0.1% m/vol SDS) and 
resolving gel buffer (375mM Tris-HCl pH 8.8, 0.1% m/vol SDS) were used for all SDS-
PAGE gels. 0.1% m/vol ammonium persulphate (Sigma) and 0.05% vol/vol N,N,N′,N′-
Tetramethylethylenediamine (Sigma) were used to the intiate polymerization of SDS-
PAGE polyacrylamide gels. 
5.1.11 Blot Quantification 
 Densitometry analysis was conducted on all images using Imagej software 
(National Institutes of Health). Linear regression analysis and repeated measures ANOVA 
were conducted using Graphpad Prism software (La Jolla, CA). All images are uncut 
(unless depicted by a black line) and representative of each experiment conducted. Several 
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overexposed images are presented to display banding pattern, but these images were not 
used for any quantification. 
5.2 Results/Discussion 
5.2.1 Separation of α-synculein by blue native Page 
 To develop the multimer-PAGE protocol we first needed to describe, in detail, the 
migration pattern of α-synuclein during BN-PAGE (Figure 24). Extraction of proteins from 
rat brain tissue using 0.5% NP40, 1% digitonin, or in the absence of detergent under typical 
lysis concentrations (25 mg tissue / mL buffer) showed efficient tissue solubilization, an 
absence of abundant high molecular weight (>150kDa) α-synuclein interactions, and 
allowed for the separation of soluble α-synuclein via BN-PAGE (Figure 24A). Monoclonal 
and polyclonal antibodies against the c-terminus of α-synuclein produced similar band 
patterns for tissue lysates. α-Synulcein migrated to the gel position of approximately 50-
146 kDa on the 2.8-13%T BN-PAGE gel. The addition of up to 50 µg lysate protein still 
produced one major band at 50 kDa. A mass shift to approximately ~100 kDa was observed 
following the extraction with digitonin and NP40. The overall protein distribution on BN-
PAGE appeared similar between extraction conditions, with the exception of an increased 
abundance of observable protein complexes with digitonin and NP40 (Figure 24A, Ponseau 
S stain). Together, these results show that under typical BN-PAGE conditions soluble α-
synuclein from rat brain tissue was separated as a single species, predominantly migrating 
between the 50-146 kDa position on BN-PAGE, in agreement with several reports [127, 
294]. 
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FIGURE 23 MIGRATION OF ALPHA-SYNUCLEIN ON BN-PAGE 
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Figure 24. Migration of α-synuclein on BN-PAGE. (A) Rat brain tissue lysates were 
resolved under typical blue native polyacrylamide gel electrophoresis (BN-PAGE) 
conditions. A total of 25 mg of rat brain tissue was homogenized in 1 mL of blue native 
page (BN-PAGE) sample buffer (50 mM BisTris, 6 N HCl, 50 mM NaCl, 10% vol/vol 
glycerol, 0.001% m/vol Ponceau S, pH ∼ 7.2). Then either 1% m/vol digitonin (Dig.) or 
0.5% vol/vol NP40 was added to the sample and incubated at 4 °C for 30 min. Samples 
were then centrifuged at 18 000g for 30 min at 4 °C, and the supernatant (S1) was retained. 
Protein concentration of the S1 was determined using bicinchoninic acid (BCA) assay 
(ThermoFisher). In total, 10 μg and 50 μg of brain tissue lysate protein were resolved using 
BN-PAGE. Proteins were then immunoblotted onto polyvinylidene fluoride (PVDF) 
membranes and blue dye removed by washing the membrane with 100% methanol. PVDF 
membranes were then stained with ponseau S, imaged, and subsequently probed with both 
polyclonal and monoclonal anti-α-synuclein antibodies. (B) Rat brain tissue was then 
disrupted under high tissue to buffer ratio (m/vol) and separated by BN-PAGE. To do this, 
200 mg rat brain tissue was homogenized, as described above, in 1 mL of BN-PAGE 
sample buffer in the absence of detergents. A total of 5–50 μg of total protein input of the 
undiluted S1 fraction was loaded into the first six wells of BN-PAGE gel. The S1 sample 
was then serial diluted from 0.8 to 4 mg protein/mL and 30 μg of protein loaded into the 
remaining wells (last six lanes). (C) Rat brain tissue lysates separated by BN-PAGE in two 
dimensions. A total of 200 mg of rat brain tissue was homogenized as described above. In 
total, 30 μg of the lysate was then resolved on a 2.8–13%T BN-PAGE gel. The gel lane 
was then excised and cast into a 2.8–13%T BN-PAGE gel perpendicular to the first 
dimension direction of migration. The sample was separated again via 2.8–13%T BN-
PAGE. Top panel represents the immunoblot of first dimension BN-PAGE and the middle 
panel depicts immunoblot following the second dimension BN-PAGE. Bottom panel 
depicts ponseau S staining of the blotted proteins from the second dimension BN-PAGE. 
All membranes were probed with anti-α-synuclein antibodies and the appropriate HRP 
conjugated secondary antibodies. All separations shown were conducted using 2.8–13%T 
linear gradient BN-PAGE gels. Blue arrows indicate the direction of migration during BN-
PAGE electrophoresis. All data representative of 3–10 experiments. 
 
 Previous reports demonstrate high lysis concentrations preserve α-synuclein 
multimers. Therefore, we then resolved high concentration rat brain tissue lysates (200 mg 
tissue / 1 mL buffer) in the absence of detergents, and observed several α-synuclein species 
migrating to 50 kDa, ~100 kDa, 600 kDa, and 1048 kDa following BN-PAGE (Figure 
24B). The mass shift of α-synuclein was sensitive to both total protein input, and to some 
extent, sample dilution. Under conditions of high sample concentration and/or high total 
protein input α-synuclein preferentially migrates to the 100 kDa BN-PAGE gel position. 
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At the highest total protein input (50 µg protein) the predominant species of α-synuclein 
had an apparent mass of 100 kDa and two other massive species, at 600 kDa and 1048 kDa, 
could clearly be observed, albeit far less abundant than the 100 kDa position. The mass 
shift of α-synuclein during BN-PAGE was not completely lost following dilution of the 
sample, suggesting that the sample concentration at initial tissue lysis was also a crucial 
factor for the observed BN-PAGE mass shift. Interestingly, once the majority of α-
synuclein had shifted to 100 kDa, several minor bands remained at the original position 
(more clearly seen in Figure 25B, bottom panel) suggesting the original band may be 
comprised of several species with distinct masses. Together, these results show that α-
synuclein migrates to several positions on BN-PAGE depending on how the sample is 
prepared and that an unknown dilution sensitive factor was responsible for this apparent 
mass shift.  
 Next, we tested whether the observed α-synuclein mass-shift was a progressive 
process (i.e. a product of electrophoresis) by separating tissue lysates via BN-PAGE in 2 
dimensions. Following the first dimension separation of 30 µg brain lysate by BN-PAGE 
one main band at 50 kDa and a minor band just above ~100 kDa, were observed (Figure 
24C, top panel), as was shown previously in figure 24B. When we subsequently separated 
the BN-PAGE gel lane by BN-PAGE perpendicular to the original migration direction we 
again observed two distinct α-synuclein species at 50 kDa and ~100 kDa (25C, middle 
panel), both at the original positions of the 1D-BN-PAGE. This suggests that the mass shift 
of α-synuclein during BN-PAGE was either due to a saturable process (i.e. non-
progressive) or the observed massive species existed in the original sample. The lack of a 
111 
 
 
 
progressive mass shift during the second dimension BN-PAGE makes it highly unlikely 
that buffer components (i.e. coomassie blue g-250, Bis-Tris, aminocaporic acid, and 
tricine) were responsible for the observed mass shift. 
5.2.2 Endogenous lipids determine α-synuclein migration distance during BN-
PAGE. 
 An unknown biological factor or factors, lost upon dilution of the lysate and 
influenced the initial lysis concentration, were causing a mass shift of α-synuclein during 
BN-PAGE. Endogenous phospholipids are nearly insoluble amphiphiles that have the 
potential to form small soluble aggregates, termed micelles. Micelles form at threshold 
concentrations and are sensitive to dilution [302]. Since α-synuclein is known to 
multimerize upon phospholipid membrane binding [291], endogenous lipid micelle-α-
synuclein complex could be responsible for the α-synuclein mass shift during BN-PAGE. 
To test whether endogenous lipids were responsible for the apparent mass shift of α-
synuclein, we removed lipids from the brain tissue lysates and then resolved the lipid free 
proteins by BN-PAGE. We found α-synuclein formed one distinct 50 kDa species in the 
absence of endogenous lipids (Figure 25A) similar to what was observed in low-lysis 
concentration detergent free samples (See figure 24A). When 0.5% NP40 was added to 
lipid free proteins we observed a mass shift too approximately of ~100 kDa with only a 
small amount of the 50 kDa α-synuclein species remaining (visualized a small spots 
towards the perimeter of the lane). The mass shift was similar to that observed with BN-
PAGE of NP40 tissue extracts (Figure 24A). NP40/brain-lipid mixed micelles were then 
added to the lipid free proteins and another mass shift was observed, with α-synuclein now 
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running at ~50, ~100, and ~200 kDa, similar to that observed in the detergent free high 
concentration samples (refer to figure 24B). Therefore, lipid and detergent micelles alone 
could produce a substantial apparent mass shift (+400% mass) during 1D-BNP. 
Interestingly, the micelles and endogenous lipids could be observed on the back of PVDF 
blots of the BN-PAGE following transfer, mostly stacked at the bottom of the membrane 
(Figure 25A, middle panel). Strikingly, the α-synuclein migration pattern was identical to 
the observed micelle migration pattern on the PVDF membrane. Ponceau S staining 
confirmed that the observed micelle positions were not highly proteinaceous (i.e. below 
ponseau S detection threshold, ~10 µg protein per lane). Taken together this data 
demonstrates that α-synuclein was migrating with endogenous lipids and/or detergent 
micelles during BN-PAGE, and this effect was likely responsible for mass shifts observed 
when tissue was disrupted at high concentrations.  
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Figure 25. Lipids determine α-synuclein migration pattern on BN-PAGE. Sample lipid 
content determines the migration of α-synuclein during BN-PAGE. (A) 200 mg rat brain 
tissue was homogenized in 1 mL of blue native page (BN-PAGE) sample buffer (50 mM 
BisTris, 6 N HCl, 50 mM NaCl, 10% vol/vol glycerol, 0.001% m/vol Ponceau S, pH ∼ 
7.2) and incubated on ice for 30 min. The sample was centrifuged then at 18 000g for 30 
min, S1 retained, and protein content determined using bicinchoninic acid (BCA) assay. 
Samples were then adjusted to a final concentration of 2 mg protein/mL. A volume of 150 
μL of the samples were mixed with 600 μL of methanol and 150 μL of chloroform. A 
volume of 450 μL of ultrapure water was then added to the sample and mixed thoroughly. 
Following centrifugation at 18 000g for 5 min, the upper aqueous phase was discarded and 
the lower phase resuspended in 600 μL of methanol. The sample was centrifuged at 18 000g 
for 5 min. The liquid was discarded and precipitate (proteins) retained. Separately, bulk 
lipids were isolated by homogenizing 1 g of rat brain tissue in a mixture of chloroform and 
methanol (2:1). Following sonication for 2 min, the homogenate was vortexed well, 4 mL 
of PBS added, and vortexed again. The sample was then allowed to sit for 5 min to allow 
the solution to separate into two phases. The organic phase containing the purified lipids 
was removed and dried under vacuum. The lipid pellet was then completely dissolved in 
200 μL of 10% NP40. The precipitated lipid free proteins were dissolved in BN-PAGE 
sample buffer, BN-PAGE sample buffer containing 0.5% w/v NP40, or BN-PAGE sample 
buffer containing 0.5% w/v NP40 mixed lipid micelles. Samples were mixed thoroughly, 
incubated on ice for 30 min, and mixed thoroughly again. All samples were then 
centrifuged at 18 000g and the resulting 10 μg of protein of the soluble fraction resolved 
by BN-PAGE. Top panel depicts immunobloting of samples with anti-α-synuclein 
antibody. Middle panel depicts the white light image of polyvinylidene fluoride (PVDF) 
membrane immediately following transfer of the BN-PAGE gel. Bottom panel depicts 
ponseau S staining of PVDF membrane following the removal of G250 from the membrane 
by washing in 100% methanol for ∼5 min. (B) 25, 50, 100, and 200 mg of rat brain tissue 
was homogenized in 1 mL of BN-PAGE sample buffer as described above and resolved 
via BN-PAGE. A total of 30 μg of total proteins were resolved in each lane without sample 
dilution (left column panels) and following dilution of samples to 2 mg protein/mL (right 
column panels). Top row depicts white light image of PVDF membrane immediately 
following transfer. Middle row depicts subsequent ponseau S staining of the PVDF 
membrane following removal of G-250. Bottom row depicts the immunoreactivity of α- 
synuclein. (C) Increasing concentrations of G-250 (0–2%) was added to rat brain tissue 
lyates from high concentration homogenization conditions (200 μg tissue/mL buffer). A 
total of 30 μg of protein was then resolved via BN-PAGE. Top panel depicts white light 
image of PVDF membrane. Middle row depicts ponseau S staining of PVDF membrane 
following removal of G-250. Bottom  row dipicts the immunoreactivity of alpha-synuclein. 
(D) Lipid to protein content of insoluble fraction following tissue homogenization at 
different tissue to buffer ratios. 
 
When we resolved brain lipid/detergent mixed micelles by BN-PAGE we noticed 
that they could be clearly visualized following transfer to PVDF membranes (Figure 25A, 
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middle panel). Next we asked whether a similar pattern could be observed when tissue was 
lysed at high concentrations. Such a pattern would presumably confirm the hypothesis of 
endogenous lipid micelles being responsible for the observed mass shift during BN-PAGE.  
Results show that indeed the same type of pattern was observable most noticeably when 
tissue was lysed at high concentrations (Figure 25B, top panel). As with the lipid/detergent 
micelles, α-synuclein migration patterned mirrored the apparent endogenous lipid 
structures (Figure 25B, bottom panel) following BN-PAGE. Dilution of the samples did 
not abolish the visualization of the lipids, but instead resulted in their shift to lower, discrete 
bands. Again, α-synuclein migration mirrored the position shift of the endogenous lipid 
micelles upon sample dilution. Gross protein distribution was relatively unaffected by the 
lipid structures migrating on BN-PAGE (Figure 25B, Middle panel). Together, these 
observations demonstrate that α-synuclein was co-migrating with soluble endogenous lipid 
structures. 
 Coomassie G-250 incorporates into detergent micelles [303], imparting a net 
negative charge, carrying them to the dye front during BN-PAGE, ultimately preventing 
distortion of protein [298]. We wanted to determine whether G-250 could alter the 
distribution of the apparent endogenous lipid micelles and produce a corresponding mass 
shift in α-synuclein. When 0.01-1% G250 was added directly to samples from high 
concentration lysis conditions, the original lipid smear on the PVDF membrane was no 
longer observable (Figure 25C, Top Panel). Gross protein migration appeared unaffected 
by G-250 treatments, but α-synuclein migration became more focused to a position of 50 
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kDa as the G-250 concentration increased. Therefore, excess G-250 added directly to the 
sample prevents the lipid mediated mass shift during BN-PAGE.  
 Lipids extracted under high concentration lysis conditions determined the 
electrophoretic mobility of α-synuclein during BN-PAGE; however it was unclear whether 
high concentration tissue lysis resulted in increased lipid extraction from tissue. To directly 
address this we measured the lipid and protein content in the remaining insoluble pellet 
(P1) at several lysis concentrations (Figure 25D). Results showed a sharp decrease in the 
lipid/protein ratio in the insoluble pellet when tissue was disrupted at high concentrations 
(i.e. 50-200 mg tissue / mL buffer).  Interestingly, all lysis conditions above 50 mg tissue / 
mL buffer had similar lipid extraction efficacy. We attempted to directly measure the lipid 
content in S1 fractions but the lipid concentration was near the assay’s threshold for 
detection (~5 µg lipid) and we were unable to obtain quantitative results. Even without the 
S1 lipid concentration it was clear that high lysis concentrations were increasing ratio of 
lipid to protein extracted from tissue. 
 Mass shift of a protein during BN-PAGE electrophoresis is commonly interpreted 
as a formation of protein complexes. However, as we have demonstrated here, the 
electrophoretic mobility of α-synuclein during BN-PAGE can vary drastically depending 
on sample preparation (specifically sample lipid content). A previous report demonstrated 
a similar effect for the mitochondrial protein carrier protein AAC319 [304]. Therefore, 
BN-PAGE alone is insufficient to accurately detect and describe soluble α-synuclein 
multimers.  
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5.2.3 α-Synuclein multimers can be resolved via SDS-PAGE following in-gel 
chemical crosslinking 
Chemical crosslinking methods can be used to selectively capture protein-protein 
interactions. Once protein-protein interactions are captured the samples can be separated 
in the presence of SDS micelles via traditional SDS-PAGE. SDS solubilizes lipids [305], 
denatures proteins [306], thereby avoiding complications involved with BN-PAGE when 
separating lipid binding proteins, in this case α-synuclein. Therefore, following separation 
of tissue lysates via BN-PAGE, we incubated BN-PAGE gel lanes in several crosslinking 
solutions and then resolved them using 2D-SDS-PAGE (Figure 26A). Results showed that 
crosslinking with 0.1 mM DSP, 0.1 mM DTSSP (not shown), 1% Glutaraldehyde, 0.1 mM 
DSG, but not 1% PFA, produced several high molecular weight α-synuclein products in 
addition to the monomer detected following 2D-SDS-PAGE. We also observed two 
massive α-synuclein species of low abundance that were only captured and detectable with 
DSG or DSP. These elute from the BN-PAGE positions corresponding to the two high 
molecular weight species (~600 kDa and ~1048 kDa) clearly seen following BN-PAGE in 
figure 25B. Both species were far less massive on the SDS-PAGE (~80 kDa, and 170 kDa, 
respectively). Because DSP and DSG crosslinking is relatively specific for protein-protein 
interactions, the 600 kDa and 1048 kDa apparent masses on BN-PAGE were like due to 
processes other than true multimerization (e.g. lipid/detergent binding), as opposed to true 
multimers of 600 and 1048 kDa. PFA was ineffective at capturing α-synuclein multimers 
most likely because the spacer-arm length of PFA is relatively short (2Å) while the 
effective crosslinkers had much longer spacer arm length (≥7Å). Several other reports have 
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also demonstrated the successful capture of α-synuclein multimers using crosslinkers with 
similar spacer-arm length [127, 292-294] 
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Figure 26. Multimer-PAGE format. Rat brain tissue was homogenized in blue native page 
(BN-PAGE) sample buffer (50 mM Bis-Tris, 6N HCl, 50 mM NaCl, 10% vol/vol glycerol, 
0.001% m/vol Ponceau S, pH 7.2) at a ratio of 200 mg of wet tissue to 1 mL of buffer. 
Following centrifugation at 18 000g for 30 min at 4 °C, the protein content of the S1 
fraction was determined by bicinchoninic acid (BCA) assay. (A) 30μg protein per lane was 
resolved via BN-PAGE. Individual lanes were then excised, washed with phosphate 
buffered saline pH 7.4 (PBS), and incubated in PBS solutions containing 0.1 mM 
dithiobis(succinimidyl propionate) (DSP), 0.1 mM disuccinimidyl glutarate (DSG), 1% 
glutaraldehyde (GLUT), or 1% paraformaldehyde (PFA) for 30 min at 4 °C. The excised 
gel pieces were then cast into SDS-PAGE and run perpendicular to the original migration 
direction. (B) Rat brain tissue was homogenized in PBS at a ratio of 200 mg wet tissue/1 
mL buffer. Samples were centrifuged at 18 000g for 30 min at 4 °C. The sample was then 
diluted from 4 to 1 mg protein/mL. Following dilution, 1 mM DSG or 1 mM DSP was 
added to the samples and incubated for 10 min at 4 °C. The reaction was then quenched 
with 100 mM Tris- HCl pH 8.0 for 15 min at 4 °C. The 5× SDS-PAGE sample buffer was 
added to each sample, mixed well, and 10 μg of protein loaded into each lane of a 3–16%T 
SDS-PAGE gel. The 5 mM DTT was added to the 4 mg protein/mL DSP cross-linked 
sample to cleave the cross-linker (lane 1). (C) Increasing concentrations of total soluble 
protein were resolved via BN-PAGE (from the left; 4, 8, 12, 16, 20, 24, 28, 32, 36, and 40 
μg of protein). BN-PAGE gel was cut above and below the 66 kDa molecular weight 
marker (red dotted box), washed with PBS, incubated with 0.1 mM DSP, and cast into a 
SDS-PAGE gel. Left panel depicts white light image of gel following BN-PAGE. Right 
panel depicts immunoblotting of the second dimension SDS-PAGE. All blots probed with 
rabbit polyclonal anti-α-synuclein antibody and appropriate horse radish peroxidase (HRP) 
conjugated secondary antibody. Images are representative of 3–5 separate experiments. 
 
 It remained unclear whether any α-synuclein multimers existed in solution prior to 
electrophoresis or were products of BN-PAGE. To address this, we directly crosslinked the 
soluble brain extracts using 1 mM DSP or DSG, and resolved them via 4-16% SDS-PAGE 
(Figure 26B). Results show that α-synuclein multimers could be detected in lystates using 
both DSP and DSG crosslinkers. These multimers ranged from 34 kda to >170 kDa, and 
appeared to be formed predominantly by diffusion mediated crosslinking. Serial dilution 
of the sample prior to crosslinking prevented the capture of multimeric species, and for 
unclear reasons, also resulted in reduced immunodetection of the monomer (i.e. 17 kDa). 
Because directly crosslinking the sample did not produce α-synuclein multimers 
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comparable to the in-gel crossslinking of BN-PAGE, the α-synuclein multimers observed 
following BN-PAGE were most likely, to some extent, products of electrophoresis.  
 Once we had determined that several multimers were found at the 50-100 kDa 
positions of the BN-PAGE gel, we then “scaled up” and optimized the procedure to make 
comparisons of many samples more reliable and less time consuming. To do this we 
exploited the observation that under most sample conditions nearly all native α-synuclein 
migrated to the ~50-100 kDa position on the BN-PAGE gel, and simply cut the gel just 
below the 66 kDa marker and just at the 146 kDa marker and ran the 2D-SDS-PAGE 
parallel to the BN-PAGE lanes (Figure 26C). The excised gel should encompass the 40-
146 kDa positions, to ensure all α-synuclein is resolved by 2D-SDS-PAGE. This technique 
allowed the experimental conditions to be nearly identical between samples. Using this 
“scaled up” procedure would allow the crosslinked α-synuclein products to form more 
discrete bands when separated by 2D-SDS-PAGE, as opposed to smeared blebs observed 
with running the entire excised lanes, making them easier to visualize and compare. Several 
experimental conditions could now be run on single gel making comparisons between the 
extracts simple and reproducible. Furthermore, several multimers at the gel position could 
be quantified simultaneously, as opposed to only the typically two α-synuclein species 
observed following BN-PAGE. For simplicity, we termed the entire process as “multimer-
PAGE,” with the presented blots representing the blotted 2D-SDS-PAGE of crosslinked 
native complexes.  
5.2.4 Optimization of in-gel chemical crosslinking 
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 Diffusion based chemical crosslinking can randomly covalently bind proteins 
forming progressively massive products only limited by the diffusion of the protein in 
solution. Protocols using chemical crosslinking of proteins should be carefully validated to 
avoid diffusion based products, unless the product is desired, as was later exploited here to 
produce the α-synuclein multimer molecular weight “standard” (see figure 27E). 
Generally, crosslinker concentration, time of crosslinking, and the molecular structure of 
the crosslinker are manipulated to determine true products (i.e. those that existed prior to 
crosslinking) vs. diffusion based (i.e. those that formed during crosslinking). Here we 
tested two crosslinking molecules DSP and DSG, both of which have been used in tissue 
and solution to stabilize α-synuclein multimers 6. Crosslinking the excised BN-PAGE gel 
with as little as 0.1 mM DSP (Figure 27A) or DSG (Figure 27B) was sufficient to capture 
α-synuclein multimers. For reasons that are unclear, increasing DSG concentrations 
appeared to reduce the detection of both multimeric and monomeric α-synuclein. Because 
of the unusual behavior of DSG during in-gel crosslinking, we chose to use 0.1 mM DSP 
for the remaining studies. The main α-synuclein species observed following in-gel 
crosslinking was smeared between 34-130 kDa on the SDS-PAGE. Next we tested what 
crosslinker incubation time was optimal to capture the multimers (Figure 28C). Gels 
incubated with 0.1 mM DSP for 5 min preferentially capture αS80. The crosslinking time 
to capture multimers was so rapid it strongly suggested that diffusion based crosslinking 
was not a main driving factor of α-synuclein multimers detection following multimer-
PAGE protocol. Crosslinking produced nearly equal multimer abundance at 30 and 45 min, 
and therefore 30 min was chosen for the remaining studies.  
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 During validation of the multimer-PAGE protocol we observed that optimal 
resolution of crosslinked products during SDS-PAGE requires that excised gel pieces be 
cast directly into the SDS-PAGE gel as described in the methods. Alternatively, when gel 
pieces were placed directly on top of a preformed SDS-PAGE gel (also mentioned in 
methods) lane distortion became evident (See Figure 27C) but did not appear to effect 
quantification. Therefore, this method can be used when sample processing speed is 
crucial, as it is more time intensive to cast excised gels directly into SDS-PAGE gels. We 
also observed that using a 12%T SDS-PAGE with a stacking layer ultimately provided 
superior band resolution to 3-16%T SDS-PAGE gels. 
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.Figure 27. Optimization of in-gel chemical cross-linking and multimer-PAGE gel format. 
10, 20, and 40 μg of rat soluble brain tissue lysate were resolved by blue native 
polyacrylamide electrophoresis (BN-PAGE). 2.8–13% linear BN-PAGE gels were cut 
just above and below the 66 kDa molecular weight marker following electrophoresis. The 
excised gel pieces were washed in phosphate buffered saline pH 7.4 (PBS) for 30 min at 
4 °C. Excised BN-PAGE gel pieces were incubated with cross-linking solution and cast 
directly to SDS-PAGE gels. The cross-linked proteins were resolved by SDS-PAGE 
perpendicular to the original direction of sample migration. SDS-PAGE gels were then 
immunoblotted. Excised gel pieces incubated with either (A) 0.1–2 mM dithiobis 
(succinimidyl propionate) (DSP) (B) or 0.1–2 mM disuccinimidyl glutarate (DSG). (C) 
Excised gel pieces incubated with 0.1 mM DSP for 5–45 min. (D) 30 μg of rat brain 
tissue lysate separated by BN-PAGE, blotted, and probed for parkin (Left panel). 10, 20, 
30, and 40 μg of lysate protein resolved by BN-PAGE. BN-PAGE gel was excised 
between 40 and 242 kDa positions, incubated with 0.1 mM DSP for 30 min at 4 °C, and 
resolved via SDS-PAGE. Immunoblotting for parkin and α-synuclein shown (Right 
panels). (E) Purified α-synuclein was dissolved in PBS and diluted to a concentration of 5 
mg protein/mL. The 2 mM DSP was added to the sample and incubated for 10 min at 4 
°C. The reaction was quenched with 100 mM Tris-HCl pH 8.0. 200 ng of α-synuclein 
resolved on 12%T SDS-PAGE. (F) Increasing protein input resolved by 2.8–13%T BN-
PAGE and 6%T BN-PAGE. Samples were allowed to migrate the length of the 2.8–
13%T BN-PAGE and the 66 kDa gel position excised as before. In contrast, samples 
were allowed to migrate on approximately 2 cm into the resolving gel on the 6%T BN-
PAGE, and this 2 cm gel piece excised. In-gel cross-linking was performed and both 
excised gel pieces resolved via SDS-PAGE. Bands are labeled with their apparent 
corresponding species according the standard (E). Dotted red lines indicate position of 
gel excision. All blots probed with rabbit polyclonal anti-α-synuclein antibody and 
appropriate horse radish peroxidase (HRP) conjugated secondary antibody. Images are 
representative of three separate experiments. 
 
 Next we tested the specificity of multimer-PAGE for α-synuclein. To do this we 
ran the multimer-PAGE protocol and probed for the E3 ligase parkin, a small globular 
soluble protein not known to interact with lipids or form progressively massive multimers. 
We found that parkin also migrates to approximately the same BN-PAGE gel position as 
α-synuclein (Figure 27D), making it a good internal control. Following ultimer-PAGE we 
observed no detectable crosslinked parkin multimers following multimer-PAGE protocol. 
Instead we saw one species located at ~43 kDa. This position is slightly below the 50 kDa 
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position where parkin is normally found. The slight discrepancy in MW of parkin is likely 
due to the stabilization of a compact tertiary structure of parkin by chemical crosslinking, 
which can increase proteins mobility on SDS-PAGE [307, 308]. The migration of parkin 
during multimer-PAGE was in stark contrast to α-synuclein, which under the same 
experimental conditions produced abundant multimers. This finding demonstrates that 
multimer-PAGE is relatively specific for α-synuclein and gross diffusion based protein 
crosslinking was not a key factor. 
 To determine stoichiometry of α-synuclein multimers following multimer-PAGE 
we generated a molecular weight “standard” by crosslinking concentrated purified α-
synuclein (5 mg purified α-synuclein / 1 mL) with 2 mM DSP and separated the resulting 
products by SDS-PAGE (Figure 27E). Results show five species at gel positions 
corresponding to the molecular weights of 17 (αS17), 35 (αS35), 50 (αS56), 80 (αS80), and 
100 kDa (αS100). α-Synuclein was detected above 130 kDa position but was poorly 
resolved by SDS-PAGE, and therefore was disregarded as a undefined α-synuclein 
multimers species. The observed multimers were likely captured primarily via diffusion 
controlled crosslinking because there was an inverse relationship between multimers 
abundance and the observed molecular weight, which likely occurs if multimers were 
crosslinked in a step-wise fashion.  
 We next wanted to determine the optimal polyacrylamide gel format for multimer-
PAGE (Figure 27F). We found that 6%T BN-PAGE gel followed by 12%T SDS-PAGE 
gel provided the greatest resolution of α-synuclein multimers with the least effort. We 
simply ran the 6%T BN-PAGE gel (with 2.8%T well gel) at 100V until all soluble proteins 
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had migrated ~2 cm into the resolving gel. The gel was excised as before and cast into the 
12%T SDS-PAGE. The new gel format had several key advantages; 1) avoided hand 
pouring linear gradient polyacrylamide gels which can be time-consuming and have poor 
reproducibility 2) ensured all α-synuclein (and other proteins) in the sample were resolved 
by multimer-PAGE 3) crosslinked products migrated out of a single 6%T BN-PAGE gel 
to the SDS-PAGE gel more consistently allowing for increased band resolution 4) allowed 
for investigation of protein complexes other that α-synuclein without extensive validation 
of BN-PAGE migration (i.e. do not need to know a BN-PAGE migration pattern) 5) faster 
BN-PAGE run times (~30 min at 100V). 
5.2.5 Optimization of brain tissue sample preparation and separation 
 Once in-gel crosslinking and electrophoresis conditions were optimized we then 
tested the influence of sample preparation on multimer-PAGE output. First, we 
investigated whether lipid content of the sample would alter the observed multimer pattern.  
We had already observed that α-synuclein migrated with endogenous brain lipids during 
BN-PAGE (Figure 25A, B, and C) however when we assessed these samples using 
multimer-PAGE we found little evidence of any multimeric α-synuclein species in any of 
the samples (Figure 28A). Neither proteins alone nor proteins reconstituted into 
lipid/detergent micelles produced detectable multimers. This suggests that although α-
synuclein was strongly interacting with lipid/detergent mixed micelles the binding to these 
micelles alone was insufficient to produce multimers. Furthermore, multimers observed 
following multimer-PAGE of tissue lysates were likely not due to protein-lipid 
crosslinking, as these products would then be predicted to be in abundance in the presence 
128 
 
 
 
of excess brain lipids. However, phosphatidalserine and phosphatidylethanolamine both 
contain primary amines so protein-lipid crosslinked products cannot be conclusively ruled 
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out. 
Figure 28. Effect of sample preparation on observed multimer abundance. Sample 
preparation determines observed multimer abudance and pattern. Rat brain tissue was 
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homogenized in blue native page (BN-PAGE) sample buffer (50 mM BisTris, 6 N HCL, 
50 mM NaCl, 10% vol/vol glycerol, 0.001% m/vol Ponseau S, pH 7.2) at a ratio of 200 mg 
wet tissue/1 mL buffer. Following centrifugation at 18 000g for 30 min at 4 °C, the protein 
content of the S1 fraction was determined by the bicinchoninic acid (BCA) assay. (A) 300 
μg proteins from the sample was precipitated and resusupended in either BN-PAGE sample 
buffer containing either 0.5% NP40 or 0.5% NP40 mixed lipid micelles. Protein (10 μg) 
was resolved by multimer-PAGE. (B) 50–200 ng of purified α-synuclein and 30 μg of brain 
tissue lysate were resolved via multimer-PAGE. (C) 0–1% G250 directly added to S1 
samples. 30 μg of these samples was separated by multimer-PAGE. (D) Rat brain tissue 
was disrupted in BN-PAGE sample buffer at a tissue mass to buffer ratio of 25, 50, 100, 
and 200. A total of 30 μg of protein from each lysis condition was resolved via multimer-
PAGE. SDS-PAGE of S1 and P1 found in the bottom two panels. (E) Rat brain tissue was 
homogenized in a tissue mass to a buffer ratio of 25 and 100. Increasing total protein input 
was then resolved via multimer-PAGE. (From the left: 5, 10, 20, 30, and 40 μg protein). 
All samples were centrifuged at 18,000g for 30 min prior to BN-PAGE. All blots probed 
with rabbit polyclonal anti-α-synuclein antibody and appropriate horse radish peroxidase 
(HRP) conjugated secondary antibody. Images are representative of 2–4 separate 
experiments. 
 
 Since recombining separated components (i.e. lipids and proteins) of complex 
biological samples did not produce detectable multimers by BN-PAGE, we wanted to 
determine whether α-synuclein alone could assembly into multimers during multimer-
PAGE. To test this, we resolved increasing α-synuclein input (50-200 ng) by multimer-
PAGE and found multimers, to a limited extent, could be detected (Figure 28B). However, 
multimers from purified α-synuclein required excess protein input, and were qualitatively 
distinct from those found in tissue lysates. High molecular weight α-synuclein multimers 
(i.e. αS56, αS80, and αS100) are preferentially detected in lysates while αS35 is the primary 
multimer detected when using purified α-synuclein. The multimer pattern when using 
purified α-synuclein was indicative of diffusion based crosslinking and distinct from 
multimers from lysates, as previously reported [294]. Therefore, α-synuclein was 
insufficient to produce the observed multimers in complex biological samples. 
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 G-250 incorporates into micelles and can form micelle like structures in water, and 
therefore we wanted to know whether G-250 could affect multimer detection (Figure 28C). 
G-250 added directly to the sample produced increased multimer abundance only when G-
250 concentrations were relatively high (0.5% and 1%). G-250 concentrations below 0.5% 
(first three lanes) were similar in multimer abundance and distribution. Because samples 
are not typically exposed to G-250 concentrations above 0.5% during multimer-PAGE 
protocol, this effect is likely minimal. 
 Previously we demonstrated that disruption of brain tissue at high concentrations 
increased relative lipid extraction and altered the migration of α-synuclein during BN-
PAGE (See Figure 26D, B), so we explored whether the ratio of tissue to lysis buffer 
influenced the abundance of observed multimers. Results showed that when tissue was 
disrupted at increasing concentrations multimers in the S1 fraction were in greater 
abundance but the pattern was relatively unchanged (Figure 28D). αS80 and αS100 
appeared to be particularly abundant with αS56 being lower in abundance. Interestingly, 
the total amount of α-synuclein extracted (i.e. S1 fraction) per protein was similar when 50 
mg tissue per mL buffer or greater was used for tissue lysis. Despite the similar extraction 
efficacy, multimers were clearly more abundant. Both the 100 and 200 mg tissue per mL 
buffer showed nearly the same multimer abundance, and therefore 100 mg tissue per mL 
buffer condition was selected for multimer quantification.  
 Few multimers were detected at typical tissue lysis concentration (i.e. 25 mg tissue/ 
mL buffer) when 20 µg total protein was input into multimer-PAGE (See figure 28D). 
However, our previous data suggested that, to some extent, α-synuclein multimers were 
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being formed during electrophoresis (See Figure 26C and B). Therefore, we next asked 
whether increasing sample input of from low and high lysis concentrations would produce 
observable multimers. Results show that as sample input increased, multimers became 
more abundant in both the low and high concentration tissue lysis samples (Figure 28E). 
α-Synuclein multimers were detectable with 10 µg protein in the high concentration lysis 
but required 15 µg following low concentration tissue lysis. Multimer-abundance increased 
disproportionally to monomer abundance following both lysis concentrations. This 
observation, as seen previously (Figure 26C), seems to support the idea that multimers 
were forming during multimer-PAGE and do not exist in the original sample. Therefore, 
although lysis at high concentration allows for ease of multimer detection, it doesn’t seem 
absolutely necessary to produce multimers given sample input into the multimer-PAGE is 
sufficiently high.  
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5.2.6 Using multimer-PAGE to measure the stoichiometry of α-synuclein multimers 
in biological samples  
Next we wanted to determine a standardized method to analyze the data produced by 
multimer-PAGE.  To do this we exploited the observation that the ratio of αS80 to αS17 
increases linearly with increasing protein input into multimer-PAGE (see figure 26C). This 
phenomenon allowed the assessment of multimerization while avoiding variability from 
factors such as relative α-synuclein abundance in the sample.  
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Figure 29. Quantification of α-synuclein multimers using multimer-PAGE. Multimer-
PAGE can be used to compare many complex biological samples. Brain tissue from 4 male 
Sprague–Dawley rats was weighed and homogenized in BN-PAGE sample buffer (100 mg 
tissue/mL buffer). Samples were centrifuged at 18 000g for 30 min at 4 °C. The supernatant 
was retained and 10, 20, and 30 μg of protein separated by multimer-PAGE. Multimer-
PAGE of samples from the hypothalamus (A) and cortex (B). Top panels depict 
immunoblotting for α-synuclein. Bottom panels depict ponseau S stain of multimer-PAGE 
blots prior to immunoprobe. (C) The ratio of 17 kDa (αS17) to 80 kDa (αS80) α-synuclein 
was calculated using ImageJ software and values are plotted for each protein input. The R2 
for each line is depicted on the graph. (D) Bar graph comparing the multimer curve slopes 
between the two brain regions. (“Rate of multimer formation” = slope of multimer curves. 
*students t test, t (6) = 11.29, p < 0.0001, n = 4). 
 
 We generated a multimer curve by separating 10, 20, and 30 µg protein of lysates 
from the rat hypothalamus (Figure 29A) and frontal cortex (Figure 29B) via multimer-
PAGE. Care was taken to ensure tissue was disrupted in 1 mL BN-PAGE sample buffer 
per 100 mg tissue. Once the multimer curve was generated (Figure 29C) we could plot the 
ratio of αS80 to αS17 at each protein input. The corresponding slope of the multimer curve 
could then be calculated and compared. We refer to the calculated slope as the rate of 
multimer formation because the line likely represents the propensity of α-synuclein to form 
multimers during multimer-PAGE.  We then compared multimer formation between two 
distict brain regions (29D).  Results show, that within each brain region, animals had 
similar rate of multimer formation, resulting in very little variability. However, when we 
compared the two brain regions there was significant (Students t-test, t (6) = 11.29, 
p<0.0001, n = 4) reduction in the rate of multimer formation in the hypothalamus when 
compared to the frontal cortex. The significance the regional difference in multimer 
formation is not realized here, but the method appears to provide reproducible and accurate 
measurement of the α-synuclein multimer abundance between different biological samples.  
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5.2.7 Final optimized protocol for α-synuclein multimer-PAGE 
 The final optimized protocol for α-synuclein multimer-PAGE involves four key 
steps and takes approximately 1 day to complete (Figure 30). With this protocol we could 
routinely measure and compare several high molecular weight α-synuclein species across 
complex biological samples. Effort was taken to ensure the process wasn’t overly 
complicated and could be conducted using common lab equipment. Although this protocol 
was optimized for α-synuclein detection it should be emphasized that experimentation with 
protein separation, crosslinking, and sample handing conditions could potentially help 
answer questions about numerous other protein complexes. This technique likely has broad 
applicability to the study of the stoichiometry of numerous other protein-complexes. 
Although the current protocol is limited to measuring “low-n” multimers consisting of ~10 
or less α-synuclein molecules, the SDS-PAGE gel format could be easily adjusted to study 
ever more massive multimeric species. 
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Figure 30. Final optimized protocol for α-synuclein multimer-PAGE. First, rat brain tissue 
was homogenized in blue native page electrophoresis (BN-PAGE) sample buffer (50 mM 
BisTris, 6 N HCl, 50 mM NaCl, 10% vol/vol glycerol, 0.001% m/vol Ponseau S, pH ∼7.2 
) at a specific buffer to tissue ratio (100 mg of wet tissue per 1 mL of buffer) (top panel). 
Homogenization was conducted on ice and consisted of 30 gentle strokes in a 7 mL glass 
dounce homogenizer. Samples were then centrifuged for 30 min at 18 000g, and the 
supernatant (S1) containing the soluble biological molecules was retained. Samples were 
then prepared to load into a BN-PAGE gel (see Step II). To do this, protein content of this 
sample was then determined using bicinchoninic acid (BCA) assay and the S1 diluted to 2 
mg protein/mL using BN-PAGE sample buffer. In order to compare samples, 10, 20, and 
30 μg of each sample was loaded into a 6%T BN-PAGE gel. A 100 V potential was applied 
to the gel until the sample had migrated to approximately 2 cm into the resolving layer of 
the 6%T BN-PAGE gel. The gel was then removed, well gel discarded, and the 2 cm 
section of gel containing the samples was excised. The excised gel piece was then washed 
in phosphate buffered saline pH 7.4 (PBS) for approximately 30 min at 4 °C (see step III). 
The PBS solution should be changed at least 3 times during the washing. Then the gel piece 
is placed in 10 mL of PBS and 40 μL of 25 mM dithiobis(succinimidyl propionate) (DSP) 
dissolved in DMSO added to the PBS. The gel is incubated in this cross-linking solution 
for 30 min at 4 °C, then the solution is discarded and replaced with quenching solution 
(125 mM Tris-HCL pH 6.8, 2% SDS) and incubated for 60 min at room temperature. The 
excised gel piece is then placed between glass plates and cast into 12%T SDS-PAGE gel. 
A constant voltage of 100 V is then applied to the gel using SDS-PAGE running buffer 
until coomassie dye has left the end of the gel. The 12%T SDS-PAGE gel was then 
electroblotted onto polyvinylidene fluoride (PVDF) membranes and probed with several 
α-synuclein antibodies (see Step IV). Densitometry analysis can then be conducted on the 
observed bands using imageJ software. The slope of the lines plotting multimer abundance 
and total protein input could be used to compare samples. (“ST” = well for molecular 
weight standard). 
5.3 Conclusions 
 α-Synuclein formed several soluble multimers during BN-PAGE provided that 
lipid interactions were preserved during tissue lysis. Preservation of lipid interactions likely 
stabilized α-synuclein secondary structure [295, 309] subsequently “seeding” multimer 
formation [291] and/or stabilizing existing multimers. We found that a practical method to 
preserve lipid interactions involved disrupting the tissue in small buffer volumes (i.e. 50-
200 mg tissue / mL buffer) in the absence of detergents. The high ratio of tissue to buffer 
increased the extraction of lipids from tissue. Extracted lipids behaved like endogenous 
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micelles. Although we did not provide a direct description of these micelles, they are 
logically consistent with the fact that free phospholipids are almost completely insoluble 
in water and the lipid structures migrated on BN-PAGE as complexes (i.e. above the dye 
front) and not monomers (i.e. with the dye front). The α-synuclein species observed 
following the multimer-PAGE, once optimized, were in general agreement with the 
previously reported α-synuclein multimers [290, 292-294] , and distinct from those 
produced by diffusion mediated protein crosslinking.   
 Future studies are needed to explore the applicability of the multimer-PAGE 
technique. Studies that may be fruitful should focus on the possible heterogeneity (e.g. 
differences in protein folding, post-translational modification etc.) of the observed α-
synuclein multimers and how this may confer/abolish stability. Liquid chromatography 
Mass Spectrometry (LC-MS) would be particularly useful in identifying possible 
heterogeneity post-translational modifications between multimers; although mass 
adjustments to account for the crosslinker would need to be applied, as has been done 
numerous reports [310]. LC-MS may also allow for the identification of the specific lipid(s) 
interacting with α-synuclein [311] . It is also important to further validate multimer-PAGE 
across several PD models to determine its usefulness in describing the pathology of the 
disease.    
 Multimer-PAGE provides several unique advantages over in-solution crosslinking 
or native-PAGE alone. Kinetics of the chemical crosslinking reaction could be controlled 
precisely making the comparison between many samples easily reproducible. The pre-
separation of proteins appeared to reduce diffusion based crosslinking, probably because 
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the movement of complexes in the sample was restricted to the immediate vicinity of their 
position in the polyacrylamide gel, making chance interactions with other proteins unlikely. 
Multimer-PAGE seemed useful in detecting stable protein complexes other that α-
synuclein multimers. In this regard, multimer-PAGE may be a particularly valuable 
supplemental technique for BN-PAGE, to verify true protein complexes, as protein 
mobility on BN-PAGE alone clearly isn’t sufficient [304]. For example, multimer-PAGE 
detected parkin as a monomer (50 kDa) in contrast to a previous report that found parkin 
to be exclusively a tetramer, based on BN-PAGE experiments [312]. Multimer-PAGE 
format also allows the simultaneous comparison of many biological samples, so that, 
relative protein complex abundance can be compared on a single blot. Although not 
reported here, gels could also be incubated with solutions containing experimental 
molecules to assess their influence on complex stability.  
 Lipid-protein crosslinking could occur between α-synuclein and phosphatidalserine 
or phosphatidylethanolamine. This interpretation of the data has the advantage of 
explaining the seemingly anomalous behavior of α-synuclein following sample dilution 
prior to chemical crosslinking (seen in figure 26B). DSP treatment enhances α-synuclein 
detection on PVDF membranes as described previously [313]. The enhancement is lost 
upon sample dilution. Because we observed that α-synuclein association with endogenous 
lipids was sensitive to dilution, it could be that upon dilution α-synuclein disassociates 
from endogenous lipids, reverting to an unstable intrinsically dynamic protein in solution. 
Crosslinking of free α-synuclein would then likely form a more compact structure as 
adjacent lysine residues of α-synuclein cross-link to each other. In contrast, if lipid-protein 
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crosslinking occurred between α-synuclein and several phospholipids, α-synuclein would 
not only have a larger molecular radius but would presumably be more hydrophobic, 
allowing for enhanced PVDF binding.  Data provided here is insufficient to conclusively 
affirm or reject this interpretation and future studies should aim to address this potentially 
important molecular behavior of soluble α-synuclein. 
 Overall, multimer-page is a useful technique to study protein complexes in great 
detail. Multimer-PAGE was used successfully to describe and compare soluble α-synuclein 
multimers across complex biological samples.  
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Figure 31. Summary of multimer-PAGE technique. Depicted is a conceptual process 
underlying the multimer-PAGE technique. First tissue is disrupted taking care to preserve 
intact protein complexes. During native extraction α-synuclein likely is in dynamic 
interaction with lipid/detergent micelles. The micelles containing α-synuclein are separated 
by blue native gel electrophoresis. Subsequent chemical crosslinking stabilizes the 
separated protein complexes. These complexes can then be resolved using SDS-PAGE. 
The technique can be setup to resolve and compare α-synuclein multimers between 14 
samples.  Ultimately, this technique is usuful in the measurement of α-synuclein multimer 
abundance in biological samples.  
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
6 Self-administration model of neurotoxicity  
6.1.1 Key findings 
Adult male Long-Evans can be trained to readily self-administered 0.1 mg / kg / 
infusion of METH using an FR5 schedule of reinforcement. Long-Evans rats self-
administered approximately 2 mg METH / kg bodyweight per 4 h session. Following 14 
consequetive days of METH self-administration degeneration in striatal TH labeled axons 
or perbutation in striatal dopamine were not observed. 
6.1.2 Conclusions 
Long-Evans rats readily self-administer METH, albeit, less robustly than that 
reported for Sprague-Dawley rats. Furthermore, short-access METH self-administration 
investigated here does not produce robust striatal DAergic neurotoxicity. Therefore, short-
access METH self-administration is not a robust rodent model of METH neurotoxicity. 
6.1.3 Future Directions 
 Future investigations into the etiology and treatment of METH neurotoxicity should 
focus on either a binge METH or extended access METH self-administration models. 
Extended access METH self-administration neurotoxicity models have been demonstrated 
elsewhere [65, 160]. Extended access models allow for exposure to higher doses of METH, 
and potentially, can better mimic human use. 
 Here we did not observe reductions in striatal DAergic markers 21 days following 
METH self-administration. Long-term (>7 days) depletion of striatal DA can be indicative 
of physical damage and loss of striatal DAergic axons. Because we did not observe 
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reductions in striatal DA 21 days following METH, physical damage to striatal DAergic 
axons is unlikely. Future studies should address the possibility that damage to striatal axons 
occurs at low levels, and closer to the time of METH exposure. Studies looking at striatal 
health and function at an earlier timepoint (ie 24-48h) following METH exposure will help 
clarify if any neurotoxicity is taking place, which may not be obvious 21 days following 
METH self-administration. For example it may be fruitful to assess reactive gliosis and 
microglia activation in the striatum in animals who recently have self-administered METH. 
Because activated microglia activation is observed in the brains of human METH users, 
the confirmation of this effect a rodent self-administration paradigm would lend clinical 
validity to the model.  Acute microglia activation together with a lack of long-term striatal 
DAergic deficits would help confirm the models validity as approximating human METH 
use.   
 METH administration in rodents tends to be highly variable, and the cause remains 
unclear. This is in contrast to other drugs of abuse like cocaine and opiates which produce 
robust operant responding in most rats. Because suseptiblility to drug taking is a central 
issue to METH abuse, investions into the root causes are particularly important. Future 
fruitful studies should explore the contribution of genetics and environment on variable 
responding of rats for METH. To assess the genetic contribution to METH self-
administration animals should be first categorized into high and low responders based on 
performance during the METH self-administration session. Exome sequencing of these 
two groups could give insight into functional genetic contributions to the phenotype. Once 
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potential functional targets are identified, then knockdown and/or knockout models can be 
explored to verify the contribution of the identified target to self-administration. 
6.2 Role of axonal transport in METH neurotoxicity 
6.2.1 Key findings 
Immunoreactivity of AcetTUB is decreased in the striatum 3 days following binge 
METH. Co-localization between AcetTUB and TH labled axons decreaseed in the striatum 
3 days following binge METH. Treatment with EpoDL prevented the METH-induced loss 
of striatal AcetTUB, TH, and DAT. EpoDL prevented METH-induced reactive gliosis. 
Immunoreactivity of DAT is increased in the striatum 3 days following EpoDL treatment. 
6.2.2 Conclusions 
METH exposure results in destabilized MT of striatal DAerigic axons. EpoD can 
be used to prevent the METH-induced destabilization of MT in DAergic axons. EpoD may 
influence DA neurotransmission in the striatum and could serve as a novel therapeutic 
intervention for METH neurotoxicity. 
6.2.3 Future Directions 
 Future investigations should focus on the neuroprotective effects of EpoD. To do 
this, an optimal dosing regimen should be determined, using the dose range presented here 
as a guide.  High doses of EpoD can be neurotoxic, as suggested here, and elsewhere.  The 
effect of EpoD on striatal DAT and DA levels should also be investigated. Because EpoDL 
increased both striatal DAT and DA, EpoD could possibly be used as a novel DA enhancing 
therapy for diseases such as PD. 
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The role of MT in METH neurotoxicity should be further investigated. Here we 
found evidence that stable MT were lost in DAergic axons following METH. However, 
this evidence is based on the indirect measure of MT PTM. Future investigations should 
attempt to verify the loss of stable MT through other methods than those used here. For 
example, the conditional deletion or overexpression of FLOXED Hdac6 (gene encoding 
HDAC6) in DA neurons of the nigralstriatal pathway could potentially clarify the role of 
AcetTUB in METH neurotoxicity. HDAC6 is a required enzyme for the deacetylation of 
MT. Measuring the METH neurotoxicity in these animals would help clarify the role of 
AcetTUB in METH neurotoxicity. Our results suggest that HDAC6 may serve a neurotoxic 
role in nigrostriatal DAergic neurons. However, HDAC6 could also be neuroprotective 
because of its known functions in the removal of toxic/misfolded protein aggregates.  
 Impaired axonal transport following binge METH should be verified. Measuring 
axonal transport in vivo is technically challenging and therefore we chose to measure PTM 
of MT. However, these PTM are a relatively indirect measure of axonal transport, and 
therefore, do not necessarily indicate impaired transport.  Deficits in axonal transport could 
be verified in primary neuron culture using fluorescent quantum dots (QDOT) as the 
transported cargo [314]. We had explored the microinjection of QDOT in the substantia 
nigra to measure axonal transport in vivo but found extensive transport throughout the brain 
(data not shown here) and therefore the technique was not particularly useful to study 
axonal transport selectively in nigrostrial DA neurons. An alternative to QDOT based cargo 
would be the use of labeling strategies for a cell specific cargo for example DAT. This 
method would have the advantage of being DA neuron specific and sensitive. However, 
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collecting meaningful live images of tagged-DAT in vivo would be difficult with currently 
available technologies (i.e. cannot penetrate deep tissue structures and resolution is 
limited). Therefore, the examination of axonal transport via post-mortem analysis of brain 
tissue slices (i.e. IHC) would still be necessary. 
6.3 Role of Parkin in METH neurotoxicity 
6.3.1 Key findings 
PKO rats are hyposensitive to the acute locomotor activating effects of METH. 
PKO rats develop PD-like phenotype following exposure to high dose METH. PKO rats 
are hypersensitive to METH induced DA depletion in the striatum but not METH-induced 
reduction of striatal DAT or TH. PKO rats have reduced levels of striatal AcetTUB, but 
are insensitive to the AcetTUB lowering effects of binge METH. 
6.3.2 Conclusions 
Parkin plays a role in maintaining function of the nigrostriatal dopamine pathway.  
Parkin does not play a role in maintating striatal AcetTUB levels. 
6.3.3 Future directions 
Several studies have suggested a role of parkin for the turnover and stability of MT 
[315-319]. Here we present evidence that parkin appears to play a role in METH induced 
neurotoxicity in the striatum. Behavioural data seems to suggest that parkin may have an 
important role in maintaining proper DA function in the nigrostriatal system. We 
hypothesized that parkin may maintain DAergic neuron health through the maintance of 
axonal transport, but when we measured AcetTUB levels in the striatum following parkin 
overexpression, we saw no alteration in the striatal AcetTUB levels. This is despite the 
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apparent reduction in AcetTUB levels in PKO rats, as measured by western blot and IHC. 
Using a PTM of α-tubulin (ie AcetTUB) as a marker of axonal transport is fraught with 
interpretational difficulties. Future studies should focus on assessing the process of axonal 
transport directly via either primary neuron cultures or in vivo imaging techniques. Current 
in vivo imaging techniques are relatively insensitive and technically challenging. Imaging 
in primary neuron culture is a more sensitive and allows for easy experimental 
manipulation. Parkin overexpression and knockdown in these types of models will likely 
yield more direct answers to the question of what is parkins role in axonal transport.  
 We demonstrate that PKO rats develop a distinct motor impairment phenotype upon 
the toxic insult of binge METH. It’s still not clear why PKO rats are sensitive to METH. 
Fruitful future studies should focus the possible exaggerated hyperthermia response in the 
rats. Because we externally cooled rat in these studies we can not accurately determine any 
sensitivity to METH-induced hyperthermia. Another important study to help determine the 
molecular causes of PKO sensistivity is to investigate ubiquitination targets downstream 
of parkin.  Newer proteomic approaches allow for the large scale identification of 
differentially ubiquitinated protiens [320]. Running this type of this large scale unbiased 
analysis could help discover regulatory targets downstream of parkin that may be important 
for the observed phenotype.  
6.4 Measuring α-Synuclein tetramers 
6.4.1 Key findings 
BN-PAGE was insufficient to determine α-synuclein multimer stoichiometry in 
brain lysates. This was partially due to soluble α-synuclein migrating within a 
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lipid/detergent structure during BN-PAGE to a position of 66-200 kDa. The limitation of 
BN-PAGE could be circumvented by using in-gel chemical crosslinking of native proteins. 
Using this new technique, termed multimer-PAGE, we observed predominately three α-
synuclein species of 17, 56, and 80 kDa. Multimer-PAGE, has potential to be used to 
measure protein stoichiometry of many other protein complexes in biological samples.  
6.4.2 Conclusions  
α-Synuclein forms several stable soluble multimers in the brain. Using multimer-
PAGE the stoichiometry of α-synuclein multimers can be determined and compared 
between many complex biological samples. 
6.4.3 Future Directions  
Future studies should determine if binge METH treatment alters the ratio of α-
synuclein monomer to tetramer in the striatum. Preliminary studies in our lab suggest that 
directly treating gels with DA and METH can inhibit endogenous α-synuclein tetramer 
stability (data not shown). This finding is preliminary, but it seems to suggest that METH 
directly and indirectly (via DA) promotes the shift from the α-synuclein tetramer to the 
disordered monomer (i.e. the aggregation prone species). To investigate this hypothesis 
multimer-PAGE should be conducted in striatal lysates of rats treated with binge METH. 
Further studies should employ multimer-PAGE to investigate role of α-synuclein 
multimers in DA vesicle transport. Numerous studies show that α-synuclein is primarily 
involved in neurotransmitter packaging, exocytosis, and vesicle trafficking [321]. The 
exact role of α-synuclein in the axonal transport of DA containing vesicles is unknown. 
What is known is the multimerization of α-synuclein on vesicle membranes is intimately 
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tied to the vesicle trafficking function of α-synuclein. Therefore, the measured ratio of α-
synuclein monomer to tetramer may be indicative of impaired axonal transport of DA 
vesicles. In this scenario, METH and/or excess cytosolic DA would impair the formation 
of α-synuclein multimers on the surface of vesicles. The inhibition of multimer formation 
would increase monomeric α-synuclein (i.e. the species associated with aberrant 
aggregation). The net result would be the toxic aggregation of α-synuclein and impaired 
vesicular transport. 
The absolute ratio of soluble α-synuclein monomer to tetramer in the striatum 
should be determined. To do this, future studies need to investigate the lipid binding role 
of α-synuclein. The interaction of α-synuclein with an unknown soluble lipid (s) is strongly 
implicated here and elsewhere. The interaction with α-synuclein and the free lipid pool 
likely determines the measured α-synuclein stoichiometry by multimer-PAGE. By 
determining the exact nature of α-synuclein interaction with free lipids will result in a much 
deeper understanding of α-synuclein function. The lipid (s) could be easily determined by 
mass spectrometry of the lipids isolated from purified α-synuclein. Once it is determined 
which lipids α-synuclein is binding, and more importantly, how many molecules of lipid 
α-synuclein binds endogenously, it could be determined the stoichiometry of the 
hypothesized α-synuclein-lipid particle. 
6.5 General Discussion  
6.5.1 The role of axonal transports role in clinical METH neurotoxicity 
Currently there is a lack of direct evidence for axonal transport deficits in the brain 
of human METH users. However, there are several reasons to believe that heavy METH 
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use could impair axonal transport in the nigralstriatal dopamine pathway. First there is an 
accumulation of oxidative products and reduction of antioxidant molecules in the striatum 
of heavy METH users [321]. This observation suggest that oxidative stress plays a role in 
damage to the striatal DAergic nerve teminals. Clearance of oxidativily damaged cellular 
components, and the restoration of homeostatsis at striatal DAergic nerve terminals, would 
likely involve the processes of axonal transport. Accumulation of cytoskeletal associtated 
protein tau and plasma membrane associtated cytoskeletal filament protein spectrin II are 
cleaved in the hippocampus and cortex of rats treated with METH [322]. Cleaved tau can 
inhibit kinesin mediated axonal transport [323] and therefore axonal transport maybe 
inhibited following toxic doses of METH. Inhibition of retrograde transport would 
presumably be important to remove oxidatively damage organelles and other cellular 
components. Oxidative stress in METH users could disrupt axonal transport by damaging 
the necessary components such as MT’s and motoroproteins. Indeed damage to the axonal 
transport machinery has been observed in animal models of several other 
neurodegenerative disorder [324, 325].  
DAergic axon components, such as DAT and DA, recover following abstinence 
from METH [326, 327]. Axonal transport is required specifically for DAT which is not 
locally synthesized in the striatal nerve terminals. Therefore, to some extent anterograde 
axonal transport is required for the observed restoration of striatal DAT. Restoration of 
DAergic nerve terminal components by enhancing axonal transport would presumably help 
restore normal DAergic nerve terminal function. However, increasing the availability of 
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DAT at the nerve terminal could result in undesirable results such as increasing the 
addictive properties of METH [51]. 
Addressing the role of axonal transport dysfunction in human METH users is 
experimentally challenging. In vivo monitoring of axonal transport remains beyond current 
technologies limiting the direct observation of axonal transport in human METH users. 
However, several of the tubulin PTM’s explored here may allow for the assessment of 
axonal transport fidelity in METH users. The use of AcetTUB and DeTyTUB may be 
particularly useful, in that both of these PTM’s were altered in our rat model of METH 
neurotoxicity. There assessment would be limited to post-mortem tissue samples, which 
subsequently limits the conclusions of such studies.  
Induced pluripotent stem cells (iPSC) technology may allow for the assessment of 
axonal transport in neurons derived from METH users [328]. iPSCs can be cultured from 
fibroblast cells of patients currently using METH, which can in turn be differentiated into 
DAergic cells[329]. Axonal transport could then be directly monitored in these neurons 
using labeling strategies and microscopy [330]. Although this model has the advantage of 
directly measuring axonal transport in human patient’s neurons, the phenotype of the 
neurons would poorly recapitulate METH exposed neurons in the brain.  
6.5.2 EpoD as a treatment for METH neurotoxicity 
EpoD was originally developed as an anticancer treatment[331]. Subsequent 
development for neurodegenerative disease was explored because EpoD selectively 
accumulates in the brain, in contrast to other MT stabilizing componds that do not cross 
the blood brain barrier. Clinical trials of EpoD were conducted by Bristol-Myers Squibb 
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for the treatment of alzhiemers disease but were discontinued in 2013. There are currently 
no ongoing clinical trials investigating the use of EpoD for treatment of Alzeimer’s 
diseases. 
Development of EpoD as a treatment for axonal transport dysfunction in the CNS 
is impeded by potential off target effects. Known taxol compounds, such as paclitaxel, can 
induce peripheral neuropathy, but they do not cross the blood brain barrier [332]. EpoD, 
readily crosses the blood brain barrier [152] and could induce neuropathly in the CNS. Our 
data seems to suggest, at least with the highest does tested, some adverse neurotoxicity is 
occurring the central nervous system. Chronic stabilization of MT’s in cells of the central 
nervous system likely have widesweeping effects because MTs are involved in many 
cellular functions. For this reason, treatment with EpoD may be most beneficial if done 
acutely following injury, for example, following overdose of METH.  In this situation, 
EpoD may increase axonal transport and allow for neurons to more efficiently clear 
damaged cellular components and restore function cellular compoents to the striatal nerve 
terminals. In this vein, studies that explore the use of low dose EpoD following neural 
injury may be more successful than pretreatement. Furthermore, treatment following 
neuronal injury is more clinically applicable as neuronal injury (METH overdose) is 
unpredicatable. 
6.5.3 Modeling METH neurotoxicity in rodents 
METH self-administration models have been used for many years to study 
addictive properties of METH. Self-administration models have been under-utilized for 
METH neurotoxicity studies. The primary reason is that drug responding in rodents does 
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not mimic human users. Because the half-life of METH in rodents is short (~2 h) they 
administer METH continuously over a period of many hours. Human users will often 
administer single large doses of METH 1-2 times a day because the half-life of METH is 
~12 h. Determining an accurate model of human use is very important, because depending 
on the model used METH exposure can lead to very different outcomes [333].  
6.5.4 α-Synuclein and METH neurotoxicity 
α-Synuclein’s possible role in METH neurotoxicity remains obscure. Several 
studies have suggested that METH may increase α-synuclein expression in the brain[118]. 
Overexpression of α-synuclein can lead to neurodegeneration in DAergic neruons [334]. 
Therefore, it is possible that the effect of METH on α-synuclein expression may impact the 
health and function of DAergic neurons. However, this hypothesis remains to be directly 
assessed. 
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ABSTRACT 
AXONAL TRANSPORT, PARKIN, AND Α-
SYNUCLEIN; NOVEL THERAPEUTIC TARGETS TO 
TREAT METHAMPHETAMINE NEUROTOXICITY 
by 
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Advisor: Dr. Anna Moszczynska 
Major: Pharmaceutical Sciences 
Degree: Doctor of Philosophy 
Methamphetamine (METH) is a commonly abuse psychostimulant. 
Exposure to chronic high doses of METH can result in neurotoxicity primarily 
characterized by damage to striatal dopaminergic (DAergic) axons. There are 
currently no therapeutic interventions for METH neurotoxicity. To some extent 
damage to striatal DAergic axons is reversible and DAergic axon function may 
return following abstinence from METH. The reversible nature of METH 
neurotoxicity suggests that normal striatal function could be restored following 
exposure to METH. However, potential targets to treat METH neurotoxicity are 
needed. Axonal transport is required for restoration of DAergic axon components 
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damaged or lost following METH. Here we investigated several potential novel 
drug targets to treat METH neurotoxicity including with emphasis on targeting 
axonal transport. We also investigated the E3 ligase parkin and the aggregation 
prone nerve terminal protein α-synuclein. To investigate the role of axonal transport 
in METH neurotoxicity we treated a rat model of METH neurotoxicity with axonal 
transport enhancing drug, epothilone D. Results show that epothilone D could to 
some extent prevent METH-induced damage to DAergic axons in the striatum. To 
investigate parkin’s role in METH neurotoxicity we treated parkin knockout rats 
with a neurotoxic dose of METH. We found that parkin knockout rats were 
hypersensitive to the METH induced DAergic neurotoxicity, confirming the 
neuroprotective role of parkin for DAergic neurons. To investigate the role of α-
synuclein in METH neurotoxicity we developed a novel method of measuring α-
synuclein oligomerization in complex biological samples. In conclusion, here we 
lay the experimental foundation for three potential targets of METH neurotoxicity. 
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